EP4045054A1 - Nano-enabled immunotherapy in cancer - Google Patents
Nano-enabled immunotherapy in cancerInfo
- Publication number
- EP4045054A1 EP4045054A1 EP20876826.7A EP20876826A EP4045054A1 EP 4045054 A1 EP4045054 A1 EP 4045054A1 EP 20876826 A EP20876826 A EP 20876826A EP 4045054 A1 EP4045054 A1 EP 4045054A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- drug carrier
- lipid
- cancer
- icd
- carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 234
- 201000011510 cancer Diseases 0.000 title claims abstract description 139
- 238000009169 immunotherapy Methods 0.000 title abstract description 4
- 239000002105 nanoparticle Substances 0.000 claims abstract description 219
- 239000003112 inhibitor Substances 0.000 claims abstract description 214
- 239000000203 mixture Substances 0.000 claims abstract description 157
- 239000000232 Lipid Bilayer Substances 0.000 claims abstract description 144
- 239000000411 inducer Substances 0.000 claims abstract description 107
- 238000000034 method Methods 0.000 claims abstract description 95
- 230000037361 pathway Effects 0.000 claims abstract description 94
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims abstract description 82
- 229960001156 mitoxantrone Drugs 0.000 claims abstract description 79
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims abstract description 79
- 238000012384 transportation and delivery Methods 0.000 claims abstract description 64
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 54
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims abstract description 42
- 229960001756 oxaliplatin Drugs 0.000 claims abstract description 42
- 229960004679 doxorubicin Drugs 0.000 claims abstract description 40
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims abstract description 32
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims abstract description 32
- 239000002539 nanocarrier Substances 0.000 claims abstract description 27
- 239000003937 drug carrier Substances 0.000 claims description 293
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 191
- 150000002632 lipids Chemical class 0.000 claims description 159
- 239000002086 nanomaterial Substances 0.000 claims description 151
- 229920001223 polyethylene glycol Polymers 0.000 claims description 112
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 110
- 150000003904 phospholipids Chemical class 0.000 claims description 106
- 235000012000 cholesterol Nutrition 0.000 claims description 96
- 238000009472 formulation Methods 0.000 claims description 81
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 claims description 79
- 239000002502 liposome Substances 0.000 claims description 79
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 78
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 59
- 230000037449 immunogenic cell death Effects 0.000 claims description 54
- 239000000377 silicon dioxide Substances 0.000 claims description 54
- -1 R2016 Chemical compound 0.000 claims description 48
- 229910021389 graphene Inorganic materials 0.000 claims description 48
- 239000000463 material Substances 0.000 claims description 41
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 40
- 239000003814 drug Substances 0.000 claims description 37
- 230000000694 effects Effects 0.000 claims description 37
- 229940079593 drug Drugs 0.000 claims description 35
- 239000011148 porous material Substances 0.000 claims description 35
- 150000001875 compounds Chemical class 0.000 claims description 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims description 29
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 claims description 28
- 230000006698 induction Effects 0.000 claims description 28
- 239000002245 particle Substances 0.000 claims description 27
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 24
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 24
- 230000008685 targeting Effects 0.000 claims description 23
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 22
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 21
- 229930195729 fatty acid Natural products 0.000 claims description 21
- 239000000194 fatty acid Substances 0.000 claims description 21
- 150000004665 fatty acids Chemical class 0.000 claims description 21
- 239000000725 suspension Substances 0.000 claims description 21
- GOLCXWYRSKYTSP-UHFFFAOYSA-N Arsenious Acid Chemical compound O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims description 20
- WMWLMWRWZQELOS-UHFFFAOYSA-N bismuth(iii) oxide Chemical compound O=[Bi]O[Bi]=O WMWLMWRWZQELOS-UHFFFAOYSA-N 0.000 claims description 20
- 230000002195 synergetic effect Effects 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 17
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims description 16
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims description 15
- 150000001841 cholesterols Chemical class 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 229960004768 irinotecan Drugs 0.000 claims description 14
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 14
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 14
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 14
- 229930012538 Paclitaxel Natural products 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 13
- 229960001592 paclitaxel Drugs 0.000 claims description 13
- 230000009885 systemic effect Effects 0.000 claims description 13
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 13
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 12
- 238000000576 coating method Methods 0.000 claims description 12
- 239000000839 emulsion Substances 0.000 claims description 12
- 229920001427 mPEG Polymers 0.000 claims description 12
- AEUCYCQYAUFAKH-DITNKEBASA-N 1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCC\C=C/CCCCCCCC AEUCYCQYAUFAKH-DITNKEBASA-N 0.000 claims description 11
- AVCZHZMYOZARRJ-JWLMTKEBSA-N PC(14:1(9Z)/14:1(9Z)) Chemical compound CCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCC AVCZHZMYOZARRJ-JWLMTKEBSA-N 0.000 claims description 11
- 239000011248 coating agent Substances 0.000 claims description 11
- GHPGOEFPKIHBNM-UHFFFAOYSA-N antimony(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Sb+3].[Sb+3] GHPGOEFPKIHBNM-UHFFFAOYSA-N 0.000 claims description 10
- BERDEBHAJNAUOM-UHFFFAOYSA-N copper(I) oxide Inorganic materials [Cu]O[Cu] BERDEBHAJNAUOM-UHFFFAOYSA-N 0.000 claims description 10
- KRFJLUBVMFXRPN-UHFFFAOYSA-N cuprous oxide Chemical compound [O-2].[Cu+].[Cu+] KRFJLUBVMFXRPN-UHFFFAOYSA-N 0.000 claims description 10
- VSAISIQCTGDGPU-UHFFFAOYSA-N phosphorus trioxide Inorganic materials O1P(O2)OP3OP1OP2O3 VSAISIQCTGDGPU-UHFFFAOYSA-N 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 10
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 9
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 9
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical compound C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 claims description 9
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 9
- 229960001467 bortezomib Drugs 0.000 claims description 9
- 239000000969 carrier Substances 0.000 claims description 9
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 9
- 229960004316 cisplatin Drugs 0.000 claims description 9
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 8
- 108010006654 Bleomycin Proteins 0.000 claims description 8
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 8
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 8
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 8
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 8
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 8
- 101001000212 Rattus norvegicus Decorin Proteins 0.000 claims description 8
- FVJZSBGHRPJMMA-DHPKCYQYSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-octadecanoyloxypropyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-DHPKCYQYSA-N 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 229960001561 bleomycin Drugs 0.000 claims description 8
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 8
- 229960004397 cyclophosphamide Drugs 0.000 claims description 8
- FVJZSBGHRPJMMA-UHFFFAOYSA-N distearoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-UHFFFAOYSA-N 0.000 claims description 8
- 229960003668 docetaxel Drugs 0.000 claims description 8
- 229960001904 epirubicin Drugs 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 8
- 229960000908 idarubicin Drugs 0.000 claims description 8
- 238000007920 subcutaneous administration Methods 0.000 claims description 8
- BIABMEZBCHDPBV-BEBVUIBBSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-BEBVUIBBSA-N 0.000 claims description 7
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 7
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 7
- 239000004472 Lysine Substances 0.000 claims description 7
- 229960000975 daunorubicin Drugs 0.000 claims description 7
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 7
- 238000004108 freeze drying Methods 0.000 claims description 7
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 7
- 230000031998 transcytosis Effects 0.000 claims description 7
- 230000002792 vascular Effects 0.000 claims description 7
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 6
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 6
- 239000006185 dispersion Substances 0.000 claims description 6
- 230000000799 fusogenic effect Effects 0.000 claims description 6
- 238000007918 intramuscular administration Methods 0.000 claims description 6
- 230000032258 transport Effects 0.000 claims description 6
- 239000000443 aerosol Substances 0.000 claims description 5
- 230000008021 deposition Effects 0.000 claims description 5
- 238000001361 intraarterial administration Methods 0.000 claims description 5
- 238000007917 intracranial administration Methods 0.000 claims description 5
- 238000007913 intrathecal administration Methods 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 5
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 claims description 4
- 206010070863 Toxicity to various agents Diseases 0.000 claims description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 4
- 150000003863 ammonium salts Chemical class 0.000 claims description 4
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 4
- 238000009826 distribution Methods 0.000 claims description 4
- 230000005934 immune activation Effects 0.000 claims description 4
- WEPNHBQBLCNOBB-FZJVNAOYSA-N sucrose octasulfate Chemical compound OS(=O)(=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@H](COS(=O)(=O)O)O[C@]1(COS(O)(=O)=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](COS(O)(=O)=O)O1 WEPNHBQBLCNOBB-FZJVNAOYSA-N 0.000 claims description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 claims description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 4
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 claims 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- 229920000362 Polyethylene-block-poly(ethylene glycol) Polymers 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 abstract description 30
- 229940002612 prodrug Drugs 0.000 abstract description 24
- 239000000651 prodrug Substances 0.000 abstract description 24
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract description 10
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract description 10
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract description 10
- 201000002528 pancreatic cancer Diseases 0.000 abstract description 8
- 230000030833 cell death Effects 0.000 abstract description 6
- 238000012385 systemic delivery Methods 0.000 abstract description 2
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 218
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 218
- ZADWXFSZEAPBJS-SNVBAGLBSA-N (2r)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 description 105
- 210000004027 cell Anatomy 0.000 description 91
- 229950009034 indoximod Drugs 0.000 description 85
- 102000004082 Calreticulin Human genes 0.000 description 28
- 108090000549 Calreticulin Proteins 0.000 description 28
- 239000002671 adjuvant Substances 0.000 description 27
- 238000002255 vaccination Methods 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 23
- 210000003169 central nervous system Anatomy 0.000 description 23
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 21
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 20
- 230000000670 limiting effect Effects 0.000 description 20
- 201000008968 osteosarcoma Diseases 0.000 description 20
- 238000011282 treatment Methods 0.000 description 20
- 206010006187 Breast cancer Diseases 0.000 description 19
- 208000026310 Breast neoplasm Diseases 0.000 description 19
- 238000013459 approach Methods 0.000 description 19
- 239000003446 ligand Substances 0.000 description 19
- 230000004044 response Effects 0.000 description 18
- 125000005647 linker group Chemical group 0.000 description 17
- 230000004913 activation Effects 0.000 description 16
- 239000000427 antigen Substances 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- 238000003786 synthesis reaction Methods 0.000 description 16
- 206010009944 Colon cancer Diseases 0.000 description 15
- TXUWMXQFNYDOEZ-UHFFFAOYSA-N 5-(1H-indol-3-ylmethyl)-3-methyl-2-sulfanylidene-4-imidazolidinone Chemical compound O=C1N(C)C(=S)NC1CC1=CNC2=CC=CC=C12 TXUWMXQFNYDOEZ-UHFFFAOYSA-N 0.000 description 14
- 241000282414 Homo sapiens Species 0.000 description 14
- 201000005962 mycosis fungoides Diseases 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 229940037003 alum Drugs 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- 239000000017 hydrogel Substances 0.000 description 13
- 230000028993 immune response Effects 0.000 description 13
- ZADWXFSZEAPBJS-UHFFFAOYSA-N racemic N-methyl tryptophan Natural products C1=CC=C2N(C)C=C(CC(N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-UHFFFAOYSA-N 0.000 description 13
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 12
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 12
- 102100037907 High mobility group protein B1 Human genes 0.000 description 12
- 230000001684 chronic effect Effects 0.000 description 12
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 12
- 238000012377 drug delivery Methods 0.000 description 12
- 230000002496 gastric effect Effects 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 12
- 201000001441 melanoma Diseases 0.000 description 12
- 208000029742 colonic neoplasm Diseases 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- ZADWXFSZEAPBJS-JTQLQIEISA-N 1-methyl-L-tryptophan Chemical compound C1=CC=C2N(C)C=C(C[C@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-JTQLQIEISA-N 0.000 description 10
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 10
- 108700010013 HMGB1 Proteins 0.000 description 10
- 101150021904 HMGB1 gene Proteins 0.000 description 10
- 206010025323 Lymphomas Diseases 0.000 description 10
- 229930003427 Vitamin E Natural products 0.000 description 10
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 10
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 229940046009 vitamin E Drugs 0.000 description 10
- 235000019165 vitamin E Nutrition 0.000 description 10
- 239000011709 vitamin E Substances 0.000 description 10
- XHLKOHSAWQPOFO-UHFFFAOYSA-N 5-phenyl-1h-imidazole Chemical compound N1C=NC=C1C1=CC=CC=C1 XHLKOHSAWQPOFO-UHFFFAOYSA-N 0.000 description 9
- 208000003174 Brain Neoplasms Diseases 0.000 description 9
- 241000124008 Mammalia Species 0.000 description 9
- 210000000612 antigen-presenting cell Anatomy 0.000 description 9
- 230000021615 conjugation Effects 0.000 description 9
- 210000004443 dendritic cell Anatomy 0.000 description 9
- 230000009977 dual effect Effects 0.000 description 9
- 230000003389 potentiating effect Effects 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical class N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 9
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 8
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 8
- 206010003571 Astrocytoma Diseases 0.000 description 8
- 201000008271 Atypical teratoid rhabdoid tumor Diseases 0.000 description 8
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 8
- 206010004593 Bile duct cancer Diseases 0.000 description 8
- 206010006143 Brain stem glioma Diseases 0.000 description 8
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 8
- 208000009798 Craniopharyngioma Diseases 0.000 description 8
- 206010014733 Endometrial cancer Diseases 0.000 description 8
- 206010014759 Endometrial neoplasm Diseases 0.000 description 8
- 206010014967 Ependymoma Diseases 0.000 description 8
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 8
- 206010061252 Intraocular melanoma Diseases 0.000 description 8
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 8
- 208000007766 Kaposi sarcoma Diseases 0.000 description 8
- 208000008839 Kidney Neoplasms Diseases 0.000 description 8
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 8
- 208000034578 Multiple myelomas Diseases 0.000 description 8
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 8
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 8
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 8
- YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical compound O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 description 8
- 206010033128 Ovarian cancer Diseases 0.000 description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 description 8
- 206010035226 Plasma cell myeloma Diseases 0.000 description 8
- 206010039491 Sarcoma Diseases 0.000 description 8
- 208000009359 Sezary Syndrome Diseases 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 208000024313 Testicular Neoplasms Diseases 0.000 description 8
- 206010057644 Testis cancer Diseases 0.000 description 8
- 201000005969 Uveal melanoma Diseases 0.000 description 8
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 8
- 208000008383 Wilms tumor Diseases 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 8
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 8
- 238000005755 formation reaction Methods 0.000 description 8
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 8
- 208000024348 heart neoplasm Diseases 0.000 description 8
- 208000018795 nasal cavity and paranasal sinus carcinoma Diseases 0.000 description 8
- 201000002575 ocular melanoma Diseases 0.000 description 8
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 8
- 102000007863 pattern recognition receptors Human genes 0.000 description 8
- 108010089193 pattern recognition receptors Proteins 0.000 description 8
- 208000010626 plasma cell neoplasm Diseases 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 201000003120 testicular cancer Diseases 0.000 description 8
- 208000008732 thymoma Diseases 0.000 description 8
- 210000000626 ureter Anatomy 0.000 description 8
- 229960005486 vaccine Drugs 0.000 description 8
- 230000001093 anti-cancer Effects 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 7
- 229940127089 cytotoxic agent Drugs 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 229910052751 metal Inorganic materials 0.000 description 7
- 239000002184 metal Substances 0.000 description 7
- 150000002739 metals Chemical class 0.000 description 7
- 229910052961 molybdenite Inorganic materials 0.000 description 7
- CWQXQMHSOZUFJS-UHFFFAOYSA-N molybdenum disulfide Chemical compound S=[Mo]=S CWQXQMHSOZUFJS-UHFFFAOYSA-N 0.000 description 7
- 239000004417 polycarbonate Substances 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 210000003289 regulatory T cell Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 208000030507 AIDS Diseases 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 102000002689 Toll-like receptor Human genes 0.000 description 6
- 108020000411 Toll-like receptor Proteins 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 238000011532 immunohistochemical staining Methods 0.000 description 6
- 230000002601 intratumoral effect Effects 0.000 description 6
- 201000007270 liver cancer Diseases 0.000 description 6
- 208000014018 liver neoplasm Diseases 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 201000005202 lung cancer Diseases 0.000 description 6
- 208000020816 lung neoplasm Diseases 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 208000021010 pancreatic neuroendocrine tumor Diseases 0.000 description 6
- 238000001959 radiotherapy Methods 0.000 description 6
- 229910021428 silicene Inorganic materials 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000011277 treatment modality Methods 0.000 description 6
- 239000000439 tumor marker Substances 0.000 description 6
- IQXADJSHEBDZPO-UHFFFAOYSA-N (1e)-1-[amino-(phenanthren-9-ylamino)methylidene]-2-methylguanidine;hydrochloride Chemical compound Cl.C1=CC=C2C(NC(=N)NC(=N)NC)=CC3=CC=CC=C3C2=C1 IQXADJSHEBDZPO-UHFFFAOYSA-N 0.000 description 5
- YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 description 5
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 5
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 5
- WKHJQIQDQXGUOD-UHFFFAOYSA-N 4-(benzylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydrobenzo[g]chromene-5,10-dione Chemical compound OC1C(C)(C)OC(C(C2=CC=CC=C2C2=O)=O)=C2C1NCC1=CC=CC=C1 WKHJQIQDQXGUOD-UHFFFAOYSA-N 0.000 description 5
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 5
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 description 5
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 description 5
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 5
- 108010034143 Inflammasomes Proteins 0.000 description 5
- FBKMWOJEPMPVTQ-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide Chemical compound NS(=O)(=O)NCCNC1=NON=C1C(=NO)NC1=CC=C(F)C(Br)=C1 FBKMWOJEPMPVTQ-UHFFFAOYSA-N 0.000 description 5
- 239000005642 Oleic acid Substances 0.000 description 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 5
- 102000004503 Perforin Human genes 0.000 description 5
- 108010056995 Perforin Proteins 0.000 description 5
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 5
- 208000000453 Skin Neoplasms Diseases 0.000 description 5
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 description 5
- WJAASTDRAAMYNK-UHFFFAOYSA-N benzyl carbamimidothioate;hydron;chloride Chemical compound Cl.NC(=N)SCC1=CC=CC=C1 WJAASTDRAAMYNK-UHFFFAOYSA-N 0.000 description 5
- PHBHIYCWGKONRK-UHFFFAOYSA-N benzyl n-(1h-indol-2-ylmethyl)carbamodithioate Chemical compound C=1C2=CC=CC=C2NC=1CNC(=S)SCC1=CC=CC=C1 PHBHIYCWGKONRK-UHFFFAOYSA-N 0.000 description 5
- 238000009739 binding Methods 0.000 description 5
- BQYIXOPJPLGCRZ-REZTVBANSA-N chembl103111 Chemical compound CC1=NC=C(CO)C(\C=N\NC(=O)C=2C=CN=CC=2)=C1O BQYIXOPJPLGCRZ-REZTVBANSA-N 0.000 description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 5
- 229940090949 docosahexaenoic acid Drugs 0.000 description 5
- 229940000406 drug candidate Drugs 0.000 description 5
- 229950010033 ebselen Drugs 0.000 description 5
- 229950006370 epacadostat Drugs 0.000 description 5
- UEKKREMMIOJMRO-RUZDIDTESA-O exiguamine A Chemical compound O=C1N(C)C(=O)N(C)[C@@]11C(C(=O)C2=C(NC=C2CCN)C2=O)=C2C2=C(CC[N+]3(C)C)C3=CC(O)=C2O1 UEKKREMMIOJMRO-RUZDIDTESA-O 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- SGIKNMBQDBAPSS-UHFFFAOYSA-N methyl n-[(6-bromo-3h-isoindol-1-yl)methyl]carbamodithioate Chemical compound C1=C(Br)C=C2C(CNC(=S)SC)=NCC2=C1 SGIKNMBQDBAPSS-UHFFFAOYSA-N 0.000 description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 229930192851 perforin Natural products 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- OICPHWKXRZQFNB-UHFFFAOYSA-N prop-2-enyl n-(1h-indol-2-ylmethyl)carbamodithioate Chemical compound C1=CC=C2NC(CNC(=S)SCC=C)=CC2=C1 OICPHWKXRZQFNB-UHFFFAOYSA-N 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 210000004872 soft tissue Anatomy 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- GPWHCUUIQMGELX-VHQDNGOZSA-N 1,2-dipalmitoleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCC GPWHCUUIQMGELX-VHQDNGOZSA-N 0.000 description 4
- YTRRAUACYORZLX-UHFFFAOYSA-N 1-cyclohexyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CCCCC1 YTRRAUACYORZLX-UHFFFAOYSA-N 0.000 description 4
- SEULWJSKCVACTH-UHFFFAOYSA-N 1-phenylimidazole Chemical compound C1=NC=CN1C1=CC=CC=C1 SEULWJSKCVACTH-UHFFFAOYSA-N 0.000 description 4
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 4
- JRGOZUPASNAZDD-UHFFFAOYSA-N 3-butyl-9h-pyrido[3,4-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=NC(CCCC)=C2 JRGOZUPASNAZDD-UHFFFAOYSA-N 0.000 description 4
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 4
- 229910002706 AlOOH Inorganic materials 0.000 description 4
- 206010061424 Anal cancer Diseases 0.000 description 4
- 208000007860 Anus Neoplasms Diseases 0.000 description 4
- 206010073360 Appendix cancer Diseases 0.000 description 4
- 206010004146 Basal cell carcinoma Diseases 0.000 description 4
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 4
- 206010005003 Bladder cancer Diseases 0.000 description 4
- 206010005949 Bone cancer Diseases 0.000 description 4
- 208000018084 Bone neoplasm Diseases 0.000 description 4
- 208000011691 Burkitt lymphomas Diseases 0.000 description 4
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 208000037138 Central nervous system embryonal tumor Diseases 0.000 description 4
- 206010008342 Cervix carcinoma Diseases 0.000 description 4
- 201000009047 Chordoma Diseases 0.000 description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 4
- 208000006168 Ewing Sarcoma Diseases 0.000 description 4
- 208000017259 Extragonadal germ cell tumor Diseases 0.000 description 4
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 4
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 4
- 208000021309 Germ cell tumor Diseases 0.000 description 4
- 208000017604 Hodgkin disease Diseases 0.000 description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 4
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 4
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 4
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 4
- 206010023825 Laryngeal cancer Diseases 0.000 description 4
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 4
- 206010062038 Lip neoplasm Diseases 0.000 description 4
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 4
- 208000004059 Male Breast Neoplasms Diseases 0.000 description 4
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 4
- 206010025557 Malignant fibrous histiocytoma of bone Diseases 0.000 description 4
- 208000032271 Malignant tumor of penis Diseases 0.000 description 4
- 206010027406 Mesothelioma Diseases 0.000 description 4
- 208000003445 Mouth Neoplasms Diseases 0.000 description 4
- 206010028193 Multiple endocrine neoplasia syndromes Diseases 0.000 description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 4
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 4
- 229930192627 Naphthoquinone Natural products 0.000 description 4
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 4
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 4
- 206010029260 Neuroblastoma Diseases 0.000 description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 4
- 208000000160 Olfactory Esthesioneuroblastoma Diseases 0.000 description 4
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 4
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 4
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 4
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 4
- 208000002471 Penile Neoplasms Diseases 0.000 description 4
- 206010034299 Penile cancer Diseases 0.000 description 4
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 4
- 206010034811 Pharyngeal cancer Diseases 0.000 description 4
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 4
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 description 4
- 206010038389 Renal cancer Diseases 0.000 description 4
- 201000000582 Retinoblastoma Diseases 0.000 description 4
- MADCIJNZRPUFBC-UHFFFAOYSA-N S=C(NCCC1=CNC2=CC=CC=C12)[SH2]CC1=CC=CN=C1 Chemical compound S=C(NCCC1=CNC2=CC=CC=C12)[SH2]CC1=CC=CN=C1 MADCIJNZRPUFBC-UHFFFAOYSA-N 0.000 description 4
- PHAWPOYWGPAKAO-UHFFFAOYSA-N S=C(NCCC1=CNC2=CC=CC=C12)[SH2]CC1=CC=NC=C1 Chemical compound S=C(NCCC1=CNC2=CC=CC=C12)[SH2]CC1=CC=NC=C1 PHAWPOYWGPAKAO-UHFFFAOYSA-N 0.000 description 4
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 4
- 206010061934 Salivary gland cancer Diseases 0.000 description 4
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 4
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 4
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 4
- 206010043515 Throat cancer Diseases 0.000 description 4
- 201000009365 Thymic carcinoma Diseases 0.000 description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 description 4
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 4
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 4
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 4
- 206010046392 Ureteric cancer Diseases 0.000 description 4
- 206010046431 Urethral cancer Diseases 0.000 description 4
- 206010046458 Urethral neoplasms Diseases 0.000 description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 description 4
- 206010047741 Vulval cancer Diseases 0.000 description 4
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 4
- 230000033289 adaptive immune response Effects 0.000 description 4
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 4
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 4
- 230000030741 antigen processing and presentation Effects 0.000 description 4
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 4
- 201000011165 anus cancer Diseases 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 208000021780 appendiceal neoplasm Diseases 0.000 description 4
- 208000001119 benign fibrous histiocytoma Diseases 0.000 description 4
- 210000000941 bile Anatomy 0.000 description 4
- 208000026900 bile duct neoplasm Diseases 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 206010006007 bone sarcoma Diseases 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 201000000220 brain stem cancer Diseases 0.000 description 4
- 208000002458 carcinoid tumor Diseases 0.000 description 4
- 201000010353 central nervous system germ cell tumor Diseases 0.000 description 4
- 201000010881 cervical cancer Diseases 0.000 description 4
- 230000000973 chemotherapeutic effect Effects 0.000 description 4
- 208000006990 cholangiocarcinoma Diseases 0.000 description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 4
- 229960004106 citric acid Drugs 0.000 description 4
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 4
- 239000012990 dithiocarbamate Substances 0.000 description 4
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 4
- 208000014616 embryonal neoplasm Diseases 0.000 description 4
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 4
- 201000004101 esophageal cancer Diseases 0.000 description 4
- 208000032099 esthesioneuroblastoma Diseases 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 4
- 208000024519 eye neoplasm Diseases 0.000 description 4
- 238000009093 first-line therapy Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 201000010175 gallbladder cancer Diseases 0.000 description 4
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 4
- 201000009277 hairy cell leukemia Diseases 0.000 description 4
- 201000010536 head and neck cancer Diseases 0.000 description 4
- 208000014829 head and neck neoplasm Diseases 0.000 description 4
- 201000010235 heart cancer Diseases 0.000 description 4
- ASSILCUOYWFGHU-UHFFFAOYSA-N hexyl n-(1h-indol-2-ylmethyl)carbamodithioate Chemical compound C1=CC=C2NC(C\N=C(S)/SCCCCCC)=CC2=C1 ASSILCUOYWFGHU-UHFFFAOYSA-N 0.000 description 4
- 201000008298 histiocytosis Diseases 0.000 description 4
- 201000006866 hypopharynx cancer Diseases 0.000 description 4
- 230000015788 innate immune response Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 201000010982 kidney cancer Diseases 0.000 description 4
- 210000000244 kidney pelvis Anatomy 0.000 description 4
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 4
- 210000001821 langerhans cell Anatomy 0.000 description 4
- 206010023841 laryngeal neoplasm Diseases 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 4
- 201000006721 lip cancer Diseases 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000000527 lymphocytic effect Effects 0.000 description 4
- 201000000564 macroglobulinemia Diseases 0.000 description 4
- 201000003175 male breast cancer Diseases 0.000 description 4
- 208000010907 male breast carcinoma Diseases 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 4
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 208000037970 metastatic squamous neck cancer Diseases 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000000693 micelle Substances 0.000 description 4
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 4
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 4
- 208000025113 myeloid leukemia Diseases 0.000 description 4
- 150000002791 naphthoquinones Chemical class 0.000 description 4
- 229920005615 natural polymer Polymers 0.000 description 4
- 201000008106 ocular cancer Diseases 0.000 description 4
- 201000005443 oral cavity cancer Diseases 0.000 description 4
- 201000006958 oropharynx cancer Diseases 0.000 description 4
- 208000003154 papilloma Diseases 0.000 description 4
- 208000029211 papillomatosis Diseases 0.000 description 4
- 208000007312 paraganglioma Diseases 0.000 description 4
- 208000028591 pheochromocytoma Diseases 0.000 description 4
- 208000010916 pituitary tumor Diseases 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 4
- 230000007115 recruitment Effects 0.000 description 4
- 206010038038 rectal cancer Diseases 0.000 description 4
- 201000001275 rectum cancer Diseases 0.000 description 4
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 4
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 4
- 201000000849 skin cancer Diseases 0.000 description 4
- 201000002314 small intestine cancer Diseases 0.000 description 4
- 206010062261 spinal cord neoplasm Diseases 0.000 description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 description 4
- 208000037969 squamous neck cancer Diseases 0.000 description 4
- 238000007910 systemic administration Methods 0.000 description 4
- 201000002510 thyroid cancer Diseases 0.000 description 4
- 206010044412 transitional cell carcinoma Diseases 0.000 description 4
- 208000029387 trophoblastic neoplasm Diseases 0.000 description 4
- 229960004799 tryptophan Drugs 0.000 description 4
- 208000018417 undifferentiated high grade pleomorphic sarcoma of bone Diseases 0.000 description 4
- 201000011294 ureter cancer Diseases 0.000 description 4
- 201000005112 urinary bladder cancer Diseases 0.000 description 4
- 206010046766 uterine cancer Diseases 0.000 description 4
- 208000037965 uterine sarcoma Diseases 0.000 description 4
- 206010046885 vaginal cancer Diseases 0.000 description 4
- 208000013139 vaginal neoplasm Diseases 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 201000005102 vulva cancer Diseases 0.000 description 4
- YHTTWXCDIRTOQX-FQJIPJFPSA-N (6S,9S,15S,18R,23R,26S,29S)-18-amino-6-(4-aminobutyl)-9,26-bis(carboxymethyl)-15-[3-(diaminomethylideneamino)propyl]-2,5,8,11,14,17,25,28-octaoxo-20,21-dithia-1,4,7,10,13,16,24,27-octazabicyclo[27.3.0]dotriacontane-23-carboxylic acid Chemical compound NCCCC[C@@H]1NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]2CCCN2C(=O)CNC1=O)C(O)=O YHTTWXCDIRTOQX-FQJIPJFPSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- AWPSWILWXHEXFW-UHFFFAOYSA-N Annulin B Natural products O=C1C2=C(O)C(CC)=C(C)C=C2C(=O)C2=C1OC(C)(C(=O)OC)C(=O)C2(C)C AWPSWILWXHEXFW-UHFFFAOYSA-N 0.000 description 3
- 102000013918 Apolipoproteins E Human genes 0.000 description 3
- 108010025628 Apolipoproteins E Proteins 0.000 description 3
- 108010074708 B7-H1 Antigen Proteins 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010040721 Flagellin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 3
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 3
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 108010022871 N-end cysteine peptide tumor-homing peptide Proteins 0.000 description 3
- 102000012064 NLR Proteins Human genes 0.000 description 3
- 108091005686 NOD-like receptors Proteins 0.000 description 3
- XOJVVFBFDXDTEG-UHFFFAOYSA-N Norphytane Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 3
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108091005685 RIG-I-like receptors Proteins 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 3
- 102000004338 Transferrin Human genes 0.000 description 3
- 108090000901 Transferrin Proteins 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 230000000240 adjuvant effect Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000008512 biological response Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000000495 cryogel Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 229940014144 folate Drugs 0.000 description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 210000005007 innate immune system Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229910044991 metal oxide Inorganic materials 0.000 description 3
- 150000004706 metal oxides Chemical class 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 3
- 229960003301 nivolumab Drugs 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 3
- 244000309459 oncolytic virus Species 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 229920001059 synthetic polymer Polymers 0.000 description 3
- 229910052715 tantalum Inorganic materials 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 239000012581 transferrin Substances 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 230000001173 tumoral effect Effects 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 108090000342 C-Type Lectins Proteins 0.000 description 2
- 102000003930 C-Type Lectins Human genes 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 2
- 101000979572 Homo sapiens NLR family CARD domain-containing protein 4 Proteins 0.000 description 2
- 101001125026 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 2 Proteins 0.000 description 2
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 description 2
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 2
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 2
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 description 2
- 102100023435 NLR family CARD domain-containing protein 4 Human genes 0.000 description 2
- 108091008099 NLRP3 inflammasome Proteins 0.000 description 2
- CZCIKBSVHDNIDH-UHFFFAOYSA-N Nalpha-methyl-DL-tryptophan Natural products C1=CC=C2C(CC(NC)C(O)=O)=CNC2=C1 CZCIKBSVHDNIDH-UHFFFAOYSA-N 0.000 description 2
- 102100029441 Nucleotide-binding oligomerization domain-containing protein 2 Human genes 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000125945 Protoparvovirus Species 0.000 description 2
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 description 2
- 101500027983 Rattus norvegicus Octadecaneuropeptide Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 208000021388 Sezary disease Diseases 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 2
- 102100039357 Toll-like receptor 5 Human genes 0.000 description 2
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 description 2
- 102000057288 Tryptophan 2,3-dioxygenases Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 229950002916 avelumab Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000011852 carbon nanoparticle Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- GNTDGMZSJNCJKK-UHFFFAOYSA-N divanadium pentaoxide Chemical compound O=[V](=O)O[V](=O)=O GNTDGMZSJNCJKK-UHFFFAOYSA-N 0.000 description 2
- 229950009791 durvalumab Drugs 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 229960002751 imiquimod Drugs 0.000 description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000037451 immune surveillance Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002048 multi walled nanotube Substances 0.000 description 2
- 239000002135 nanosheet Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920003213 poly(N-isopropyl acrylamide) Polymers 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 239000004632 polycaprolactone Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 229910001404 rare earth metal oxide Inorganic materials 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000002109 single walled nanotube Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000005909 tumor killing Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 229940124931 vaccine adjuvant Drugs 0.000 description 2
- 239000012646 vaccine adjuvant Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 description 1
- XFQPQSJDMJVOBN-UHFFFAOYSA-N 1-[4-amino-2-(ethylaminomethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.C1=CC=CC2=C(N(C(CNCC)=N3)CC(C)(C)O)C3=C(N)N=C21 XFQPQSJDMJVOBN-UHFFFAOYSA-N 0.000 description 1
- KXGFMDJXCMQABM-UHFFFAOYSA-N 2-methoxy-6-methylphenol Chemical compound [CH]OC1=CC=CC([CH])=C1O KXGFMDJXCMQABM-UHFFFAOYSA-N 0.000 description 1
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 241000531891 Alburnus alburnus Species 0.000 description 1
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 1
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 101000950671 Chelon ramada Myosin light chain 3, skeletal muscle isoform Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 239000005751 Copper oxide Substances 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 101710168479 Granulysin Proteins 0.000 description 1
- 102100021186 Granulysin Human genes 0.000 description 1
- 108020005004 Guide RNA Proteins 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101710168537 High mobility group protein B1 Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 description 1
- 101001037261 Homo sapiens Indoleamine 2,3-dioxygenase 2 Proteins 0.000 description 1
- 101001011382 Homo sapiens Interferon regulatory factor 3 Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101001052506 Homo sapiens Microtubule-associated proteins 1A/1B light chain 3A Proteins 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102100040062 Indoleamine 2,3-dioxygenase 2 Human genes 0.000 description 1
- 102100029843 Interferon regulatory factor 3 Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 description 1
- 101710085994 Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 238000000719 MTS assay Methods 0.000 description 1
- 231100000070 MTS assay Toxicity 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
- 102100024178 Microtubule-associated proteins 1A/1B light chain 3A Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 229910020039 NbSe2 Inorganic materials 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920002560 Polyethylene Glycol 3000 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 1
- 102000000033 Purinergic Receptors Human genes 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 238000005741 Steglich esterification reaction Methods 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000012082 adaptor molecule Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000004908 autophagic flux Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 101150038500 cas9 gene Proteins 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910000431 copper oxide Inorganic materials 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 229940115080 doxil Drugs 0.000 description 1
- 239000003118 drug derivative Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000802 evaporation-induced self-assembly Methods 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940124670 gardiquimod Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEKANFGSDXODPD-UHFFFAOYSA-N glyphosate-isopropylammonium Chemical compound CC(C)N.OC(=O)CNCP(O)(O)=O ZEKANFGSDXODPD-UHFFFAOYSA-N 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000013388 immunohistochemistry analysis Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229910021644 lanthanide ion Inorganic materials 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 239000013335 mesoporous material Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000006676 mitochondrial damage Effects 0.000 description 1
- 229910052982 molybdenum disulfide Inorganic materials 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- SIEJRHKKLYOLQD-UHFFFAOYSA-N n'-(4-fluorophenyl)-1-methylimidazole-4-carboximidamide Chemical compound CN1C=NC(C(N)=NC=2C=CC(F)=CC=2)=C1 SIEJRHKKLYOLQD-UHFFFAOYSA-N 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 239000002073 nanorod Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229910052758 niobium Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- VQWNELVFHZRFIB-UHFFFAOYSA-N odn 1826 Chemical compound O=C1NC(=O)C(C)=CN1C(O1)CC(O)C1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=NC=NC(N)=C3N=C2)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC(C(O1)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(O)=O)CC1N1C=C(C)C(=O)NC1=O VQWNELVFHZRFIB-UHFFFAOYSA-N 0.000 description 1
- KDWFDOFTPHDNJL-TUBOTVQJSA-N odn-2006 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=S)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=S)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(S)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)[C@@H](O)C1 KDWFDOFTPHDNJL-TUBOTVQJSA-N 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000000174 oncolytic effect Effects 0.000 description 1
- 229940026778 other chemotherapeutics in atc Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000003094 perturbing effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- 229920001568 phenolic resin Polymers 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000002186 photoactivation Effects 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000011164 primary particle Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006010 pyroptosis Effects 0.000 description 1
- UKHVLWKBNNSRRR-UHFFFAOYSA-M quaternium-15 Chemical compound [Cl-].C1N(C2)CN3CN2C[N+]1(CC=CCl)C3 UKHVLWKBNNSRRR-UHFFFAOYSA-M 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 1
- 229950010550 resiquimod Drugs 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000010944 silver (metal) Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000003980 solgel method Methods 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000010301 surface-oxidation reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 229940066453 tecentriq Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- PZJJKWKADRNWSW-UHFFFAOYSA-N trimethoxysilicon Chemical compound CO[Si](OC)OC PZJJKWKADRNWSW-UHFFFAOYSA-N 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000007794 visualization technique Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000013389 whole blood assay Methods 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
Definitions
- Pancreatic ductal adenocarcinoma is an almost uniformly fatal disease with a 5-year survival outcome of less than 6% (American Cancer Society, Cancer Facts & Figures 2014, Atlanta: American Cancer Society; 2014).
- PTX paclitaxel
- irinotecan delivery has had some survival impact (Frese et al. 92012) Cancer Discov. 2(3): 260-269; Passero et al. (2016) Exp. Rev. Anticancer Therap., 16(7): 697-703).
- PTX delivery by an albumin-nanocarrier can suppress the drug-resistant tumor stroma, allowing increased gemcitabine uptake
- the delivery of irinotecan by a liposome can improve drug pharmacokinetics.
- MSNP mesoporous silica nanoparticles
- ICD immune deplete into immune replete
- One approach was to induce immunogenic conditions at the tumor site by via induced cell death (ICD).
- ICD is a specialized form of tumor cell death (Kroemer et al. (2013) Ann. Rev. Immunol., 31: 51-72) that can be triggered by specific chemotherapeutic drugs (e.g. anthracyclines, taxanes, oxaliplatin, mitoxantrone), radiation therapy, or cytotoxic viruses.
- ICD facilitates tumor antigen cross-presentation in.
- CRT calreticulin
- HMGB-l a TLR-4 ligand
- ATP a signal that activates the NRLP3 inflammasome
- ICD indoleamine 2,3-dioxygenase
- the IDO pathway is a relevant metabolic immune checkpoint pathway in breast cancer (and other cancers such as pancreatic and colon cancer) because of its overexpression at the tumor site.
- IDO-l is the first and rate-limiting enzymatic step in the catabolism of tryptophan in the kynurenine pathway, and exerts potent immunosuppressive effects as a result of the metabolic disturbance of the amino acid ratios (see, e.g., Prendergast et al. (2017) Canc. Res., 77(24): 6795-6811; Lob et al. (2009) Nat. Rev.
- IDO l-methyl-tryptophan
- IND l-methyl-tryptophan
- IND indoximod
- Our own animal studies have demonstrated that the water insolubility of IND contributes to an unfavorable PK, short, circulatory half-life and inadequate tumor retention to effectively interfere in in the activity of IDO, which is overexpressed at the tumor site.
- IDO pathway inhibitors e.g., IND
- ICD inducers e.g., doxorubicin, mitoxantrone, etc.
- this goal was accomplished by synthesizing an IDO pathway inhibitor prodrug where the IDO inhibitor (e.g., indoximod) was conjugated to a lipid moiety (e.g., cholesterol or a phospholipid) that can be assembled into a lipid bilayer which can in turn be incorporated into a drug delivlery vehicle (e.g. ⁇ a liposome).
- a lipid moiety e.g., cholesterol or a phospholipid
- this can be accomplished by synthesizing IND as a phospholipid-conjugated (or cholesterol-conjugated) prodrug that can self-assembles to form a nanovesicle (e.g., a liposome).
- a nanovesicle e.g., a liposome.
- an ICD inducer e.g., DOX, mitoxantrone (MTX), etc.
- a doxorubicin (DOX) or mitoxantrone (MTX) encapsulating nanocarrier provides a more potent ICD stimulus than the free drug, and can do so synergistically with a small molecule inhibitor (e.g., indoximod) of the IDO-l pathway. It is believed the nanocarrier is capable of facilitating this task, in part, by improving the PK of DOX and indoximod (IND) at the tumor site.
- DOX doxorubicin
- MTX mitoxantrone
- compositions and methods are provided for systemic and/or for local (peri- or intratumoral) delivery of one or more ICD-inducing agents (e.g., doxorubicin, oxaliplatin, etc.) in conjunction with delivery of an inhibitor of the IDO pathway (e.g., indoximod).
- ICD-inducing agents e.g., doxorubicin, oxaliplatin, etc.
- the IDO inhibitor is conjugated to a nanovesicle-forming moiety (e.g., comprising a phospholipid bilayer).
- a nanovesicle-forming moiety e.g., comprising a phospholipid bilayer.
- an ICD-inducing agent e.g., oxaliplatin, doxorubicin, mitoxantrone, irinotecan etc.
- an IDO inhibiting agent e.g., an IDO inhibitor -prodrug
- compositions and methods are provided for the treatment or prevention of a cancer via vaccination (e.g., subcutaneous vaccination), utilizing certain cancer cells (e.g., drug-treated cancer cells) in which ICD has been induced ex vivo.
- vaccination e.g., subcutaneous vaccination
- cancer cells e.g., drug-treated cancer cells
- ICD has been induced ex vivo.
- Various embodiments contemplated herein may include, but need not be limited to, one or more of the following:
- Embodiment 1 A composition comprising an IDO inhibitor conjugated to a moiety that forms a nanovesicle in aqueous solution.
- Embodiment 2 The composition of embodiment 1, wherein said IDO inhibitor is conjugated to a moiety selected from the group consisting of a lipid, a phospholipid, vitamin E, cholesterol, and a fatty acid.
- Embodiment 3 The composition according to any one of embodiments 1-2, wherein IDO inhibitor is conjugated directly to said moiety.
- Embodiment 4 The composition according to any one of embodiments 1-2, wherein IDO inhibitor is conjugated to said moiety via a linker.
- Embodiment 6 The composition according to any one of embodiments 2-5, wherein said IDO inhibitor is conjugated to cholesterol (CHOL).
- Embodiment 7 The composition according to any one of embodiments 1-6, wherein said IDO inhibitor comprises an agent selected from the group consisting of D-1- methyl-tryptophan (indoximod, D-1MT), L-1-methyl-tryptophan (L-1MT), a mixture of D- 1MT and L-1MT, 1-methyl-L-tryptophan (L-1MT), methylthiohydantoin-dl-tryptophan (MTH-Trp, Necrostatin), ⁇ -carbolines (e.g., 3-butyl- ⁇ -carboline), Naphthoquinone-based (e.g., annulin-B), S-allyl-brassinin, S-benzyl-brassinin, N-[2-(Indol-3-yl)ethyl]-S-
- Embodiment 8 The composition of embodiment 7, wherein said IDO inhibitor comprises 1-methyl-tryptophan.
- Embodiment 9 The composition of embodiment 8, wherein said IDO inhibitor comprises a D isomer of 1-methyl-tryptophpan.
- Embodiment 10 The composition of embodiment 8, wherein said IDO inhibitor comprises an L isomer of 1-methyl-tryptophpan.
- Embodiment 11 The composition of embodiment 8, wherein said IDO inhibitor comprises a mixture of D and L isomers of 1-methyl-tryptophpan.
- Embodiment 12 The composition of embodiment 8, wherein the IDO inhibitor conjugated to cholesterol comprises a compound having the structure:
- Embodiment 13 The composition of embodiment 8, wherein the IDO inhibitor conjugated to cholesterol comprises a compound having the structure: [0027]
- Embodiment 14 The composition of embodiment 8, wherein the IDO inhibitor conjugated to cholesterol comprises a compound having the structure: [0028]
- Embodiment 15 The composition according to any one of embodiments 1-14, wherein the conjugated IDO inhibitor forms a component of a vesicle.
- Embodiment 16 A nanovesicle drug carrier for the combined delivery of an IDO inhibitor and an inducer of immunogenic cell death (ICD), said nanovesicle drug carrier comprising: a lipid vesicle wherein said lipid vesicle comprises a lipid effective to form a vesicle comprising a lipid bilayer in an aqueous solution, where said lipid bilayer comprises a composition according to any one of embodiments 1-15; and a cargo within said vesicle where said cargo comprises an agent that induces immunogenic cell death (ICD) (ICD- inducer).
- ICD immunogenic cell death
- Embodiment 17 The nanovesicle drug carrier of embodiment 16, wherein said drug carrier contains a predefined ratio of IDO inhibitor to ICD-inducer.
- Embodiment 18 The nanovesicle drug carrier of according to any one of embodiments 16-17, wherein said lipid bilayer comprises a phospholipid, and cholesterol (CHOL).
- Embodiment 19 The nanovesicle drug carrier according to any one of embodiments 16-18, wherein said lipid bilayer comprises a phospholipid, and cholesterol- IND (Chol-IND).
- Embodiment 20 The nanovesicle drug carrier according to any one of embodiments 18-19, wherein said phospholipid comprises a saturated fatty acid with a C14- C20 carbon chain, and/or an unsaturated fatty acid with a C14-C20 carbon chain, and/or a natural lipid comprising a mixture of fatty acids with C12-C20 carbon chains.
- Embodiment 21 The nanovesicle drug carrier of embodiment 20, wherein said phospholipid comprises a phospholipid selected from the group consisting of phosphatidylcholine (DPPC), 1,2-dimyristoleoyl-sn-glycero-3-phosphocholine (DMPC), 1,2- dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-distearoyl-sn-glycero-3-phospho-rac- glycerol (DSPG), 1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol (DPPG), distearoylphosphatidylcholine (DSPC), 1,2-dieicosenoyl-sn-glycero-3-phosphocholine, and diactylphosphatidylcholine (DAPC).
- DPPC phosphatidylcholine
- DMPC 1,2-dimyristoleoyl-sn-glycero-3-phosphocholine
- Embodiment 22 The nanovesicle drug carrier of embodiment 20, wherein said phospholipid comprises a natural lipid selected from the group consisting of egg phosphatidylcholine (egg PC), and soy phosphatidylcholine (soy PC).
- Embodiment 23 The nanovesicle drug carrier of embodiment 20, wherein said phospholipid comprises distearoylphosphatidylcholine (DSPC).
- Embodiment 24 The nanovesicle drug carrier according to any one of embodiments 19-23, wherein said lipid bilayer comprises an mPEG phospholipid with a phospholipid C14-C18 carbon chain, and a PEG molecular weight ranging from about 350 Da to 5000 Da.
- Embodiment 25 The nanovesicle drug carrier of embodiment 24, wherein said lipid bilayer comprises 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-PEG (DSPE- PEG).
- Embodiment 26 The nanovesicle drug carrier of embodiment 25, wherein said DSPE-PEG comprises DPSE-PEG 2K .
- Embodiment 27 The nanovesicle drug carrier of embodiment 25, wherein said DSPE-PEG comprises DPSE-PEG5K.
- Embodiment 28 The nanovesicle drug carrier according to any one of embodiments 23-27, wherein said lipid bilayer comprises DSPC : Chol-IND : DSPE-PEG.
- Embodiment 29 The nanovesicle drug carrier of embodiment 28, wherein the ratio of DSPC:Chol-IND:DSPE-PEG ranges from 40-90% DSPC : 10%-50% Chol-IND : 1%-10% DSPE-PEG (molar ratio).
- Embodiment 30 The nanovesicle drug carrier of embodiment 29, wherein the ratio of DSPC:Chol-IND:DSPE-PEG is about 50:40:5 (molar ratio).
- Embodiment 31 The nano vesicle drug carrier according to any one of embodiments 23-27, wherein said lipid bilayer comprises DPPG : Chol-IND : DSPE-PEG.
- Embodiment 32 The nano vesicle drug carrier of embodiment 31, wherein the ratio of DPPG:Chol-IND:DSPE-PEG ranges from 40-90% DPPG : 10%-50% Chol-IND : 1%-10% DSPE-PEG (molar ratio).
- Embodiment 33 The nano vesicle drug carrier of embodiment 32, wherein the ratio of DPPG:Chol-IND:DSPE-PEG is about 50:40:5 (molar ratio).
- Embodiment 34 The nano vesicle drug carrier according to any one of embodiments 18-33, whrein said lipid bilayer comprises a cholesterol derivative selected from the group consisting of cholesterol hemisuccinate (CHEMS), lysine-based cholesterol (CHLYS), and PEGylated cholesterol (Chol-PEG).
- CHEMS cholesterol hemisuccinate
- CHLYS lysine-based cholesterol
- Chol-PEG PEGylated cholesterol
- Embodiment 35 The nano vesicle drug carrier of embodiment 34, wherein said lipid bilayer comprises CHEMS.
- Embodiment 36 The nanovesicle drug carrier of embodiment 35, wherein said bilayer comprises CHEMS ranging from about 5% (mol percent) up to about 30% total lipid.
- Embodiment 37 The nano vesicle drug carrier of embodiment 36, wherein said bilayer comprise about 10% or about 20% CHEMS or about 30% CHEMS or about 40% CHEMS.
- Embodiment 38 The nanovesicle drug carrier according to any one of embodiments 16-37, wherein the IDO inhibitor conjugated to cholesterol comprises a compound having the structure
- Embodiment 39 The nano vesicle drug carrier of embodiment 38, wherein the
- IDO inhibitor conjugated to cholesterol comprises a compound having the structure:
- Embodiment 40 The nano vesicle drug carrier of embodiment 38, wherein the IDO inhibitor conjugated to cholesterol comprises a compound having the stmcture:
- Embodiment 41 The nano vesicle drug carrier according to any one of embodiments 16-40, wherein said cargo within said vesicle comprises an agent selected from the group consisting of mitoxantrone (MTX), doxorubicin (DOX), oxaliplatin, anthracenedione, bleomycin, bortezomib, cisplatin, daunombicin, docetaxel, epirubicin, idarubicin, paclitaxel, R2016, cyclophosphamide, irinotecan and a bioreactive nanomaterial that induces ICD.
- MTX mitoxantrone
- DOX doxorubicin
- oxaliplatin anthracenedione
- bleomycin bleomycin
- bortezomib cisplatin
- daunombicin docetaxel
- epirubicin idarubicin
- paclitaxel paclitaxel
- Embodiment 42 The nano vesicle drug carrier of embodiment 41, wherein said cargo comprises mitoxantrone (MTX).
- Embodiment 43 The nano vesicle drug carrier of embodiment 41, wherein said cargo comprises oxaliplatin.
- Embodiment 44 The nanovesicle drug carrier of embodiment 41, wherein said cargo comprises doxorubicin.
- Embodiment 45 The nanovesicle drug carrier of embodiment 41, wherein said cargo comprises a bioreactive nanomaterial that induces ICD and/or innate immune activation.
- Embodiment 46 The nanovesicle drug carrier of embodiment 45, wherein said cargo comprises a nanomaterial that induces ICD where said nanomaterial is selected from the group consisting of CuO, Cu2O, Sb2O3, As2O3, Bi2O3, P2O3, ZnO, TiO2, graphene oxide, and bioreactive 2D materials other than graphene or graphene oxide.
- Embodiment 47 The nanovesicle drug carrier according to any one of embodiments 16-46, wherein when the cargo in the nanocarrier is a weak base, said carrier comprises a cargo-trapping agent.
- Embodiment 48 The nanovesicle drug carrier of embodiment 47, wherein said cargo trapping agent before reaction with the cargo drug loaded in the vesicle, is selected from the group consisting of citric acid, triethylammonium sucrose octasulfate (TEA8SOS), (NH 4 ) 2 SO 4 , an ammonium salt, a trimethylammonium salt, and a triethylammonium salt.
- TAA8SOS triethylammonium sucrose octasulfate
- NH 4 ) 2 SO 4 an ammonium salt
- a trimethylammonium salt a triethylammonium salt
- Embodiment 49 The nanovesicle drug carrier of embodiment 48, wherein said cargo-trapping agent before reaction with said drug is citric acid.
- Embodiment 50 The nanovesicle drug carrier of embodiment 48, wherein said cargo-trapping agent before reaction with said drug is ammonium sulfate.
- Embodiment 51 The nanovesicle drug carrier according to any one of embodiments 16-50, wherein said drug carrier is conjugated to a moiety selected from the group consisting of a targeting moiety, a fusogenic peptide, and a transport peptide.
- Embodiment 52 The nanovesicle drug carrier of embodiment 51, wherein said drug carrier is conjugated to a peptide that binds a receptor on a cancer cell or tumor blood vessel.
- Embodiment 53 The nanovesicle drug carrier of embodiment 52, wherein said drug carrier is conjugated to an iRGD peptide.
- Embodiment 54 The nanovesicle drug carrier of embodiment 52, wherein said drug carrier is conjugated to a targeting peptide shown in Table 5.
- Embodiment 55 The nanovesicle drug carrier according to any one of embodiments 51-54, wherein said drug carrier is conjugated to transferrin, and/or ApoE, and/or folate.
- Embodiment 56 The nanovesicle drug carrier according to any one of embodiments 51-55, wherein said drug carrier is conjugated to a targeting moiety that comprises an antibody that binds to a cancer marker.
- Embodiment 57 The nanovesicle drug carrier of embodiment 56, wherein said drug carrier is conjugated to a targeting moiety that comprises an antibody that binds a cancer marker shown in Table 4.
- Embodiment 58 The nanovesicle drug carrier according to any one of embodiments 56-57, wherein said antibody is selected from the group consisting of an intact immunoglobulin, an F(ab)'2, a Fab, a single chain antibody, a diabody, an affibody, a unibody, and a nanobody.
- Embodiment 59 The nanovesicle drug carrier according to any one of embodiments 16-58, wherein said drug carriers in suspension are stable for at least 1 month, or at least 2 months, or at least 3 months, or at least 4 months, or at least 5 months, or at least 6 months when stored at 4°C.
- Embodiment 60 The nanovesicle drug carrier according to any one of embodiments 16-59, wherein said nanoparticle drug carrier forms a stable suspension on rehydration after lyophilization.
- Embodiment 61 The nanovesicle drug carrier according to any one of embodiments 16-60, wherein said nanoparticle drug carriers, show reduced drug toxicity as compared to free drug.
- Embodiment 62 The nanovesicle drug carrier according to any one of embodiments 16-61, wherein said nanoparticle drug carrier has colloidal stability in physiological fluids with pH 7.4 and remains monodisperse to allow systemic biodistribution and is capable of entering a disease site by vascular leakage (EPR effect) or transcytosis.
- Embodiment 63 The nanovesicle drug carrier drug carrier according to any one of embodiments 16-62, wherein said carrier is colloidally stable.
- Embodiment 64 The nanovesicle drug carrier according to any one of embodiments 16-63, wherein the IDO inhibitor and the ICD inducer are synergistic in their activity against a cancer.
- Embodiment 65 The nanovesicle drug carrier according to any one of embodiments 16-64, wherein said drug carrier, when administered systemically, delivers an amount of an ICD inducer effective to induce or to facilitate induction of immunogenic cell death of a cancer cell at a tumor site.
- Embodiment 66 The nanovesicle drug carrier according to any one of embodiments 16-65, wherein said drug carrier, when administered systemically, delivers an amount of an IDO inhibitor to partially or fully inhibit the IDO enzyme or IDO pathway at a cancer site.
- Embodiment 67 A nanoparticle drug carrier for the combined delivery of an IDO inhibitor and an inducer of immunogenic cell death (ICD), said nanoparticle drug carrier comprising: a mesoporous silica nanoparticle having a surface and defining a plurality of pores that are suitable to receive molecules therein; a lipid bilayer coating the surface where said lipid bilayer comprises a composition according to any one of embodiments 1-15; and a cargo comprising an agent that induces immunogenic cell death (ICD) (ICD-inducer) disposed within said mesoporous silica particle; wherein the lipid bilayer is substantially continuous and encapsulates said nanoparticle stably sealing the plurality of pores.
- ICD immunogenic cell death
- Embodiment 68 The nanoparticle drug carrier of embodiment 67, wherein said nanoparticle drug carrier contains a predefined ratio of IDO inhibitor to ICD-inducer.
- Embodiment 69 The nanoparticle drug carrier according to any one of embodiments 67-68, wherein the IDO inhibitor and the ICD inducer are synergistic in their activity against a cancer.
- Embodiment 70 The nanoparticle drug carrier according to any one of embodiments 67-69, wherein said lipid bilayer comprises a phospholipid, and cholesterol (CHOL).
- Embodiment 71 The nanoparticle drug carrier according to any one of embodiments 67-70, wherein said lipid bilayer comprises a phospholipid, and cholesterol- IND (Chol-IND).
- Embodiment 72 The nanoparticle drug carrier according to any one of embodiments 70-71, wherein said phospholipid comprises a saturated fatty acid with a C14- C20 carbon chain, and/or an unsaturated fatty acid with a C14-C20 carbon chain, and/or a natural lipid comprising a mixture of fatty acids with C12-C20 carbon chains.
- Embodiment 73 The nanoparticle drug carrier of embodiment 72, wherein said phospholipid comprises a phospholipid selected from the group consisting of phosphatidylcholine (DPPC), 1,2-dimyristoleoyl-sn-glycero-3-phosphocholine (DMPC), 1,2- dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-distearoyl-sn-glycero-3-phospho-rac- glycerol (DSPG), 1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol (DPPG), distearoylphosphatidylcholine (DSPC), 1,2-dieicosenoyl-sn-glycero-3-phosphocholine, and diactylphosphatidylcholine (DAPC).
- DPPC phosphatidylcholine
- DMPC 1,2-dimyristoleoyl-sn-glycero-3-phosphocholine
- Embodiment 74 The nanoparticle drug carrier of embodiment 72, wherein said phospholipid comprises a natural lipid selected from the group consisting of egg phosphatidylcholine (egg PC), and soy phosphatidylcholine (soy PC).
- Embodiment 75 The nanoparticle drug carrier of embodiment 72, wherein said phospholipid comprises distearoylphosphatidylcholine (DSPC).
- Embodiment 76 The nanoparticle drug carrier according to any one of embodiments 71-75, wherein said lipid bilayer comprises an mPEG phospholipid with a phospholipid C14-C18 carbon chain, and a PEG molecular weight ranging from about 350 Da to 5000 Da.
- Embodiment 77 The nanoparticle drug carrier of embodiment 76, wherein said lipid bilayer comprises 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-PEG (DSPE- PEG).
- Embodiment 78 The nanoparticle drug carrier of embodiment 77, wherein said DSPE-PEG comprises DPSE-PEG2K.
- Embodiment 79 The nanoparticle drug carrier of embodiment 77, wherein said DSPE-PEG comprises DPSE-PEG5K.
- Embodiment 80 The nanoparticle drug carrier according to any one of embodiments 75-79, wherein said lipid bilayer comprises DSPC: Chol-IND : DSPE-PEG.
- Embodiment 81 The nanoparticle drug carrier of embodiment 80, wherein the ratio of DSPC:Chol-IND:DSPE-PEG ranges from 40-90% DSPC : 10%-50% Chol-IND : 1%-10% DSPE-PEG (molar ratio).
- Embodiment 82 The nanoparticle drug carrier of embodiment 81, wherein the ratio of DSPC:Chol-IND:DSPE-PEG is about 50:40:5 (molar ratio).
- Embodiment 83 The nanoparticle drug carrier according to any one of embodiments 75-79, wherein said lipid bilayer comprises DPPG: Chol-IND : DSPE-PEG.
- Embodiment 84 The nanoparticle drug carrier of embodiment 83, wherein the ratio of DPPG:Chol-IND:DSPE-PEG ranges from 40-90% DSPC : 10%-50% Chol-IND : 1%-10% DPPG-PEG (molar ratio).
- Embodiment 85 The nanoparticle drug carrier of embodiment 84, wherein the ratio of DPPG:Chol-IND:DSPE-PEG is about 50:40:5 (molar ratio).
- Embodiment 86 The nanoparticle drug carrier according to any one of embodiments 67-85, whrein said lipid bilayer comprises a cholesterol derivative selected from the group consisting of cholesterol hemisuccinate (CHEMS), lysine-based cholesterol (CHLYS), and PEGylated cholesterol (Chol-PEG).
- CHEMS cholesterol hemisuccinate
- CHLYS lysine-based cholesterol
- Chol-PEG PEGylated cholesterol
- Embodiment 87 The nanoparticle drug carrier of embodiment 86, wherein said lipid bilayer comprises CHEMS.
- Embodiment 88 The nanoparticle drug carrier of embodiment 87, wherein said bilayer comprises CHEMS ranging from about 5% (mol percent) up to about 30% total lipid.
- Embodiment 89 The nanoparticle drug carrier of embodiment 88, wherein said bilayer comprises about 10% or about 20% CHEMS or about 30% CHEMS or about 40% CHEMS.
- Embodiment 90 The nanoparticle drug carrier according to any one of embodiments 67-89, wherein the IDO inhibitor conjugated to cholesterol comprises a compound having the structure:
- Embodiment 91 The nanoparticle drug carrier of embodiment 90, wherein the IDO inhibitor conjugated to cholesterol comprises a compound having the structure:
- Embodiment 92 The nanoparticle drug carrier of embodiment 90, wherein the IDO inhibitor conjugated to cholesterol comprises a compound having the structure:
- Embodiment 93 The nanoparticle drug carrier according to any one of embodiments 67-92, wherein said cargo within said mesoporous silica nanoparticle comprises an agent selected from the group consisting of mitoxantrone (MTX), doxorubicin (DOX), oxaliplatin, anthracenedione, bleomycin, bortezomib, cisplatin, daunorubicin, docetaxel, irinotecan , epirubicin, idarubicin, paclitaxel, R2016, cyclophosphamide, and a bioreactive nanomaterial that induces ICD.
- MTX mitoxantrone
- DOX doxorubicin
- oxaliplatin anthracenedione
- bleomycin bleomycin
- bortezomib cisplatin
- daunorubicin docetaxel
- irinotecan epirubicin
- Embodiment 94 The nanoparticle drug carrier of embodiment 93, wherein said cargo comprises mitoxantrone (MTX).
- Embodiment 95 The nanoparticle drug carrier of embodiment 93, wherein said cargo comprises oxaliplatin.
- Embodiment 96 The nanoparticle drug carrier of embodiment 93, wherein said cargo comprises doxorubicin.
- Embodiment 97 The nanoparticle drug carrier according to any one of embodiments 67-96, wherein when the cargo in the nanocarrier is a weak base, said carrier comprises a cargo-trapping agent.
- Embodiment 98 The nanoparticle drug carrier of embodiment 97, wherein said cargo trapping agent before reaction with the cargo drug loaded in the vesicle, is selected from the group consisting of citric acid, triethylammonium sucrose octasulfate (TEA8SOS), (NH 4 ) 2 SO 4 , an ammonium salt, a trimethylammonium salt, and a triethylammonium salt.
- Embodiment 99 The nanoparticle drug carrier of embodiment 98, wherein said cargo-trapping agent before reaction with said drug is citric acid.
- Embodiment 100 The nanoparticle drug carrier of embodiment 98, wherein said cargo-trapping agent before reaction with said drug is ammonium sulfate.
- Embodiment 101 The nanoparticle drug carrier according to any one of embodiments 67-100, wherein said drug carrier is conjugated to a moiety selected from the group consisting of a targeting moiety, a fusogenic peptide, and a transport peptide.
- Embodiment 102 The nanoparticle drug carrier of embodiment 101, wherein said drug carrier is conjugated to a peptide that binds a receptor on a cancer cell or tumor blood vessel.
- Embodiment 103 The nanoparticle drug carrier of embodiment 102, wherein said drug carrier is conjugated to an iRGD peptide.
- Embodiment 104 The nanoparticle drug carrier of embodiment 102, wherein said drug carrier is conjugated to a targeting peptide shown in Table 5.
- Embodiment 105 The nanoparticle drug carrier according to any one of embodiments 101-104, wherein said drug carrier is conjugated to transferrin, and/or ApoE, and/or folate.
- Embodiment 106 The nanoparticle drug carrier according to any one of embodiments 101-105, wherein said drug carrier is conjugated to a targeting moiety that comprises an antibody that binds to a cancer marker.
- Embodiment 107 The nanoparticle drug carrier of embodiment 106, wherein said drag carrier is conjugated to a targeting moiety that comprises an antibody that binds a cancer marker shown in Table 4.
- Embodiment 108 The nanoparticle drug carrier according to any one of embodiments 106-107, wherein said antibody is selected from the group consisting of an intact immunoglobulin, an F(ab)'2, a Fab, a single chain antibody, a diabody, an affibody, a unibody, and a nanobody.
- Embodiment 109 The nanoparticle drug carrier according to any one of embodiments 67-108, wherein said drug carriers in suspension are stable for at least 1 month, or at least 2 months, or at least 3 months, or at least 4 months, or at least 5 months, or at least 6 months when stored at 4°C.
- Embodiment 110 The nanoparticle drug carrier according to any one of embodiments 67-109, wherein said nanoparticle drag carrier forms a stable suspension on rehydration after lyophilization.
- Embodiment 111 The nanoparticle drug carrier according to any one of embodiments 67-110, wherein said nanoparticle drug carriers, show reduced drag toxicity as compared to free drag.
- Embodiment 112 The nanoparticle drug carrier according to any one of embodiments 67-111, wherein said nanoparticle drag carrier has colloidal stability in physiological fluids with pH 7.4 and remains monodisperse to allow systemic biodistribution and is capable of entering a disease site by vascular leakage (EPR effect) or transcytosis.
- EPR effect vascular leakage
- Embodiment 113 The nanoparticle drug carrier drug carrier according to any one of embodiments 67-112, wherein said carrier is colloidally stable.
- Embodiment 114 The nanoparticle drug carrier according to any one of embodiments 67-113, wherein the IDO inhibitor and the ICD inducer are synergistic in their activity against a cancer.
- Embodiment 115 The nanoparticle drug carrier according to any one of embodiments 67-114, wherein said drug carrier, when administered systemically, delivers an amount of an ICD inducer effective to induce or to facilitate induction of immunogenic cell death of a cancer cell at a tumor site.
- Embodiment 116 The nanoparticle drug carrier according to any one of embodiments 67-115, wherein said drug carrier, when administered systemically, delivers an amount of an IDO inhibitor to partially or fully inhibit the IDO enzyme or IDO pathway at a cancer site.
- Embodiment 117 A nanomaterial carrier for the combined delivery of an IDO inhibitor and an inducer of immunogenic cell death (ICD), said nanomaterial carrier comprising: a nanomaterial that induces ICD; and a lipid or lipid formulation comprising a composition according to any one of embodiments 1-15, where said lipid or lipid formulation is disposed on the surface of said nanomaterial.
- ICD immunogenic cell death
- Embodiment 118 The nanomaterial carrier of embodiments 117, wherein said nanomaterial comprises a material selected from the group consisting of CuO, Cu 2 O, Sb2O3, As2O3, Bi2O3, P2O3, ZnO, TiO2, graphene oxide, and 2D materials other than graphene or graphene oxide.
- Embodiment 119 The nanomaterial carrier according to any one of embodiments 117-118, wherein said lipid or lipid formulation fully encapsulates said nanomaterial.
- Embodiment 120 The nanomaterial carrier according to any one of embodiments 117-119, wherein said lipid or lipid formulation is not a lipid bilayer.
- Embodiment 121 The nanomaterial carrier according to any one of embodiments 117-119, wherein said lipid or lipid formulation comprises a lipid bilayer.
- Embodiment 122 The nanomaterial carrier of according to any one of embodiments 117-121, wherein said lipid or lipid formulation comprises a phospholipid, and cholesterol (CHOL).
- Embodiment 123 The nanomaterial carrier according to any one of embodiments 117-122, wherein said lipid or lipid formulation comprises a phospholipid, and cholesterol-IND (Chol-IND).
- Embodiment 124 The nanomaterial carrier according to any one of embodiments 18-123, wherein said phospholipid comprises a saturated fatty acid with a C14- C20 carbon chain, and/or an unsaturated fatty acid with a C14-C20 carbon chain, and/or a natural lipid comprising a mixture of fatty acids with C12-C20 carbon chains.
- Embodiment 125 The nanomaterial carrier of embodiment 124, wherein said phospholipid comprises a phospholipid selected from the group consisting of phosphatidylcholine (DPPC), 1,2-dimyristoleoyl-sn-glycero-3-phosphocholine (DMPC), 1,2- dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-distearoyl-sn-glycero-3-phospho-rac- glycerol (DSPG), 1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol (DPPG), distearoylphosphatidylcholine (DSPC), 1,2-dieicosenoyl-sn-glycero-3-phosphocholine, and diactylphosphatidylcholine (DAPC).
- DPPC phosphatidylcholine
- DMPC 1,2-dimyristoleoyl-sn-glycero-3-phosphocholine
- Embodiment 126 The nanomaterial carrier of embodiment 124, wherein said phospholipid comprises a natural lipid selected from the group consisting of egg phosphatidylcholine (egg PC), and soy phosphatidylcholine (soy PC).
- Embodiment 127 The nanomaterial carrier of embodiment 124, wherein said phospholipid comprises distearoylphosphatidylcholine (DSPC).
- Embodiment 128 The nanomaterial carrier according to any one of embodiments 123-127, wherein said lipid or lipid formulation comprises an mPEG phospholipid with a phospholipid C14-C18 carbon chain, and a PEG molecular weight ranging from about 350 Da to 5000 Da.
- Embodiment 129 The nanomaterial carrier of embodiment 128, wherein said lipid or lipid formulation comprises 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-PEG (DSPE-PEG).
- Embodiment 130 The nanomaterial carrier of embodiment 129, wherein said DSPE_PEG comprises DPSE-PEG2K.
- Embodiment 131 The nanomaterial carrier of embodiment 129, wherein said DSPE_PEG comprises DPSE-PEG5K.
- Embodiment 132 The nanomaterial carrier according to any one of embodiments 127-131, wherein said lipid or lipid formulation comprises DSPC : Chol-IND : DSPE-PEG.
- Embodiment 133 The nanomaterial carrier of embodiment 132, wherein the ratio of DSPC:Chol-IND:DSPE-PEG ranges from 40-90% DSPC : 10%-50% Chol-IND : 1%-10% DSPE-PEG (molar ratio).
- Embodiment 134 The nanomaterial carrier of embodiment 133, wherein the ratio of DSPC:Chol-IND:DSPE-PEG is about 50:40:5 (molar ratio).
- Embodiment 135 The nanomaterial carrier according to any one of embodiments 127-131, wherein said lipid or lipid formulation comprises DPPG : Chol-IND : DSPE-PEG.
- Embodiment 136 The nanomaterial carrier of embodiment 135, wherein the ratio of DPPG:Chol-IND:DSPE-PEG ranges from 40-90% DPPG : 10%-50% Chol-IND : 1%-10% DSPE-PEG (molar ratio).
- Embodiment 137 The nanomaterial carrier of embodiment 136, wherein the ratio of DPPG:Chol-IND:DSPE-PEG is about 50:40:5 (molar ratio).
- Embodiment 138 The nanomaterial carrier according to any one of embodiments 122-137, whrein said lipid or lipid formulation comprises a cholesterol derivative selected from the group consisting of cholesterol hemisuccinate (CHEMS), lysine- based cholesterol (CHLYS), and PEGylated cholesterol (Chol-PEG).
- Embodiment 139 The nanomaterial carrier of embodiment 138, wherein said lipid or lipid formulation comprises CHEMS.
- Embodiment 140 The nanomaterial carrier of embodiment 139, wherein said bilayer comprises CHEMS ranging from about 5% (mol percent) up to about 30% total lipid.
- Embodiment 141 The nanomaterial carrier of embodiment 140, wherein said bilayer comprise about 10% or about 20% CHEMS.
- Embodiment 142 The nanomaterial carrier according to any one of embodiments 117-141, wherein said drug carrier is conjugated to a moiety selected from the group consisting of a targeting moiety, a fusogenic peptide, and a transport peptide.
- Embodiment 143 The nanomaterial carrier of embodiment 142, wherein said drug carrier is conjugated to a peptide that binds a receptor on a cancer cell or tumor blood vessel.
- Embodiment 144 The nanomaterial carrier of embodiment 143, wherein said drug carrier is conjugated to an iRGD peptide.
- Embodiment 145 The nanomaterial carrier of embodiment 143, wherein said drug carrier is conjugated to a targeting peptide shown in Table 5.
- Embodiment 146 The nanomaterial carrier according to any one of embodiments 142-145, wherein said drug carrier is conjugated to transferrin, and/or ApoE, and/or folate.
- Embodiment 147 The nanomaterial carrier according to any one of embodiments 142-146, wherein said dmg carrier is conjugated to a targeting moiety that comprises an antibody that binds to a cancer marker.
- Embodiment 148 The nanomaterial carrier of embodiment 147, wherein said dmg carrier is conjugated to a targeting moiety that comprises an antibody that binds a cancer marker shown in Table 4.
- Embodiment 149 The nanomaterial carrier according to any one of embodiments 147-148, wherein said antibody is selected from the group consisting of an intact immunoglobulin, an F(ab)'2, a Fab, a single chain antibody, a diabody, an affibody, a unibody, and a nanobody.
- Embodiment 150 The nanomaterial carrier according to any one of embodiments 117-149, wherein said dmg carriers in suspension are stable for at least 1 month, or at least 2 months, or at least 3 months, or at least 4 months, or at least 5 months, or at least 6 months when stored at 4°C.
- Embodiment 151 The nanomaterial carrier according to any one of embodiments 117-150, wherein said nanoparticle dmg carrier forms a stable suspension on rehydration after lyophilization.
- Embodiment 152 The nanomaterial carrier according to any one of embodiments 117-151, wherein said nanoparticle dmg carriers, show reduced dmg toxicity as compared to free dmg.
- Embodiment 153 The nanomaterial carrier according to any one of embodiments 117-152, wherein said nanoparticle drug carrier has colloidal stability in physiological fluids with pH 7.4 and remains monodisperse to allow systemic biodistribution and is capable of entering a disease site by vascular leakage (EPR effect) or transcytosis.
- EPR effect vascular leakage
- Embodiment 154 The nanomaterial carrier drug carrier according to any one of embodiments 117-153, wherein said carrier is colloidally stable.
- Embodiment 155 The nanomaterial carrier according to any one of embodiments 117-154, wherein the IDO inhibitor and the ICD inducer are synergistic in their activity against a cancer.
- Embodiment 156 The nanomaterial carrier according to any one of embodiments 117-155, wherein said drug carrier, when administered systemically, delivers an amount of an ICD inducer effective to induce or to facilitate induction of immunogenic cell death of a cancer cell at a tumor site.
- Embodiment 157 The nanomaterial carrier according to any one of embodiments 117-156, wherein said dmg carrier, when administered systemically, delivers an amount of an IDO inhibitor to partially or fully inhibit the IDO enzyme or IDO pathway at a cancer site.
- Embodiment 158 A pharmaceutical formulation comprising: a composition according to any one of embodiments 1-15 and a pharmaceutically acceptable carrier; and/or a nanovesicle drug carrier according to any one of embodiments 16-66 and a pharmaceutically acceptable carrier; and/or a nanoparticle drug carrier according to any one of embodiments 67-116 and a pharmaceutically acceptable carrier; and/or a nanomaterial carrier according to any one of embodiments 117-157 and a pharmaceutically acceptable carrier.
- Embodiment 159 The pharmaceutical formulation of embodiment 158, wherein said formulation comprises a composition according to any one of embodiments 1- 15 and a pharmaceutically acceptable carrier.
- Embodiment 160 The pharmaceutical formulation of embodiment 158, wherein said formulation comprises a nanovesicle drug carrier according to any one of embodiments 16-66 and a pharmaceutically acceptable carrier.
- Embodiment 161 The pharmaceutical formulation of embodiment 158, wherein said formulation comprises a nanoparticle drug carrier according to any one of embodiments 67-116 and a pharmaceutically acceptable carrier.
- Embodiment 162 The pharmaceutical formulation of embodiment 158, wherein said formulation comprises a nanomaterial carrier according to any one of embodiments 117-157 and a pharmaceutically acceptable carrier.
- Embodiment 163 The pharmaceutical formulation according to any one of embodiments 158-162, wherein said formulation is an emulsion, dispersion, or suspension.
- Embodiment 164 The pharmaceutical formulation of embodiment 163, wherein said suspension, emulsion, or dispersion is stable for at least 1 month, or at least 2 months, or at least 3 months, or at least 4 months, or at least 5 months, or at least 6 months when stored at 4°C.
- Embodiment 165 The pharmaceutical formulation according to any one of embodiments 158-164, wherein the nanovesicle drug carriers, and/or the a nanoparticle drug carriers, and/or the a nanomaterial carriers in said formulation show a substantially unimodal size distribution; and/or show a PDI less than about 0.2, or less than about 0.1.
- Embodiment 166 The pharmaceutical formulation according to any one of embodiments 158-165, wherein said formulation is formulated for administration via a route selected from the group consisting of intravenous administration, intraarterial administration, intracerebral administration, intrathecal administration, oral administration, aerosol administration, administration via inhalation (including intranasal and intratracheal delivery, intracranial administration via a cannula, and subcutaneous or intramuscular depot deposition.
- Embodiment 167 The pharmaceutical formulation according to any one of embodiments 158-165, wherein said formulation is a sterile injectable.
- Embodiment 168 The pharmaceutical formulation according to any one of embodiments 158-167, wherein said formulation is a unit dosage formulation.
- Embodiment 169 A method of treating a cancer, said method comprising: administering to a subject in need thereof an effective amount of: a composition according to any one of embodiments 1-15; and/or a nanovesicle drug carrier according to any one of embodiments 16-66; and/or a nanoparticle drug carrier according to any one of embodiments 67-116; and/or a nanomaterial carrier according to any one of embodiments 117-157.
- Embodiment 170 The method of embodiment 169, wherein said method comprises administering to a subject in need thereof an effective amount of a nanovesicle drug carrier according to any one of embodiments 16-66.
- Embodiment 171 The method of embodiment 169, wherein said method comprises administering to a subject in need thereof an effective amount of a nanoparticle drug carrier according to any one of embodiments 67-116.
- Embodiment 172 The method of embodiment 169, wherein said method comprises administering to a subject in need thereof an effective amount of a nanomaterial carrier according to any one of embodiments 117-157.
- Embodiment 173 The method according to any one of embodiments 170-
- Embodiment 174 The method according to any one of embodiments 170-
- ICD-inducer is in an amount effective to elevate calreticulin (CRT) expression in cells of said cancer.
- CRT calreticulin
- Embodiment 175 The method according to any one of embodiments 170-
- ICD-inducer is in an amount effective to elevate expression and/or release of HMGB1 and/or induction of ATP release.
- Embodiment 176 The method according to any one of embodiments 170-
- said method comprises a primary therapy in a chemotherapeutic regimen.
- Embodiment 177 The method according to any one of embodiments 170-
- said method comprises an adjunct therapy in a treatment regime that additionally comprises chemotherapy using another chemotherapeutic agent, and/or surgical resection of a tumor mass, and/or radiotherapy.
- Embodiment 178 The method according to any one of embodiments 170- 177, wherein said composition, a nanovesicle drug carrier, a nanoparticle drug carrier according, and/or nanomaterial carrier is a component in a multi-drug chemotherapeutic regimen.
- Embodiment 179 The method according to any one of embodiments 170-
- cancer is pancreatic ductal adenocarcinoma (PDAC).
- PDAC pancreatic ductal adenocarcinoma
- Embodiment 180 The method according to any one of embodiments 170- 178, wherein said cancer is a cancer selected from the group consisting of breast cancer, lung cancer, melanoma, pancreas cancer, liver cancer, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), adrenocortical carcinoma, AIDS-related cancers (e.g., Kaposi sarcoma, lymphoma), anal cancer, appendix cancer, astrocytomas, atypical teratoid/rhabdoid tumor, bile duct cancer, extrahepatic cancer, bladder cancer, bone cancer (e.g., Ewing sarcoma, osteosarcoma, malignant fibrous histiocytoma), brain stem glioma, brain tumors (e.g., astrocytomas, brain and spinal cord tumors, brain stem glioma, central nervous system atypical teratoid/rhabdoid tumor,
- ALL acute
- bile extrahepatic
- ductal carcinoma in situ DCIS
- embryonal tumors endometrial cancer, ependymoma, esophageal cancer, esthesioneuroblastoma, extracranial germ cell tumor, extragonadal germ cell tumor, extrahepatic bile duct cancer, eye cancer (e.g., intraocular melanoma, retinoblastoma), fibrous histiocytoma of bone, malignant, and osteosarcoma, gallbladder cancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumors (GIST), germ cell tumors (e.g., ovarian cancer, testicular cancer, extracranial cancers, extragonadal cancers, central nervous system), gestational trophoblastic tumor, brain stem cancer, hairy cell leukemia, head and neck cancer, heart cancer, hepatocellular (liver) cancer, histiocytosis, langerhan
- Embodiment 181 The method according to any one of embodiments 170-
- administration is via a route selected from the group consisting of intravenous administration, intraarterial administration, intracerebral administration, intrathecal administration, oral administration, aerosol administration, administration via inhalation (including intranasal and intratracheal delivery, intracranial administration via a cannula, and subcutaneous or intramuscular depot deposition.
- Embodiment 182 The method according to any one of embodiments 170-
- said administration comprises systemic administration via injection or cannula.
- Embodiment 183 The method according to any one of embodiments 170-
- administration is administration to an intra-tumoral or peri-tumoral site.
- Embodiment 184 The method according to any one of embodiments 170- 183, wherein said mammal is a human.
- Embodiment 185 The method according to any one of embodiments 170- 183, wherein said mammal is a non-human mammal.
- Embodiment 186 The method according to any one of embodiments 170- 185, wherein said nanovesicle drug carrier is administered in conjunction with administration of an immune checkpoint inhibitor.
- Embodiment 187 The method of embodiment 186, wherein said immune checkpoint inhibitor comprises an inhibitor of PD-1, PD-L1, PD-L2, PD-L3, PD-L4, CTLA- 4, LAG3, B7-H3, B7-H4, KIR and/or TIM3.
- Embodiment 188 The method of embodiment 187, wherein said checkpoint inhibitor comprises an antibody that inhibits a moiety selected from the group consisting of PD-1, PD-L1, and CTLA4.
- Embodiment 189 The method of embodiment 188, wherein said antibody comprises an antibody that inhibits PD-1.
- Embodiment 190 The method of embodiment 189, wherein said antibody comprises Pembrolizumab (Keytruda), or Nivolumab (Opdivo).
- Embodiment 191 The method of embodiment 188, wherein said antibody comprises an antibody that inhibits PD-L1.
- Embodiment 192 The method of embodiment 191, wherein said antibody comprises Atezolizumab (Tecentriq), Avelumab (Bavencio), or Durvalumab (Imfinzi).
- Embodiment 193 The method of embodiment 188, wherein said antibody comprises an antibody that inhibits CTLA-4.
- Embodiment 194 The method of embodiment 193, wherein said antibody comprises Ipilimumab (Yervoy).
- Embodiment 195 The method according to any one of embodiments 186- 194, wherein the activity of said composition according to any one of embodiments 1-15; or said nanovesicle drug carrier according to any one of embodiments 16-66; or said nanoparticle drug carrier according to any one of embodiments 67-116; or said a nanomaterial carrier according to any one of embodiments 117-157 and said immune checkpoint inhibitor is synergistic.
- Embodiment 196 A method of treating a cancer in a mammal, said method comprising: administering to an intra-tumoral or peri-tumoral site an effective amount of: a composition according to any one of embodiments 1-15; and/or a nanovesicle drug carrier according to any one of embodiments 16-66; and/or a nanoparticle drug carrier according to any one of embodiments 67-116; and/or a nanomaterial carrier according to any one of embodiments 117-157.
- Embodiment 197 A kit for the treatment or prophylaxis of a cancer said kit comprising: a container containing: a composition according to any one of embodiments 1- 15; and/or a nanovesicle drug carrier according to any one of embodiments 16-66; and/or a nanoparticle drug carrier according to any one of embodiments 67-116; and/or a nanomaterial carrier according to any one of embodiments 117-157.
- Embodiment 198 A liposome comprising a lipid bilayer, where said liposome contains mitoxantrone.
- Embodiment 199 The liposome of embodiment 198, wherein said lipid bilayer comprises a phospholipid, and cholesterol (CHOL) and/or a cholesterol derivative.
- Embodiment 200 The liposome of embodiment 199, wherein said phospholipid comprises a saturated fatty acid with a C14-C20 carbon chain, and/or an unsaturated fatty acid with a C14-C20 carbon chain, and/or a natural lipid comprising a mixture of fatty acids with C12-C20 carbon chains.
- Embodiment 201 The liposome of embodiment 200, wherein said phospholipid comprises a phospholipid selected from the group consisting of phosphatidylcholine (DPPC), 1,2-dimyristoleoyl-sn-glycero-3-phosphocholine (DMPC), 1,2- dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-distearoyl-sn-glycero-3-phospho-rac- glycerol (DSPG), 1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol (DPPG), distearoylphosphatidylcholine (DSPC), 1,2-dieicosenoyl-sn-glycero-3-phosphocholine, and diactylphosphatidylcholine (DAPC).
- DPPC phosphatidylcholine
- DMPC 1,2-dimyristoleoyl-sn-glycero-3-phosphocholine
- Embodiment 202 The liposome of embodiment 200, wherein said phospholipid comprises a natural lipid selected from the group consisting of egg phosphatidylcholine (egg PC), and soy phosphatidylcholine (soy PC).
- Embodiment 203 The liposome of embodiment 200, wherein said phospholipid comprises distearoylphosphatidylcholine (DSPC).
- Embodiment 204 The liposome according to any one of embodiments 199- 203, wherein said lipid bilayer comprises an mPEG phospholipid with a phospholipid C14- C18 carbon chain, and a PEG molecular weight ranging from about 350 Da to 5000 Da.
- Embodiment 205 The liposome of embodiment 204, wherein said lipid bilayer comprises 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-PEG (DSPE-PEG).
- Embodiment 206 The liposome of embodiment 205, wherein said DSPE- PEG comprises DPSE-PEG 2K .
- Embodiment 207 The liposome of embodiment 205, wherein said DSPE- PEG comprises DPSE-PEG 5K .
- Embodiment 208 The liposome according to any one of embodiments 203- 207, wherein said lipid bilayer comprises DSPC : Chol : DSPE-PEG.
- Embodiment 209 The liposome of embodiment 208, wherein the ratio of DSPC:Chol-IND:DSPE-PEG ranges from 40-90% DSPC : 10%-50% Chol : 1%-10% DSPE- PEG (molar ratio).
- Embodiment 210 The liposome of embodiment 209, wherein the ratio of DSPC:Chol:DSPE-PEG is about 50:40:5 (molar ratio).
- Embodiment 211 The liposome according to any one of embodiments 203- 207, wherein said lipid bilayer comprises DPPG : Chol : DSPE-PEG.
- Embodiment 212 The liposome of embodiment 211, wherein the ratio of DPPG:Chol-IND:DSPE-PEG ranges from 40-90% DPPG : 10%-50% Chol : 1%-10% DSPE- PEG (molar ratio).
- Embodiment 213 The liposome of embodiment 212, wherein the ratio of DPPG:Chol:DSPE-PEG is about 50:40:5 (molar ratio).
- Embodiment 214 The liposome according to any one of embodiments 199- 213, whrein said lipid bilayer comprises a cholesterol derivative selected from the group consisting of cholesterol hemisuccinate (CHEMS), lysine-based cholesterol (CHLYS), and PEGylated cholesterol (Chol-PEG).
- Embodiment 215 The liposome of embodiment 214, wherein said lipid bilayer comprises CHEMS.
- Embodiment 216 The liposome of embodiment 215, wherein said bilayer comprises CHEMS ranging from about 5% (mol percent) up to about 30% total lipid.
- Embodiment 217 The liposome of embodiment 216, wherein said bilayer comprise about 10% or about 20% CHEMS or about 30% CHEMS or about 40% CHEMS.
- Embodiment 218 A pharmaceutical formulation comprising: a liposome according to any one of embodiments 198-217; and a pharmaceutically acceptable carrier.
- Embodiment 219 The pharmaceutical formulation of embodiment 218, wherein said formulation is an emulsion, dispersion, or suspension.
- Embodiment 220 The pharmaceutical formulation of embodiment 219, wherein said suspension, emulsion, or dispersion is stable for at least 1 month, or at least 2 months, or at least 3 months, or at least 4 months, or at least 5 months, or at least 6 months when stored at 4°C.
- Embodiment 221 The pharmaceutical formulation according to any one of embodiments 218-220, wherein the liposomes in said formulation show a substantially unimodal size distribution; and/or show a PDI less than about 0.2, or less than about 0.1.
- Embodiment 222 The pharmaceutical formulation according to any one of embodiments 218-221, wherein said formulation is formulated for administration via a route selected from the group consisting of intravenous administration, intraarterial administration, intracerebral administration, intrathecal administration, oral administration, aerosol administration, administration via inhalation (including intranasal and intratracheal delivery, intracranial administration via a cannula, and subcutaneous or intramuscular depot deposition.
- Embodiment 223 The pharmaceutical formulation according to any one of embodiments 218-221, wherein said formulation is a sterile injectable.
- Embodiment 224 The pharmaceutical formulation according to any one of embodiments 218-223, wherein said formulation is a unit dosage formulation.
- Embodiment 225 A method of treating a cancer, said method comprising: administering to a subject in need thereof an effective amount a liposome according to any one of embodiments 198-217.
- Embodiment 226 The method of embodiment 169, wherein said method comprises a primary therapy in a chemotherapeutic regimen.
- Embodiment 227 The method of embodiment 226, wherein said method comprises an adjunct therapy in a treatment regime that additionally comprises chemotherapy using another chemotherapeutic agent, and/or surgical resection of a tumor mass, and/or radiotherapy.
- Embodiment 228 The method of embodiment 169, wherein said composition, a nanovesicle drug carrier, a nanoparticle drug carrier according, and/or nanomaterial carrier is a component in a multi-drug chemotherapeutic regimen.
- Embodiment 229 The method according to any one of embodiments 169- 228, wherein said cancer is triple negative breast cancer.
- Embodiment 230 The method according to any one of embodiments 169-
- cancer is a cancer selected from the group consisting of breast cancer, lung cancer, melanoma, pancreas cancer, liver cancer, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), adrenocortical carcinoma, AIDS-related cancers (e.g., Kaposi sarcoma, lymphoma), anal cancer, appendix cancer, astrocytomas, atypical teratoid/rhabdoid tumor, bile duct cancer, extrahepatic cancer, bladder cancer, bone cancer (e.g., Ewing sarcoma, osteosarcoma, malignant fibrous histiocytoma), brain stem glioma, brain tumors (e.g., astrocytomas, brain and spinal cord tumors, brain stem glioma, central nervous system atypical teratoid/rhabdoid tumor, central nervous system embryonal tumors, central nervous system germ cell tumors, craniopharyn
- bile extrahepatic
- ductal carcinoma in situ DCIS
- embryonal tumors endometrial cancer, ependymoma, esophageal cancer, esthesioneuroblastoma, extracranial germ cell tumor, extragonadal germ cell tumor, extrahepatic bile duct cancer, eye cancer (e.g., intraocular melanoma, retinoblastoma), fibrous histiocytoma of bone, malignant, and osteosarcoma, gallbladder cancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumors (GIST), germ cell tumors (e.g., ovarian cancer, testicular cancer, extracranial cancers, extragonadal cancers, central nervous system), gestational trophoblastic tumor, brain stem cancer, hairy cell leukemia, head and neck cancer, heart cancer, hepatocellular (liver) cancer, histiocytosis, langerhan
- Embodiment 231 The method according to any one of embodiments 169- 230, wherein said administration is via a route selected from the group consisting of intravenous administration, intraarterial administration, intracerebral administration, intrathecal administration, oral administration, aerosol administration, administration via inhalation (including intranasal and intratracheal delivery, intracranial administration via a cannula, and subcutaneous or intramuscular depot deposition.
- Embodiment 232 The method according to any one of embodiments 169- 230, wherein said administration comprises systemic administration via injection or cannula.
- Embodiment 233 The method according to any one of embodiments 169- 230, wherein said administration is administration to an intra-tumoral or peri-tumoral site.
- Embodiment 234 The method according to any one of embodiments 169- 233, wherein said mammal is a human.
- Embodiment 235 The method according to any one of embodiments 169- 233, wherein said mammal is a non-human mammal.
- the agent(s) that induce ICD exclude cisplatin, and/or in certain embodiments the agent(s) that induce ICD exclude doxorubicin.
- a lipid/lipid bilayer comprises a an IDO inhibitor conjugated to cholesterol (e.g., IND-Chol)
- an IDO inhibitor conjugated to a cholesterol deriviative e.g., IND-CHEMS
- the IDO can be conjugated to the cholesterol (IND-Chol), to the cholesterol derivative (e.g., IND- CHEMS), or to both the cholesterol and to the cholesterol deriavative.
- the terms "subject,” “individual,” and “patient” may be used interchangeably and refer to humans, as well as non-human mammals (e.g., non-human primates, canines, equines, felines, porcines, bovines, ungulates, lagomorphs, and the like).
- the subject can be a human (e.g., adult male, adult female, adolescent male, adolescent female, male child, female child) under the care of a physician or other health worker in a hospital, as an outpatient, or other clinical context.
- the subject may not be under the care or prescription of a physician or other health worker.
- a subject in need thereof refers to a subject, as described infra, that suffers from, or is at risk for a cancer as described herein.
- the subject is a subject with a cancer (e.g., pancreatic ductal adenocarcinoma (PDAC), breast cancer (e.g., drug-resistant breast cancer), colon cancer, brain cancer, and the like).
- PDAC pancreatic ductal adenocarcinoma
- breast cancer e.g., drug-resistant breast cancer
- colon cancer e.g., brain cancer, and the like.
- the methods described herein are prophylactic and the subject is one in whom a cancer is to be inhibited or prevented.
- the subject for prophylaxis is one with a family history of cancer and/or a risk factor for a cancer (e.g., a genetic risk factor, an environmental exposure, and the like).
- a risk factor for a cancer e.g., a genetic risk factor, an environmental exposure, and the like.
- the term "treat" when used with reference to treating, e.g., a pathology or disease refers to the mitigation and/or elimination of one or more symptoms of that pathology or disease, and/or a delay in the progression and/or a reduction in the rate of onset or severity of one or more symptoms of that pathology or disease, and/or the prevention of that pathology or disease.
- treat can refer to prophylactic treatment which includes a delay in the onset or the prevention of the onset of a pathology or disease.
- coadministration indicates that the first compound (or component) and the second compound (or component) are administered so that there is at least some chronological overlap in the biological activity of first compound and the second compound in the organism to which they are administered.
- Coadministration can include simultaneous administration or sequential administration. In sequential administration there may even be some substantial delay (e.g., minutes or even hours) between administration of the first compound and the second compound as long as their biological activities overlap.
- the coadminstration is over a time frame that permits the first compound and second compound to produce an enhanced therapeutic or prophylactic effect on the organism.
- the enhanced effect is a synergistic effect.
- ICD immunogenic cell death
- cytostatic agents such as anthracyclines (Obeid et al. (2007) Nature Med., 13(1): 54-61), anthracenedione (mitoxantrone, aka MTX), oxaliplatin, irinotecan, and bortezomib, or radiotherapy and/or photodynamic therapy (PDT).
- immunogenic apoptosis of cancer cells can induce an effective antitumor immune response through activation of dendritic cells (DCs) and consequent activation of specific T cell response (Spisek and Dhodapkar (2007) Cell Cycle, 6(16): 1962-1965).
- DCs dendritic cells
- ROS reactive oxygen species
- ICD In addition to facilitating tumor cell death that facilitates antigen presentation by dendritic cells, ICD is characterized by secretion or release of damage-associated molecular patterns (DAMPs), which exert additional immune adjuvant effects.
- DAMPs damage-associated molecular patterns
- Calreticulin (CRT) one of the DAMP molecules, which is normally in the lumen of the ER, is translocated to the surface of dying cell where it functions as an “eat me” signal for phagocytes.
- Other important surface exposed DAMPs are heat-shock proteins (HSPs), namely HSP70 and HSP90, which under stress condition are also translocated to the plasma membrane.
- HSPs heat-shock proteins
- HMGB1 secreted amphoterin
- ATP e.g., Apetoh et al. (2007) Nature Med.13(9): 1050- 1059; Ghiringhelli et al. (2009) Nature Med.15(10): 1170-1178).
- HMGB1 is considered to be a late apoptotic marker and its release to the extracellular space appears to be required for the optimal release and presentation of tumor antigens to dendritic cells. It binds to several pattern recognition receptors (PRRs) such as Toll-like receptor (TLR) 2 and 4, which are expressed on APCs.
- PRRs pattern recognition receptors
- TLR Toll-like receptor
- ATP binds to purinergic receptors on APCs.
- IDO inhibitor IDO pathway inhibitor
- IDO pathway inhibitor IDO pathway inhibitor
- IDO pathway inhibitor IDO pathway inhibitor
- IDO pathway inhibitor IDO pathway inhibitor of the IDO pathway
- agent a molecule or a composition
- IDO indoleamine-2,3-dioxygenase
- IDO is an intracellular heme-containing enzyme that initiates the first and rate-limiting step of tryptophan degradation along the kynurenine pathway.
- the indoleamine 2,3-dioxygenase (IDO) pathway regulates immune response by suppressing cytotoxic T cell function, enhancing regulatory T cell activity (Tregs) and enabling tumor immune escape, either at the tumor or regional lympnode sites.
- An IDO pathway inhibitor can inhibit the IDO enzyme directly or by interfering or perturbing IDO effector pathway components.
- IDO2 tryptophan 2,3-dioxygenase
- mTOR mammalian target of rapamycin
- AhR arylhydrocarbon receptor
- GCN2 general control nonderepressible 2 pathway
- AhR/IL-6 autocrine loop the AhR/IL-6 autocrine loop.
- nanocarrier and “nanoparticle drug carrier” are used interchangeably and refer to a nanostructure having a porous interior core (e.g., a “porous nanoparticle”).
- the nanocarrier comprises a lipid bilayer encasing (or surrounding or enveloping) the porous particle core.
- the nanoparticle is a porous silica nanoparticle (e.g., mesoporous silica nanoparticle or "MSNP").
- lipid refers to conventional lipids, phospholipids, cholesterol, chemically functionalized lipids for attachment of PEG and ligands, etc.
- lipid bilayer refers to any double layer of oriented amphipathic lipid molecules in which the hydrocarbon tails face inward to form a continuous non-polar phase.
- liposome or “lipid vesicle” or “vesicle” are used interchangeably to refer to an aqueous compartment enclosed by a lipid bilayer, as being conventionally defined (see, e.g., Stryer (1981) Biochemistry, 2d Edition, W. H. Freeman & Co., p.213).
- a “nanovesicle” refers to a "lipid vesicle” having a diameter (or population of vesicles having a mean diameter) ranging from about 10 nm, or from about 20 nm, or from about 30 nm, or from about 40 nm, or from about 50 nm up to about 500 nm, or up to about 400 nm, or up to about 300 nm, or up to about 200 nm, or up to about 150 nm, or up to about 100 nm, or up to about 80 nm.
- a nanovesicle has a diameter ranging from about 10 nm up to about 80 nm, or from about 50 nm up to about 70 nm.
- the lipid bilayer coated on mesoporous silica nanopaticles can be referred to as a “supported lipid bilayer” because the lipid bilayer is located on the surface and supported by a porous particle core.
- the lipid bilayer can have a thickness ranging from about 6 nm to about 7 nm which includes a 3-4 nm thickness of the hydrophobic core, plus the hydrated hydrophilic head group layers (each about 0.9 nm) plus two partially hydrated regions of about 0.3 nm each.
- the lipid bilayer surrounding the silica nanoparticle comprises a continuous bilayer or substantially continuous bilayer that effectively encapsulates and seals the nanoparticle.
- the term “selective targeting” or “specific binding” refers to use of targeting ligands on the surface of a drug delivery nanocarrier (e.g., a LB-coated nanoparticle).
- the targeting ligand(s) are on the the surface of a lipid bilayer or LB-coated nanoparticle.
- the ligands interact specifically/selectively with receptors or other biomolecular components expressed on the target, e.g., a cell surface of interest.
- the targeting ligands can include such molecules and/or materials as peptides, antibodies, aptamers, targeting peptides, polysaccharides, and the like.
- a coated mesoporous silica nanopaticle, having targeting ligands can be referred to as a “targeted nanoparticle or a targeted drug delivery nanocarrier (e.g., LB-coated nanoparticle).
- a targeted nanoparticle or a targeted drug delivery nanocarrier (e.g., LB-coated nanoparticle).
- the term “about” or “approximately” as used herein refers to being within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e. the limitations of the measurement system, i.e. the degree of precision required for a particular purpose, such as a pharmaceutical formulation. For example, "about” can mean within 1 or more than 1 standard deviation, per the practice in the art.
- “about” can mean a range of up to 20%, preferably up to 10%, more preferably up to 5% and more preferably still up to 1% of a given value.
- the term can mean within an order of magnitude, preferably within 5-fold, and more preferably within 2-fold, of a value. Where particular values are described in the application and claims, unless otherwise stated, the term “about” meaning within an acceptable error range for the particular value should be assumed.
- drug refers to a chemical entity of varying molecular size, small and large, naturally occurring or synthetic, that exhibits a therapeutic effect in animals and humans.
- a drug may include, but is not limited to, an organic molecule (e.g., a small organic molecule), a therapeutic protein, peptide, antigen, or other biomolecule, an oligonucleotide, an siRNA, a construct encoding CRISPR cas9 components and, optionally one or more guide RNAs, and the like.
- an organic molecule e.g., a small organic molecule
- a therapeutic protein e.g., a small organic molecule
- a therapeutic protein e.g., a therapeutic protein
- peptide peptide
- antigen or other biomolecule
- an oligonucleotide e.g., an siRNA
- construct encoding CRISPR cas9 components e.g., a construct encoding CRISPR cas9 components
- guide RNAs e.g., a guide RNAs, and the like.
- a "pharmaceutically acceptable carrier” as used herein is defined as any of the standard pharmaceutically acceptable carriers
- the pharmaceutically acceptable carrier can include diluents, adjuvants, and vehicles, as well as carriers, and inert, non-toxic solid or liquid fillers, diluents, or encapsulating material that does not react with the active ingredients of the invention. Examples include, but are not limited to: phosphate buffered saline, physiological saline, water, and emulsions, such as oil/water emulsions.
- the carrier can be a solvent or dispersing medium containing, for example, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
- an "antibody” refers to a protein consisting of one or more polypeptides substantially encoded by immunoglobulin genes or fragments of immunoglobulin genes or derived therefrom that is capable of binding (e.g., specifically binding) to a target (e.g., to a target polypeptide).
- the recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as myriad immunoglobulin variable region genes.
- Light chains are classified as either kappa or lambda.
- Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.
- a typical immunoglobulin (antibody) structural unit is known to comprise a tetramer.
- Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light” (about 25 kD) and one "heavy” chain (about 50-70 kD).
- the N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition.
- the terms variable light chain (V L ) and variable heavy chain (VH) refer to these light and heavy chains respectively.
- Antibodies exist as intact immunoglobulins or as a number of well characterized fragments produced by digestion with various peptidases.
- pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab)'2, a dimer of Fab which itself is a light chain joined to V H -C H 1 by a disulfide bond.
- the F(ab)' 2 may be reduced under mild conditions to break the disulfide linkage in the hinge region thereby converting the (Fab') 2 dimer into a Fab' monomer.
- the Fab' monomer is essentially a Fab with part of the hinge region (see, Fundamental Immunology, W.E. Paul, ed., Raven Press, N.Y. (1993), for a more detailed description of other antibody fragments).
- antibody as used herein also includes antibody fragments either produced by the modification of whole antibodies or synthesized de novo using recombinant DNA methodologies.
- Certain preferred antibodies include single chain antibodies (antibodies that exist as a single polypeptide chain), more preferably single chain Fv antibodies (sFv or scFv) in which a variable heavy and a variable light chain are joined together (directly or through a peptide linker) to form a continuous polypeptide.
- the single chain Fv antibody is a covalently linked VH-VL heterodimer which may be expressed from a nucleic acid including V H - and V L - encoding sequences either joined directly or joined by a peptide-encoding linker.
- the first functional antibody molecules to be expressed on the surface of filamentous phage were single-chain Fv's (scFv), however, alternative expression strategies have also been successful.
- Fab molecules can be displayed on a phage if one of the chains (heavy or light) is fused to g3 capsid protein and the complementary chain exported to the periplasm as a soluble molecule.
- the two chains can be encoded on the same or on different replicons; the important point is that the two antibody chains in each Fab molecule assemble post- translationally and the dimer is incorporated into the phage particle via linkage of one of the chains to, e.g., g3p (see, e.g., U.S. Patent No: 5733743).
- scFv antibodies and a number of other structures converting the naturally aggregated, but chemically separated light and heavy polypeptide chains from an antibody V region into a molecule that folds into a three- dimensional structure substantially similar to the structure of an antigen-binding site are known to those of skill in the art (see e.g., U.S. Patent Nos.5,091,513, 5,132,405, and 4,956,778).
- antibodies should include all that have been displayed on phage (e.g., scFv, Fv, Fab and disulfide linked Fv (see, e.g, Reiter et al. (1995) Protein Eng.
- the term "specifically binds", as used herein, when referring to a biomolecule refers to a binding reaction that is determinative of the presence of a biomolecule in heterogeneous population of molecules (e.g., proteins and other biologics).
- a biomolecule e.g., protein, nucleic acid, antibody, etc.
- the specified ligand or antibody binds to its particular "target" molecule and does not bind in a significant amount to other molecules present in the sample.
- “Two-dimensional materials (2D materials) are materials that do not require a substrate to exist. In other words, they can be isolated as freestanding one atom thick sheets. As a practical matter, this definition can be relaxed to include materials with a thickness of a few atoms (e.g., less than about 10 atoms).
- the term "substantially pure isomer” refers to a formulation or composition wherein among various isomers of a compound a single isomer is present at 70%, or greater or at 80% or greater, or at 90% or greater, or at 95% or greater, or at 98% or greater, or at 99% or greater, or said compound or composition comprises only a single isomer of the compound.
- a “bioreactive nanomaterial” refers to an engineered biomaterial that induces or catalyzes a biological response.
- the nanomaterial induces a response by virtue of one or more properties selected from the group consisting of composition, size, shape, aspect ratio, dissolution, electronic, redox, surface display, surface coating, hydrophobic, hydrophilic, an atomically thin nanosheet, or functionalized surface groups" to catalyze the biological response at various nano/bio interfaces.
- the bioreactive nanomaterial has the ability to induce ICD biological responses in cells (e.g., in tumor cells) and/or as well as activating the innate immune system through delivery of "danger signal” and adjuvant effects.
- Figure 1 shows a schematic that illustrates how dual delivery of ICD inducing chemo and IND prodrug may impact the anti-cancer immune response.
- a chemotherapeutic agent which provides an ICD stimulus
- IND which interferes in the IDO pathway
- ICD chemo such as MTO (#1) induces an ICD response (#2) in which CRT expression on the dying tumor cell surfaces provides an “eat-me” signal for DC uptake, as well as the release of HMGB-1 that delivers adjuvant stimuli to DC (#3).
- TAAs tumor-associated antigens
- IND prodrug e.g. IND-Cholesterol
- ICD pathway also allows the activation of helper and memory T cells, which may prevent disease recurrence (#10).
- FIG. 1 illustrates the structure of indoximod and various other IDO pathway inhibitors.
- Figure 3 illustrates representative examples to show the use of an ester bond to make IDO inhibitor (e.g., indoximod) pro-drug conjugates.
- IDO inhibitor e.g., indoximod
- IDO inhibitor e.g., indoximod
- Figure 5 shows construction of an IND nanovesicle by self-assembly of Chol- IND + Phospholipid.
- Figure 6. Panel A) Flow cytometry experiment showing the induction of the ICD marker, CRT, in cultured KPC pancreatic cancer cells in the presence of PBS, DOX (20 ⁇ M), OX (500 ⁇ M), and activated DOX (a.k.a. DACHPt, 500 ⁇ M) for 24 h.
- HMBG1 release was measured using ELISA.
- Panel B Animal experimentation using 2 rounds of vaccination one week apart, followed by injecting live KPC cells SC on the contralateral side. The details of the animal vaccination experiment are provided in the methods section. Tumors were collected on day 26 for size measurement and IHC analysis.
- Panel C Tumor size measurement on the contralateral side.
- Panel D Explanted tumor at the contralateral side.
- Panel E Spaghetti curves to show KPC tumor growth in the contralateral flank.
- Figure 7 illustrates the development of a dual delivery carrier for OX plus IND using lipid-bilayer coated mesoporous silica nanoparticles (OX/IND-MSNP).
- a schematic shows the structure of OX-laden MSNP, in which the drug is trapped by a lipid bilayer containing IND-Chol. This leads to stable entrapment of OX in the pores, with IND-Chol trapped in the bilayer.
- the coating procedure provides uniform and instantaneous sealing of all particle pores.
- Figure 8 illustrates a Chol-IND prodrug (Formula II) as well as the R enantiomer (Formula IIa) and L enantiomer (Formula IIb).
- Figure 9 illustrates synthesis of lysolipid conjugated 1-MT prodrugs: Stage I- II.
- Figure 10 illustrates synthesis of lysolipid conjugated 1-MT prodrugs: Stage III-IV.
- Figure 11 illustrates synthesis of lysolipid conjugated 1-MT prodrugs: Stage V-VI.
- FIG. 12 illustrates synthesis of fatty acid and cholesterol conjugated 1-MT prodrugs.
- Figure 13 illustrates a Steglich esterification (see, e.g., Steglich (1078) Agnew. Chem. Int. Ed.17(7): 522-524).
- Figure 14 illustrates an alternative synthetic strategy.
- Figure 15 illustrates and alternative Step 1 for the synthesis strategy shown in Fig.14.
- Figure 16 illustrates the synthesis of Chol-IND.
- Figure 17 shows ESI-MS results for synthesis of Boc-Indoximod (BOc-IND).
- Figure 18 shows ESI-MS results for synthesis of cholesteryl-indoximod-Boc (Chol-IND-Boc).
- Figure 19 shows. ESI-MS data of Chol-IND-NH3+TFA- salt. Thin layer chromatography profile of Chol-IND-NH3+TFA- salt was showed on the top right corner.
- FIG. 20 illustrates one design of Chol-IND liposome for ICD inducing agent delivery via a trapping agent mediated approach.
- Figure 21 shows the successful synthesis of MTX laden Chol-IND liposome. The synthesis involved preparation of lipid biofilm, rehydration in citrate solution (trapping agent), extrusion (100 nm pore size), removal of free citrate acid, drug import, and purification. CyroEM visualization is provided. The final prodrug shows single peak in the DLS analysis, suggesting the formation of a liposome formulation with low PDI.
- the MTX loading is 14.1 wt%. The loading efficiency is determined to be 78%.
- the liposome exhibits slight positive charge, i.e. +4 mV.
- This sample was made using the IND prodrug as a Chol-IND TFA salt.
- Figure 22 Successful synthesis of DOX laden Chol-IND liposome. The synthesis is similar to MTX Chol/IND liposome. In DOX formulation, the trapping agent is (NH4) 2 SO 4 , similar to Doxil. We used TFA-free Chol-IND in this case. Our synthesis led to a size controlled liposome around ⁇ 95 nm. The liposome exhibits positive charge, i.e.
- FIG. 23 We synthesized MTX laden liposome using pristine cholesterol or Chol-IND at the identical (40%) molar ratio. The particle charge was measured at different stage during synthesis. Use of prodrug led to positive charge across the board.
- Figure 24 A list of MTX laden liposomes was made using pristine cholesterol, CHEMS and Chol-IND. We reasoned that the inclusion of CHEMS in in the Chol-IND formulation should adjust the particle charge from positive to the neutral or slightly anionic. The design of the formulation is provided in the inserted table.
- C1-C4 Four formulations (C1-C4) were made, in which C3 contains 10% CHEMS and C4 contains 20% CHEMS.
- the particles size, charge and PDI were summarized in the lower panel. As expected, use of 10% and 20% CHEMS led to zeta potential values of +1 and -10 mV, respectively. Particle size measurement and PDI were not significantly changed among these formulations. The sizes of these particles are 100 ⁇ 130 nm; the PDI values are ⁇ 0.15.
- Figure 27 shows synthetic steps, NMR, MS and HPLC data of Chol-IND.
- Figure 28 shows 3 month stability of an MTX/IND co-delivery liposome.
- Figure 29 illustrates mechanisms of immunogenic cell death.
- Panel A IHC study to confirm the effect of ICD induction (e.g. CRT, HMGB1 and LC3) and immune activation (e.g. CD8/Foxp3 ratio, perforin).
- Panel D Representative IHC staining of CRT and Perforin were provided.
- Figure 31 Panel A) Orthotopic tumor-bearing 4T1 mice were IV injected with the encapsulated MTX liposomes to deliver indicated MTX dose every 3 days, for a total of 3 administrations. This includes the treatment using IND-Chol/MTX co-delivery (IND: 3 mg/kg; MTX: 3 mg/kg). The animals were sacrificed at day 23. The formulation was provided on the right panel. Panel B) All the particles were fully characterized abiotically and biotically. The capability of CRT induction was confirmed in 4T1 cells. Panel C) Tumor size measurement in the efficacy study.
- FIG. 32 panels A-B, illustrates results of an animal study in a CT26 colon cancer model.
- Panel A Subcutaneous CT26 colon cancer bearing mice were IV injected with MTX/IND co-delivery liposome to deliver 3 mg/kg MTX and 3 mg/kg IND every 3 days, for a total of 4 administrations. Detailed treatment schedule and group information are discussed in panel A.
- Panel B Tumor size measurement in the animal study. A statistically significant difference (p ⁇ 0.001) emerged as early as day 20 between dual delivery (LCIM) vs MTX only liposome.
- LCIM dual delivery
- FIG. 33 panels A-B. KPC pancreatic cells were treated by using PBS (negative control), OX (positive control) and indicated engineered nanomaterials at low and high concentrations. The choice of particle concentration is based on an MTS assay (panel A). Twenty-four hours post incubation, the total cells were harvested for CRT analysis through flow cytometry.
- ICD immunogenic cell death
- a first treatment modality involves the combination of an ICD inducer (e.g., oxaliplatin or MTX) in combination with an IDO inhibitor (e.g., indoximod) into a single nanocarrier that allows systemic (or local) biodistribution and drug delivery to tumor sites. It is believed the dual-delivery approach can provide synergistic enhancement of adaptive and innate immunity (e.g., anti-PDAC immunity), with a significant improvement in animal survival.
- the nanocarrier comprises a vesicle (i.e., a lipid bilayer enclosing a fluid).
- the nanocarrier comprises a nanoparticle (e.g., a mesoporous silica nanoparticle (MSNP) surrounded (encapusulated) by a lipid bilayer.
- a nanoparticle e.g., a mesoporous silica nanoparticle (MSNP) surrounded (encapusulated) by a lipid bilayer.
- a second treatment modality involves local delivery to a tumor or peri- tumoral region, of an agent that induces ICD (e.g., oxaliplatin) in combination with a lipid (e.g., a nanovesicle) that comprises an inhibitor of the IDO pathway (e.g., indoximod).
- ICD mesoporous silica nanoparticle
- a third treatment modality involves vaccination utilizing dying cancer cells (e.g., KPC cells) in which ICD is induced ex vivo.
- Such vaccination can generate a systemic immune response that can interfere with tumor growth at a remote site as well as allowing adoptive transfer to non-immune animals.
- Approach 1 Systemic treatment of a cancer by combined delivery of ICD and IDO inhibition.
- the first approach approach combines an ICD-inducer (e.g., doxirubicin, oxaliplatin, MTX, etc.) and an inhibitor of the IDO pathway (e.g., indoximod) into a single nanocarrier, that can provide systemic biodistribution and drug delivery to orthotopic tumor sites.
- ICD-inducer e.g., doxirubicin, oxaliplatin, MTX, etc.
- an inhibitor of the IDO pathway e.g., indoximod
- this dual-delivery approach involves the formation of lipid vesicles where a component of the lipid bilayer comprising the vesicle incorporates or is conjugated to an inhibitor of the IDO pathway (e.g., an indoximod prodrug such Chol-IND) and the vesicle contains an ICD inducer (e.g., doxorubicin (DOX), mitoxantrone (MTX), and the like).
- an ICD inducer e.g., doxorubicin (DOX), mitoxantrone (MTX), and the like.
- the nanocarrier comprises a mesoporous silica nanoparticle (MSNP) containing the ICD inducer (e.g., oxaliplatin) where the silica nanoparticle is surrounded by (encapsulated by) a lipid bilayer containing (or conjugated to) an IDO inhibitor (e.g., indoximod provided as the prodrug Chol-IND (Formula I, Fig.8).
- MSNP mesoporous silica nanoparticle
- ICD inducer e.g., oxaliplatin
- an IDO inhibitor e.g., indoximod provided as the prodrug Chol-IND (Formula I, Fig.8).
- the lipid bilayer (LB) coated MSNP also known as a silicasome (see, e.g., PCT Patent Application No: PCT/US2017/012625) is designed to provide effective dual delivery of two (or more therapeutics) and can be exploited to provide dual delivery of the ICD inducer and IDO inhibitor. Without being bound by a particular theory, it is believe that this dual-delivery approach achieved synergistic enhancement of adaptive and innate anti-PDAC or anti-colon cancer (CT26) immunity immunity, leading to a significant improvement in animal survival.
- CT26 anti-colon cancer
- a third dual-delivery approach exploits the discovery that certain nanomaterials (e.g., CuO, graphene oxide) can induce immunogenic cell death (ICD) (see, e.g., Example 5). It is also believed that other nanomaterials such as CuO, Cu 2 O, Sb 2 O 3 , As2O3, Bi2O3, P2O3, ZnO, TiO2, and 2D materials other than graphene or graphene oxide (e.g., graphene, graphyne, borophene, germanene, silicene, Si 2 BN, stanene, phosphorene, bismuthene, molybdenite, metals, 2D supracrystals, and the like may also induce immunogenic cell death.
- nanomaterials e.g., CuO, graphene oxide
- ICD immunogenic cell death
- Nanoparticles formed from these ICD inducers, or combinations thereof, can readily be coated with a lipid that contains (or is conjugated to) an IDO inhibitor (e.g., indoximod provided as the prodrug, Chol-IND (Formula I), and the like).
- an IDO inhibitor e.g., indoximod provided as the prodrug, Chol-IND (Formula I), and the like.
- the lipid coated nanomaterial thus forms a dual delivery vehicle for delivery of both an ICD-inducer and an IDO-inhibitor.
- the following dual-delivery vehicles are contemplated herein: [0316] 1) ICD-inducer/IDO-inhibitor vesicle; [0317] 2) ICD-inducer/IDO-inhibitor silicasome (LB-coated nanoparticle); [0318] 3) ICD-inducer nanomaterial (bioreactive nanomaterial) coated with IDO- inhibitor lipid (phospholipid prodrug). [0319] It will be recognized, that in addition to systemic administration, any of these carriers may be considered for local treatment of a tumor.
- any of these carriers can be administered topically (e.g., for skin tumors), or directly, e.g., to an intra- tumoral or peri-tumoral site, e.g., via injection or during a surgical procedure.
- Dual-Delivery Lipid Vesicles e.g., ICD/IDO inhibitorVesicles
- dual-delviery nanovesicles are provided for the delivery of an ICD-inducer in combination with an inhibitor of the IDO pathway and/or for the delivery of an ICD inducer and a pharmacological agent other than an ICD inducer or in combination with an ICD inducer in addition to the inhibitor of the IDO pathway.
- a nanovesicle drug carrier for the combined delivery of an inhibitor of an IDO pathway and an inducer of immunogenic cell death (ICD), where the nanovesicle drug carrier comprises a lipid vesicle where a lipid bilayer effectively forms a vesicle in an aqueous solution, and the lipid or lipid formuation comprising the vesicle is associated with (or conjugated to) an inhibitor of the indoleamine 2,3-dioxygenase (IDO) pathway (IDO pathway inhibitor); and a cargo within the vesicle where the cargo comprises an agent that induces immunogenic cell death (ICD) (ICD- inducer).
- ICD immunogenic cell death
- lipid vesicle is typically formed from a lipid bilayer.
- a lipid micelle (which does not comprise a lipid bilayer) is contemplated.
- a lipid micelle can be comprise a phospholipid prodrug (e.g., lipid-IDO pathway inhibitor conjugate) and a cargo (typically a lipophilic) cargo can be disposed inside the micelle.
- the nanovesicle provides an IDO inhibitor and an ICD inducer that are synergistic in their activity against a cancer.
- the nanovesicle drug carrier when administered systemically, delivers an amount of an ICD inducer effective to induce or to facilitate induction of immunogenic cell death of cancer cells at the tumor site.
- the nanovesicle drug carrier when administered systemically, delivers an amount of IDO inhibitor to partially or fully inhibit an IDO pathway at a cancer site.
- the inhibitor of the IDO pathway comprises an agent selected from the group consisting of 1-methyl-D-tryptophan (indoximod, D-1MT), L-1MT, methylthiohydantoin-dl-tryptophan (MTH-Trp, Necrostatin), ⁇ -carbolines (e.g., 3-butyl- ⁇ - carboline), naphthoquinone-based (e.g., annulin-B), S-allyl-brassinin, S-benzyl-brassinin, N- [2-(Indol-3-yl)ethyl]-S-methyl-dithiocarbamate, N-[2-(benzo[b]thiophen-3-yl)ethyl]-S- methyl-dithiocarbamate, N-[3-(Indol-3-yl)propyl]-S-methyl-dithiocarbamate, S-hexyl- brassinin
- the IDO inhibitor comprises indoximod. In certain embodiments the IDO inhibitor comprises substantially pure “L” indoximod or substantially pure “R” indoximod, or a racemic mixture of "D" and “L” indoximod. [0323] In certain embodiments the inhibitor of the IDO pathway, is disposed in a lipid comprising the vesicle and/or conjugated to a lipid, or other component, comprising the vesicle. In certain embodiments the vesicle comprises a phospholipid. In certain embodiments the vesicle comprises a phospholipid, and cholesterol (CHOL).
- the phospholipid comprises a saturated fatty acid with a C14-C20 carbon chain, and/or an unsaturated fatty acid with a C14-C20 carbon chain, and/or a natural lipid comprising a mixture of fatty acids with C12-C20 carbon chains.
- the phospholipid comprises a saturated fatty acid selected from the group consisting of phosphatidylcholine (DPPC), dimyristoylphosphatidylcholine (DMPC), 1,2-dioleoyl-sn- glycero-3-phosphocholine (DOPC), 1,2-Distearoyl-sn-glycero-3-phospho-rac-glycerol (DSPG), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylcholine (DSPC), diactylphosphatidylcholine (DAPC), and the like.
- DPPC phosphatidylcholine
- DMPC dimyristoylphosphatidylcholine
- DOPC 1,2-dioleoyl-sn- glycero-3-phosphocholine
- DSPG 1,2-Distearoyl-sn-glycero-3-phospho-rac-glycerol
- DPPG dipalmito
- the phospholipid comprises a natural lipid selected from the group consisting of egg phosphatidylcholine (egg PC), and soy phosphatidylcholine (soy PC).
- the phospholipid comprises an unsaturated fatty acid selected from the group consisting of 1,2-dimyristoleoyl- sn-glycero-3-phosphocholine, 1,2-dipalmitoleoyl-sn-glycero-3-phosphocholine,1,2-dioleoyl- sn-glycero-3-phosphocholine (DOPC), and 1,2-dieicosenoyl-sn-glycero-3-phosphocholine.
- DOPC 1,2-dieicosenoyl-sn-glycero-3-phosphocholine.
- the vesicle comprises an mPEG phospholipid with a phospholipid C14-C18 carbon chain, and a PEG molecular weight ranging from about 350 Da to 5000 Da.
- the vesicle comprises 1,2-distearoyl-sn-glycero-3- phosphoethanolamine-PEG (DSPE-PEG).
- the vesicle comprises DPSE-PEG2K.
- the IDO inhibitor is conjugated to a component of said vesicle.
- the IDO inhibitor is conjugated to a moiety selected from the group consisting of a lipid, PHGP, vitamin E, cholesterol, and a fatty acid.
- the IDO inhibitor is conjugated directly to the moiety, while in other embodimetns, the IDO inhibitor is conjugated to the moiety via a linker. In certain embodiments the IDO inhibitor is conjugated to a phospholipid. In certain embodiments the IDO inhibitor is conjugated to vitamin E. In certain embodiments the IDO inhibitor is conjugated to cholesterol (CHOL (see, e.g., Formula II)) or to CHEMs, or to squalene. In certain embodiments the IDO inhibitor is conjugated to a fatty acid (e.g., oleic acid or docosahexaenoic acid).
- a fatty acid e.g., oleic acid or docosahexaenoic acid.
- the vesicle comprises about 75% PL, about 20% IND- cholesterol, and about 5% DSPE-PEG2K.
- the ICD inducer comprises a chemotherapeutic agent selected from the group consisting of doxorubicin (DOX), mitoxantrone (MTX), oxaliplatin, anthracenedione, bleomycin, bortezomib, cisplatin, daunorubicin, docetaxel, epirubicin, idarubicin, mitoxanthrone, paclitaxel, R2016, irinotecan and cyclophosphamide.
- the ICD inducer comprises doxorubicin.
- the ICD inducer comprises mitoxantrone.
- the bilayered vesicle comprises PL/Chol-IND/DSPE- PEG. In certain embodiments the bilayered vesicle comprises DSPC/Chol-IND/DSPE- PEG2K. In certain embodiments the bilayered vesicle comprises DSPC/Chol-IND/DSPE- PEG2K in the molar ratio 50:40:5.
- the bilyaerd vesicle e.g., liposome
- the bilyaerd vesicle can additionally include cholesteryl hemisuccinate (CHEMS) and/or the cholesteryl hemisuccinate can be conjugated to an IDO pathway inhibitor (indoximod).
- CHEMS cholesteryl hemisuccinate
- indoximod IDO pathway inhibitor
- a liposome is formatted that is about 100 nm in size, with slightly negative charge, and about 5 to about 20% drug loading capacity.
- Different lipid compositions can be optimized by, for example, varying the molar ratios of IND-Chol, cholesterol, CHEMS, DSPE, and the like.
- the bilayered vesicle comprises IND-Chol (salt free) 30% : CHEMS 20% : DSPC 45% : DSPE-PEG2K 5%.
- This liposome formulation is now subjected to animal experiment. Dual-Delivery (ICD-inducer/IDO-inhibitor) LB Coated MSNPs (ICD/IDO Silicasomes).
- a dual delivery carrier for an ICD inducer e.g., oxaliplatin, mitoxantrone (MTX), etc.
- an IDO inhibitor e.g., indoximod
- the carrier comprises lipid-bilayer coated nanoparticles (e.g., mesoporous silica nanoparticles).
- the IDO inhibitor e.g., indoximod
- the IDO inhibitor is provided disposed in and/or conjugated to a component of the lipid bilayer (e.g.
- the ICD inducer is provided on or in (e.g., within the pores) of the nanoparticle, e.g., effectively sealed/encapsulated by the lipid bilayer.
- the ICD inducer can be provided in or conjugated to the lipid bilayer while the IDO inhibitor is contained on or within the nanoparticle.
- Such lipid bilayer coated nanoparticle drug delivery systems are capable of delivering two (or more) active agents in precise concentration ratios as desired.
- the "dual-delivery carrier” comprises indoximod conjugated to a component of the lipid bilayer (e.g., as IND- Cholesterol (IND-Chol) (Formula I) or IND-Cholesterol hemisuccinate (IND-CHEMS), while the ICD inducer (e.g., doxorubicin (DOX), mitoxantrone (MTX), oxaliplatin, irinotecan etc.) is disposed within the nanoparticle.
- IND-Chol IND- Cholesterol
- IND-CHEMS IND-CHEMS
- ICD inducer e.g., doxorubicin (DOX), mitoxantrone (MTX), oxaliplatin, irinotecan etc.
- ICD-inducer e.g., doxorubicin (DOX), mitoxantrone (MTX), oxaliplatin (OX)
- DOX doxorubicin
- MTX mitoxantrone
- OX oxaliplatin
- a nanoparticle drug carrier for the combined delivery of an inhibitor of an IDO pathway and an inducer of immunogenic cell death (ICD)
- the nanoparticle drug carrier comprises: a mesoporous silica nanoparticle having a surface and defining a plurality of pores that are suitable to receive molecules therein; a lipid bilayer coating the surface; a first cargo comprising an inhibitor of the indoleamine 2,3-dioxygenase (IDO inhibitor); and a second cargo comprising an agent that induces immunogenic cell death (ICD) (ICD-inducer); where the lipid bilayer is substantially continuous and encapsulates the nanoparticle stably sealing the plurality of pores.
- the nanoparticle drug carrier contains a predefined ratio of IDO inhibitor to ICD-inducer.
- the IDO inhibitor and the ICD inducer are synergistic in their activity against a cancer (e.g., against PDAC).
- the drug carrier when administered systemically, is effective to deliver an amount of an ICD inducer effective to initiate or to facilitate induction of immunogenic cell death of a cancer cell.
- the drug carrier when administered systemically, will effectively deliver an amount of IDO inhibitor to partially or fully inhibit an IDO pathway at a cancer site.
- the drug carrier can contain/provide a lower dose ICD inducer and/or IDO inhibitor than when these agents are used individually.
- the combination of the ICD inducer and the IDO inhibitor can achieve an anti-cancer activity that cannot be achieved by the use of either agent alone.
- the IDO inhibitor is disposed in the lipid bilayer and/or conjugated to a component (e.g., PL, Chol, Chol derivative (e.g., cholesterol hemisuccinate), etc.) comprising the lipid bilayer while the ICD inducer is disposed in the plurality of pores.
- the ICD-inducer comprises a chemical or biological agent described in Table 2, above.
- the ICD-inducer comprises a chemotherapeutic agent selected from the group consisting of doxorubicin (DOX), mitoxantrone (MTX), oxaliplatin (OX) anthracenedione, bleomycin, bortezomib, cisplatin, daunorubicin, docetaxel, epirubicin, idarubicin, paclitaxel, R2016, irinotecan and cyclophosphamide.
- the ICD-inducer comprises doxirubicin (DOX).
- the ICD-inducer comprises mitoxantrone (MTX). In certain embodiments the ICD-inducer comprises oxaliplatin (OX).
- the ICD inducer comprises an ICD inducing nanomaterial (e.g., CuO, Cu2O, Sb2O3, As2O3, Bi2O3, P2O3, ZnO, TiO2, graphene oxide, 2D materials other than graphene or graphene oxide (e.g., graphene, graphyne, borophene, germanene, silicene, Si2BN, stanene, phosphorene, bismuthene, molybdenite, metals, 2D supracrystals, and the like) as described above or in Example 10.
- nanomaterial e.g., CuO, Cu2O, Sb2O3, As2O3, Bi2O3, P2O3, ZnO, TiO2, graphene oxide, 2D materials other than graphene or graphene oxide (e.g., graphene,
- the ICD-inducing nanomaterial can be contained on or within the nanoparticle.
- an ICD-inducing nanomaterial can be coated with a lipid or with a lipid bilayer.
- the ICD-inducing nanomaterial can incorporate one or more drugs as described herein.
- the nanomaterial may contain the IDO inhibitor, both of which can be released at a target site (e.g., cancer cell).
- the surface can be functionalized to deliver the IDO- inhibitor.
- the IDO inhibitor comprises an agent selected from the group consisting of 1-methyl-D-tryptophan (indoximod, D-1MT), L-1MT, methylthiohydantoin-dl-tryptophan (MTH-Trp, Necrostatin), ⁇ -carbolines (e.g., 3-butyl- ⁇ - carboline), Naphthoquinone-based (e.g., annulin-B), S-allyl-brassinin, S-benzyl-brassinin, N-[2-(Indol-3-yl)ethyl]-S-methyl-dithiocarbamate, N-[2-(benzo[b]thiophen-3-yl)ethyl]-S- methyl-dithiocarbamate, N-[3-(Indol-3-yl)propyl]-S-methyl-dithiocarbamate, S-hexyl- brassinin,
- the IDO inhibitor comprises an agent shown in Table 3, above. In certain embodiments the IDO inhibitor comprises indoximod.
- the nanoparticle drug carrier(s) can be fabricated so that a population of the drug carriers in suspension shows essentially a substantially unimodal size distribution; and/or shows a PDI less than about 0.2, or less than about 0.1; and/or shows a coefficient of variation in size less than about 0.1 or less than about 0.05.
- the nanoparticle dmg carriers may distribute to developing tumor sites on IV injection. In certain embodiments the nanoparticle drug carrier forms a stable suspension on rehydration after lyophilization.
- the nanoparticle drug carriers show reduced dmg toxicity as compared to free drug and/or dmg in liposomes.
- the nanoparticle drug carrier has colloidal stability in physiological fluids with pH 7.4 and remains monodisperse to allow systemic biodistribution and is capable of entering a disease site by vascular leakage (EPR effect) or transcytosis.
- nanoparticle e.g. , mesoporous silica core
- lipid bilayer formulations e.g., lipid bilayer formulations, and methods of synthesis are described in the sections below and in the examples.
- silicasome drug carriers described herein comprise a porous silica (or other material) nanoparticle (e.g., a silica body having a surface and defining a plurality of pores that are suitable to receive molecules therein) coated with a lipid bilayer.
- the silica nanoparticle can be a mesoporous silica nanoparticle.
- the fact that the nanoparticle is referred to as a silica nanoparticle does not preclude materials other than silica from also being incorporated within the silica nanoparticle.
- the silica nanoparticle may be substantially spherical with a plurality of pore openings through the surface providing access to the pores.
- the silica nanoparticle can have shapes other than substantially spherical shapes.
- the silica nanoparticle can be substantially ovoid, rod-shaped, a substantially regular polygon, an irregular polygon, and the like.
- the silica nanoparticle comprises a silica body that defines an outer surface between the pore openings, as well as side walls within the pores.
- the pores can extend through the silica body to another pore opening, or a pore can extend only partially through the silica body such that that it has a bottom surface of defined by the silica body.
- the silica body is mesoporous. In other embodiments, the silica body is microporous.
- “mesoporous” means having pores with a diameter between about 2 nm and about 50 nm, while “microporous” means having pores with a diameter smaller than about 2 nm.
- the pores may be of any size, but in typical embodiments are large enough to contain one or more therapeutic compounds therein. In such embodiments, the pores allow small molecules, for example, therapeutic compounds such as anticancer compounds to adhere or bind to the inside surface of the pores, and to be released from the silica body when used for therapeutic purposes.
- the pores are substantially cylindrical.
- the nanoparticles comprise pores having pore diameters between about 1 nm and about 10 nm in diameter or between about 2 nm and about 8 nm. In certain embodiments the nanoparticles comprise pores having pore diameters between about 1 nm and about 6 nm, or between about 2 nm and about 5 nm. Other embodiments include particles having pore diameters less than 2.5 nm. In other embodiments, the pore diameters are between 1.5 and 2.5 nm. Silica nanoparticles having other pore sizes may be prepared, for example, by using different surfactants or swelling agents during the preparation of the silica nanoparticles.
- the nanoparticles can include particles as large (e.g., average or median diameter (or other characteristic dimension) as about 1000 nm. However, in various embodiments the nanoparticles are typically less than 500 nm or less than about 300 nm as, in general, particles larger than 300 nm may be less effective in entering living cells or blood vessel fenestrations. In certain embodiments the nanoparticles range in size from about 40 nm, or from about 50 nm, or from about 60 nm up to about 100 nm, or up to about 90 nm, or up to about 80 nm, or up to about 70 nm. In certain embodiments the nanoparticles range in size from about 60 nm to about 70 nm.
- Some embodiments include nanoparticles having an average maximum dimension between about 50 nm and about 1000 nm. Other embodiments include nanoparticles having an average maximum dimension between about 50 nm and about 500 nm. Other embodiments include nanoparticles having an average maximum dimension between about 50 nm and about 200 nm. In some embodiments, the average maximum dimension is greater than about 20nm, greater than about 30nm, greater than 40nm, or greater than about 50nm. Other embodiments include nanoparticles having an average maximum dimension less than about 500 nm, less than about 300nm, less than about 200nm, less than about 100 nm or less than about 75 nm. As used herein, the size of the nanoparticle refers to the average or median size of the primary particles, as measured by transmission electron microscopy (TEM) or similar visualization technique.
- TEM transmission electron microscopy
- Illustrative mesoporous silica nanoparticles include, but are not limited to
- mesoporous silica nanoparticles are synthesized by reacting tetraethyl orthosilicate (TEOS) with a template made of micellar rods. The result is a collection of nano-sized spheres or rods that are filled with a regular arrangement of pores. The template can then be removed by washing with a solvent adjusted to the proper pH (see, e.g., Trewyn et al. (2007) Chem.
- TEOS tetraethyl orthosilicate
- mesoporous particles can also be synthesized using a simple sol-gel method (see, e.g., Nandiyanto, et al. (2009) Microporous and Mesoporous Mat.120(3): 447-453, and the like).
- tetraethyl orthosilicate can also be used with an additional polymer monomer (as a template).
- 3-mercaptopropyl)trimethoxysilane is used instead of TEOS.
- the mesoporous silica nanoparticles are cores are synthesized by a modification of the sol/gel procedure described by Meng et al. (2015) ACS Nano, 9(4): 3540-3557.
- 50 mL of CTAC is mixed with 150 mL of H 2 O in a flask (e.g., a 500 mL conical flask), followed by stirring (e.g., at 350 rpm for 15 min at 85°C). This us followed by the addition of 8 mL of 10% triethanolamine for 30 min at the same temperature.
- 7.5 mL of the silica precursor, TEOS is added dropwise at a rate of 1 mL/min using a peristaltic pump.
- the solution is stirred at 350 rpm at 85°C for 20 min, leading to the formation particles with a primary size of ⁇ 65 nm.
- the surfactant can be removed by washing the particles with a mixture of methanol/HCl (500:19 v/v) at room temperature for 24 h.
- the particles can be centrifuged at 10000 rpm for 60 min and washed three times in methanol.
- porous silica nanoparticles e.g., mesoporous silica
- similar methods can be used with other porous nanoparticles.
- Numerous other mesoporous materials that can be used in drug delivery nanoparticles are known to those of skill in the art.
- mesoporous carbon nanoparticles could be utilized.
- Mesoporous carbon nanoparticles are well known to those of skill in the art (see, e.g., Huang et al. (2016) Carbon, 101: 135-142; Zhu et al. (2014) Asian J. Pharm. Sci., 9(2): 82-91; and the like).
- mesoporous polymeric particles can be utilized.
- the syntheses of highly ordered mesoporous polymers and carbon frameworks from organic ⁇ organic assembly of triblock copolymers with soluble, low-molecular-weight phenolic resin precursors (resols) by an evaporation induced self-assembly strategy have been reported by Meng et al.(2006) Chem. Mat.6(18): 4447-4464 and in the references cited therein.
- the nanoparticles described herein are illustrative and non-limiting. Using the teachings provided herein numerous other lipid bilayer coated nanoparticles will be available to one of skill in the art.
- the drug carrier nanoparticles described herein comprise a porous nanoparticle (e.g. a mesoporous silica nanoparticle (MSNP)) coated with a lipid bilayer.
- the bilayer composition is optimized to provide a rapid and uniform particle coating, to provide colloidal and circulatory stability, and to provide effective cargo retention, while also permitting a desirable cargo release profile.
- the lipid bilayer comprises a combination of a phospholipid, cholesterol, and in certain embodiments, a IDO-lipid conjugate, a pegylated lipid (e.g., DSPE-PEG2000), or a factionalized pegylated lipid (e.g., DSPE-PEG2000- maleimide) to facilitate conjugation with targeting or other moieties.
- a coated lipid film procedure can be utilized in which MSNP suspensions are added to a large lipid film surface, coated on, e.g., a round- bottom flask.
- the mesoporous silica nanoparticles are coated with a lipid bilayer that incorporates the IDO inhibitor coupled to a lipid (e.g., a phospholipid) or to cholesterol.
- a lipid e.g., a phospholipid
- the mesoporous silica nanoparitcles are coated with a lipid bilayer comprising IND-Chol, as well as serving to encapsulate the ICD inducer (e.g., doxorubicin (DOX), mitoxantrone (MTX), oxaliplatin, etc.) in the porous interior (see, e.g,. Figure 7, panel a).
- the mesoporous silica nanoparitcles are coated with a lipid bilayer comprising Chol-IND, as well as serving to encapsulate doxirubicin, or oxaliplatin in the porous interior ( Figure 7, panel a).
- lipid bilayer composition can be optimized for an OX/IND or for an MTX/IND drug delivery carrier (e.g., a bilayer coated nanoparticle). This can accomplished, for example, by using a DSPC/Cho-IND/DSPE-PEG2K or a DSPC/Chol- IND/CHEMS/DSPE-PEG2k mixture at various ratios and measuring the incorporated IND.
- the biofilm can be laid down at the bottom of a round bottom flask, to which the OX-soaked or MTX-soaked, or other ICD inducer soaked) MSNPs are added, followed by sonication (see, e.g., Liu et al.
- lipid bilayer formulation described above and in the Examples is illustrative and non-limiting. Depending on the drug(s) being loaded into the drug delivery carrier and the desired release profile, in various embodiments different lipid bilayer formulations can be used and an optimal formulation can be determined.
- the lipid bilayer can comprise: 1) one or more saturated fatty acids with C14-C20 carbon chain, such as dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), and diactylphosphatidylcholine (DAPC); and/or 2) One or more unsaturated fatty acids with a C14-C20 carbon chain, such as 1,2- dimyristoleoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoleoyl-sn-glycero-3- phosphocholine,1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dieicosenoyl-sn- glycero-3-phosphocholine; and/or 3) Natural lipids comprising a mixture of fatty acids with C12-C20 carbon chain, such as dimyristoylphosphatidy
- cholesteryl hemisuccinate (CHEMS) that carryies one negative charge at pH >6.5 in the formulation.
- CHEMS cholesteryl hemisuccinate
- These lipids are illustrative but non- limiting and numerous other lipids are known and can be incorporated into a lipid bilayer for formation of a drug delivery nanocarrier (e.g., a bilayer-coated nanoparticle).
- the drug carrier comprises bilayer comprising a lipid (e.g., a phospholipid), cholesterol (e.g., IND-Chol), and a PEG functionalized lipid (e.g., a mPEG phospholipid).
- a lipid e.g., a phospholipid
- cholesterol e.g., IND-Chol
- PEG functionalized lipid e.g., a mPEG phospholipid
- the mPEG phospholipids comprises a C14- C18 phospholipid carbon chain from, and a PEG molecular weight from 350-5000 (e.g., MPEG 5000, MPEG 3000, MPEG 2000, MPEG 1000, MPEG 750, MPEG 550, MPEG 350, and the like).
- the mPEG phospholipid comprises DSPE-PEG5000, DSPE-PEG3000, DSPE-PEG2000, DSPE-PEG1000, DSPE-PEG750, DSPE-PEG550, or DSPE-PEG350.
- MPEGs are commercially available (see, e.g., //avantilipids.com/product- category/products/polymers-polymerizable-lipids/mpeg-phospholipids).
- lipid bilayer comprises an mPEG phospholipid with a phospholipid C14-C18 carbon chain, and a PEG molecular weight ranging from about 350 Da to 5000 Da.
- the lipid bilayer comprises DPSE-PEG 2K .
- the lipid bilayer comprises 1,2-distearoyl-sn-glycero- 3-phosphoethanolamine-PEG (DSPE-PEG).
- the IDO inhibitor is conjugated to a moiety that forms a component of a vesicle structure in aqueous solution and is provided in the lipid bilayer (see, e.g., conjugated IDO inhibitors, supra.).
- the IDO inhibitor is conjugated to a moiety such as a lipid, vitamin E, cholesterol, and a fatty acid (see, e.g., Examples 1 and 2).
- the IDO inhibitor is conjugated directly to the vesicle-forming moiety and in other embodiments the IDO inhibitor is conjugated to the vesicle-forming moiety via a linker (e.g., via a homo-bifunctional or hetero-bifunctional linker).
- the inhibitor of the IDO pathway is conjugated to a lipid, and/or to vitamin E, and/or to cholesterol (CHOL), and/or to a fatty acid (e.g., oleic acid, docosahexaenoic acid, etc.).
- the IDO inhibitor is conjugated to a cholesterol.
- the IDO inhibitor is conjugated to a phospholipid comprising the lipid bilayer or to cholesterol comprising said lipid bilayer. In certain embodiments the IDO inhibitor is directly conjugated to cholesterol.
- the ratio of phospholipid: IND-CHOL:PEG is about phospholipid (50-90 mol%): CHOL (10-50 mol%) : PEG (1-10 mol%).
- the bilayer comprises DSPC/Cho-IND/DSPE-PEG2K. In certain embodiments the bilayer comprises DSPC/Cho-IND/DSPE-PEG2K in the molar ratio 50:40:5.
- the lipid bilayer is formulated to form a substantially uniform and intact bilayer encompassing the entire nanoparticle. In certain embodiments the lipid bilayer is formulated so that the mesoporous silica nanoparticle is colloidally stable.
- Dual Delivery Lipid-Coated ICD-Inducing Nanomaterials [0361] It was discovered that certain nanomaterials are effective ICD inducers (see, e.g., Example 5). In certain embodiments these ICD-inducing nanomaterials can be administered simply as nanoparticles.
- the nano particles can be combined with a lipid where the lipid is associated with (e.g., complexed with or conjugated to) an IDO pathway inhibitor (e.g., indoximod).
- the lipid can compire an IND conjugated phospholipid (IND-PL) or IND conjugated cholesterol (Chol-IND) (Formula I).
- IND-PL IND conjugated phospholipid
- Chol-IND IND conjugated cholesterol
- the lipid readily coats all or a part of the surface of the nanoparticle.
- a nanomaterial carrier for the combined delivery of an inhibitor of an IDO pathway and an inducer of immunogenic cell death (ICD), where the nanomaterial carrier comprises a nanomaterial that induces ICD; and a lipid or lipid formulation comprising an IDO pathway inhibitor where the lipid or lipid formulation is disposed on the surface of said nanomaterial.
- the lipid or lipid formulation fully encapsulates the nanomaterial, while in other embodiments, the lipid or lipid formulation is disposed on a surface of the nanoparticle, but does not fully encapsulate the nanoparticle.
- the lipid or lipid formulation can form a lipid bilayer, while more typically, the lipid or lipid formulation is not a lipid bilayer.
- the ICD-inducing nanomaterial comprises one or more ICD-inducing nanomaterials selected from the group consisting of CuO, Cu2O, Sb2O3, As2O3, Bi 2 O 3 , P 2 O 3 , ZnO, TiO 2 , graphene oxide, 2D materials other than graphene or graphene oxide (e.g., graphene, graphyne, borophene, germanene, silicene, Si2BN, stanene, phosphorene, bismuthene, molybdenite, metals, 2D supracrystals, and the like) and other ICD-inducing nanomaterials as described herein.
- the nanomaterial comprises copper oxide (CuO). In certain embodiments the nanomaterial comprises graphene oxide (GO).
- the IDO pathway inhibitor associated with the lipid or lipid formulation comprises an agent selected from the group consisting of 1-methyl-D- tryptophan (indoximod, D-1MT), L-1MT, methylthiohydantoin-dl-tryptophan (MTH-Trp, Necrostatin), ⁇ -carbolines (e.g., 3-butyl- ⁇ -carboline), naphthoquinone-based (e.g., annulin- B), S-allyl-brassinin, S-benzyl-brassinin, N-[2-(Indol-3-yl)ethyl]-S-methyl-dithiocarbamate, N-[2-(benzo[b]thiophen-3-yl)ethyl]-S-methyl-dithiocarbamate, N-[3-(Indoximod, D-1MT), L
- the IDO pathway inhibitor associated with the lipid or lipid formulation comprises 1 methyl- tryptophan (1MT)).
- the 1 methyl-tryptophan is a substantially pure "D" isomer of 1-methyl-tryptophan (D-1MT), while in other embodiments, the 1-methyl- tryptophan is a substantially pure "L” isomer of 1-methyl-tryptophan "L-1MT.
- the 1-methyl-tryptophan comprises a mixture of the D and L isomers.
- the IDO pathway inhibitor is conjugated to a lipid or to a component of the lipid formulation.
- the IDO pathway inhibitor is conjugated to a moiety selected from the group consisting of a lipid (e.g., phospholipid), vitamin E, cholesterol, cholesterol derivative (e.g., cholesterol hemisuccinate (CHEMS)) and a fatty acid.
- a lipid e.g., phospholipid
- the IDO inhibitor is conjugated directly to the moiety, while in other emobodiments, the IDO inhibitor is conjugated to the moiety via a linker.
- the IDO pathway inhibitor is conjugated to PGHP, vitamin E, cholesterol (CHOL), a fatty acid, (e.g., oleic acid or docosahexaenoic acid), or to a lipid (e.g., a phospholipid).
- the IDO pathway inhibitor is conjugated to a phospholipid.
- phospholipids include, but are not limited to phospholipids comprising a saturated fatty acid with a C14-C20 carbon chain, and/or an unsaturated fatty acid with a C14-C20 carbon chain, and/or a natural lipid comprising a mixture of fatty acids with C12-C20 carbon chains.
- the phospholipid comprises a saturated fatty acid selected from the group consisting of phosphatidylcholine (DPPC), dimyristoylphosphatidylcholine (DMPC), distearoylphosphatidylcholine (DSPC), and diactylphosphatidylcholine (DAPC).
- DPPC phosphatidylcholine
- DMPC dimyristoylphosphatidylcholine
- DSPC distearoylphosphatidylcholine
- DAPC diactylphosphatidylcholine
- the phospholipid comprises a natural lipid selected from the group consisting of egg phosphatidylcholine (egg PC), and soy phosphatidylcholine (soy PC).
- the phospholipid comprises an unsaturated fatty acid selected from the group consisting of 1,2-dimyristoleoyl-sn-glycero-3- phosphocholine, 1,2-dipalmitoleoyl-sn-glycero-3-phosphocholine,1,2-dioleoyl-sn-glycero-3- phosphocholine (DOPC), and 1,2-dieicosenoyl-sn-glycero-3-phosphocholine.
- DOPC 1,2-dieicosenoyl-sn-glycero-3-phosphocholine.
- the phospholipid comprises 1-palmitoy1-2-hydroxy-sn-glycero-3- phosphocholine.
- the IDO pathway inhibitor comprises an agent selected from the group consisting of 1-methyl-D-tryptophan (indoximod), 1-methyl-L- tryptophan, methylthiohydantoin-dl-tryptophan, Necrostatin-1, Ebselen, Pyridoxal Isonicotinoyl Hydrazone, Norharmane, CAY10581, 2-Benzyl-2-thiopseudourea hydrochloride, Norharmane hydrochloride, INCB024360, S-allyl-brassinin, S-benzyl- brassinin, 5-Bromo-brassinin, 4-phenylimidazole Exiguamine A, and NSC401366.
- the IDO pathway inhibitor comprises indoximod.
- the IDO pathway inhibitor comprises substantially pure "L” isomer of 1-methyl-tryptophan, or a substantially pure “D” isomer of 1-methyl-tryptophan, or a racemic mixture of "D” and “L” isomers of 1-methyl-tryptophan.
- the 1-methyl-tryptophan is conjugated to cholesterol (e.g.,Chol-IND, Formula I) and/or to cholesterol hemisuccinate (CHEMS-IND).
- the lipid bilayer comprises both cholesterol and a cholesterol derivative (e.g., CHEMS)
- the 1-methyl-tryptophan conjugated to the cholesterol or to CHEMS or to both cholesterol and to CHEMS.
- a second treatment modality involves local delivery to a tumor or peri- tumoral region, of an agent that induces ICD (e.g., doxirubicin, oxaliplatin, etc.) in combination with an inhibitor of the IDO pathway (e.g., indoximod).
- the IDO inhibitor can be complexed with or conjugated to a moiety (e.g., a lipid) that forms a vesicle (e.g., a nanovesicle).
- an ICD inducer in combination with an IDO inhibitor induces recruitment of cytotoxic CD8+ lymphocytes, depletion of Tregs, reversal of the CD8 + /Foxp3 + ratio, cytotoxic tumor killing, and tumor shrinkage at the local site. It is believed that these adaptive immune responses can be accompanied by boosting of the innate immune system, as reflected by CRT and HMGB1 expression, as well as the activation of a DC population, particularly well-suited for generating cytotoxic T cell responses.
- a method of treating a cancer in a mammal involves administering to an intra-tumoral or peri- tumoral site an effective amount of an inhibitor of the indoleamine 2,3-dioxygenase (IDO) pathway (an IDO inhibitor) in conjunction with an effective amount of an agent that induces immunogenic cell death (ICD) (an ICD-inducer).
- the effective amount of the ICD-inducer is an amount effective to elevate calreticulin (CRT) expression and/or to elevate expression and/or release of HMGB1 and/or introduce ATP release in cells of the cancer.
- ICD inducers are well known to those of skill in the art and ICD inducers suitable for this method will readily be recognized in view of the teachings provided herein.
- Illustrative ICD inducers include, but are not limited to chemotherapeutic agent(s) that induce ICD such as oxaliplatin, anthracenedione, bleomycin, bortezomib, cisplatin, daunorubicin, docetaxel, doxorubicin, epirubicin, idarubicin, mitoxanthrone, oxaliplatin, paclitaxel, R2016 (a heterocyclic quinolone derivative described by Son et al.
- ICD inducers include oncolytic viruses (see, e.g., Angelova et al. (2014) J. Virol., 88(10): 5263-52760.
- One illustrative suitable oncolytic virus is an oncolytic parvovirus (e.g., H-PV).
- H-PV oncolytic parvovirus
- the ability to induce ICD is an intrinsic property of the nanomaterial (e.g., chemical reaction of the material and/or receptor binding of the nanomaterial is not required for induction of ICD). Accordingly, in certain embodiments the tumor or peritumoral space is treated with a nanomaterial that induces ICD.
- Such materials include, but are not limited to e.g., CuO, Cu2O, Sb2O3, As2O3, Bi2O3, P2O3, ZnO, TiO 2 , graphene oxide, 2D materials other than graphene or graphene oxide (e.g., graphene, graphyne, borophene, germanene, silicene, Si2BN, stanene, phosphorene, bismuthene, molybdenite, metals, 2D supracrystals, etc.) and the like) (see, e.g., Example 2) nanoparticles comprising such materials. In certain embodiments the nanoparticle is entirely fabricated from said materials.
- the nanoparticle comprises a doped material containing said materials.
- the nanoparticle comprises a core-shell structure compmrising said ICD inducing materials.
- ICD is induced by contacting the cancer cells with a nanomaterial (e.g., CuO, Sb 2 O 3 , ZnO, TiO 2 , and graphene oxide) that induced ICD.
- a nanomaterial e.g., CuO, Sb 2 O 3 , ZnO, TiO 2 , and graphene oxide
- two or more ICD inducers can be used to induce ICD via local delivery.
- the ICD inducer comprises at least oxaliplatin, or doxirubicin e.g., as described in Examples 3 and 4.
- the ICD inducer can be used in conjunction with an IDO inhibitor.
- IDO inhibitors Numerous IDO inhibitors are known to those of skill in the art (see, discussion below) and the use of one or more of these IDO inhibitors is contemplated.
- the IDO inhibitor(s) comprise a conjugated IDO inhibitor as described herein.
- the IDO inhibitors comprise indoximod or a conjugated indoximod as described below and in Examples 1 and 2.
- the IDO inhibitors comprise substantially pure "D" indoximod, or substantially pure “L” indoximod, or conjugated substantially pure "D” indoximod, or conjugated substantially pure "L” indoximod.
- the ICD inducer and the inhibitor of the IDO pathway are delivered locally to a target site.
- the ICD inducer and the inhibitor of the IDO pathway can be delivered directly to a tumor site, e.g., by injection, or through a cannula.
- the ICD inducer and the inhibitor of the IDO pathway are delivered into a tumor mass and/or into a peritumoral site.
- the ICD inducer and the inhibitor of the IDO pathway can be delivered as separate reagents. Alternatively, they can be delivered as a combined formulation.
- the combined formulation comprise nanovesicles and/or lipid bilayer coated silica nanoparticles, e.g.
- the ICD inducer and the IDO pathway inhibitor are delivered via an implantable depot delivery system (e.g., encapsulated in a controlled release polymer, a hydrogel, and the like).
- both the ICD inducer and the the IDO pathway inhibitor are in implantable depot delivery systems and in other embodiments only the the IDO pathway inhibitor or the ICD inducer is in an implantable depot delivery system.
- the ICD inducer and the IDO pathway inhibitor are used in combination as a primary therapy.
- the ICD inducer and the IDO pathway inhibitor are used as an adjunct therapy, e.g., in combination with other chemotherapeutics, and/or surgery, and/or radio therapy.
- the ICD inducer and the the IDO pathway inhibitor are delivered to a surgical site during or after removal of a tumor mass.
- Illustrative cancers include, but are not limited to pancreatic ductal adenocarcinoma (PDAC), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Adrenocortical carcinoma, Kaposi sarcoma, anal cancer, appendix cancer, astrocytoma, atypical teratoid/rhabdoid tumor, bile duct cancer, extrahepatic cancer, bladder cancer, bone cancer (e.g., Ewing sarcoma, osteosarcoma, malignant fibrous histiocytoma), brain stem glioma, brain tumors (e.g., astrocytomas, brain and spinal cord tumors, brain stem glioma, central nervous system atypical teratoid/rhabdoid tumor, central nervous system embryonal tumors, central nervous system germ cell tumors, craniopharyngioma, ependymoma, breast cancer, bronchial tumors,
- bile extrahepatic
- ductal carcinoma in situ DCIS
- embryonal tumors endometrial cancer, ependymoma, esophageal cancer, esthesioneuroblastoma, extracranial germ cell tumor, extragonadal germ cell tumor, extrahepatic bile duct cancer, eye cancer (e.g., intraocular melanoma, retinoblastoma), fibrous histiocytoma of bone, malignant, and osteosarcoma, gallbladder cancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumors (GIST), germ cell tumors (e.g., ovarian cancer, testicular cancer, extracranial cancers, extragonadal cancers, central nervous system), gestational trophoblastic tumor, brain stem cancer, hairy cell leukemia, head and neck cancer, heart cancer, hepatocellular (liver) cancer, histiocytosis, langerhan
- the cancer to be treated is cancer pancreatic ductal adenocarcinoma (PDAC) and in certain embodiments, the ICD inducer comprises oxaliplatin and the IDO inhibitor comprises indoximod or a conjugated indoximod as described below in in Example 1. Approach 3 -- Vaccination to prevent or treat a cancer.
- PDAC cancer pancreatic ductal adenocarcinoma
- the ICD inducer comprises oxaliplatin and the IDO inhibitor comprises indoximod or a conjugated indoximod as described below in in Example 1.
- Approach 3 -- Vaccination to prevent or treat a cancer.
- methods are provided for the prevention or treatment of a cancer that involve vaccinating a subject (e.g., a human, or a non-human mammal) to induce an immune response directed against one or more cancers.
- subjects that have a family history for cancer in general or for particular cancers, and/or that have a genetic risk for a cancer may be vaccinated prophylactically to prevent the development of a cancer.
- the vaccination is used as a primary therapy in the treatment of a cancer.
- the vaccination is used as an adjunct therapy, e.g., in combination with surgery, and/or other chemotherapy regimen, and/or radiation therapy.
- a method for the treatment and/or prevention of a cancer in a mammal comprising providing cancer cells in which immunogenic cell death (ICD) has been induced ex vivo, and vaccinating the mammal with these cells, where the vaccination induces an anti-cancer immunogenic response.
- the cancer cells are cells derived from an existing cancer, e.g., obtained during a biopsy, or after surgical resection of a tumor mass).
- the cancer cells are cells obtained from the subject that is to be treated and comprise an autologous transplant.
- the cells are obtained from a different subject of the same species or can even be obtained from a different species.
- the cancer cells are cells from a cancer cell line.
- the cell line is an animal cell line from the same species that is to be treated.
- Similalry where a human is to be treated a human cell line will typically be used.
- Numerous cancer cell lines are known to those of skill in the art. Illustrative, but non-limiting examples of suitable cell lines are shown in Table 1. Table 1. Illustrative, but non-limiting, cell lines that can be used to produce dying cancer cells in which immunogenic cell death (ICD) has been induced.
- ICD immunogenic cell death
- the cancer cells used in the vaccination are of the same type of cancer that is to be treated and/or prevented. It will be recognized however, that vaccination with cells of one type of cancer may generate an immune response directed against a different cancer and/or against multiple cancers. In certain embodiments the vaccination is with cells from multiple different types (e.g., 2 or more cancers, 3 or more cancers, 4 or more cancers, 5 or more cancers, 6 or more cancers, 7 or more cancers, 8 or more cancers, 9 or more cancers, 10 or more cancers, etc.) in which ICD is induced.
- multiple different types e.g., 2 or more cancers, 3 or more cancers, 4 or more cancers, 5 or more cancers, 6 or more cancers, 7 or more cancers, 8 or more cancers, 9 or more cancers, 10 or more cancers, etc.
- illustrative cancers to be treated or prevented include, but are not limited to pancreatic ductal adenocarcinoma (PDAC), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Adrenocortical carcinoma, Kaposi sarcoma, anal cancer, appendix cancer, astrocytoma, atypical teratoid/rhabdoid tumor, bile duct cancer, extrahepatic cancer, bladder cancer, bone cancer (e.g., Ewing sarcoma, osteosarcoma, malignant fibrous histiocytoma), brain stem glioma, brain tumors (e.g., astrocytomas, brain and spinal cord tumors, brain stem glioma, central nervous system atypical teratoid/rhabdoid tumor, central nervous system embryonal tumors, central nervous system germ cell tumors, craniopharyngioma, ependymo
- PDAC pancreatic
- bile extrahepatic
- ductal carcinoma in situ DCIS
- embryonal tumors endometrial cancer, ependymoma, esophageal cancer, esthesioneuroblastoma, extracranial germ cell tumor, extragonadal germ cell tumor, extrahepatic bile duct cancer, eye cancer (e.g., intraocular melanoma, retinoblastoma), fibrous histiocytoma of bone, malignant, and osteosarcoma, gallbladder cancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumors (GIST), germ cell tumors (e.g., ovarian cancer, testicular cancer, extracranial cancers, extragonadal cancers, central nervous system), gestational trophoblastic tumor, brain stem cancer, hairy cell leukemia, head and neck cancer, heart cancer, hepatocellular (liver) cancer, histiocytosis, langerhan
- the cells used in the vaccination include cells of one or more of these cancers.
- Methods of inducing immunogenic cell death are well known to those of skill in the art.
- ICD is induced by contacting the cells (e.g., primary tumor cells, cancer cell lines, etc.) with one or more chemotherapeutic agent(s) that induce ICD.
- Such agents include, but are not limited to oxaliplatin, anthracenedione, bleomycin, bortezomib, cisplatin, daunorubicin, docetaxel, doxorubicin, epirubicin, idarubicin, mitoxanthrone, paclitaxel, irinotecan, R2016 (a heterocyclic quinolone derivative described by Son et al. (2017) Plos One, DOI:10.1371, which is incorporated herein by reference for the compounds described therein), and cyclophosphamide.
- the ICD chemo reagents may also include the drug derivatives, i.e.
- ICD infecting the cells with an oncolytic virus.
- oncoviruses that induce ICD include, but are not limited to Parvovirus (e.g., H-PV (see, e.g., Angelova et al. (2014) J. Virol., 88(10): 5263-5276), and the like), Adenovirus (AD) (e.g., hTERT-Ad (see, e.g., Boozari et al.
- HSV Herpes simplex virus
- G207 see, e.g., Toda et al. (1999) Hum. Gene. Ther.10: 385-393
- HSV-1716 see, e.g., Benencia et al. (2005) Mol. Ther., 12: 789-8020
- T- VEC see, e.g., Hu et al. (2006) Clin.
- HSV-2 ⁇ PK mutant see, e.g., Colunga et al. (2010) Gene Ther., 17: 315-327), and the like
- Poxvirus e.g., vSP (see, e.g.,Guo et al. (2005) Cancer Res.65: 9991-9998, vvDD (see, e.g., John et al. (2012) Cancer Res., 72: 1651-1660)
- Pexa-Vec see, e.g., Heo et al. (2013) Nat.
- Arbovirus see, e.g., VSV-GFP (Indiana serotype) (see, e.g., Wongthida et al. (2010) Cancer Res.70: 4539-4549), VSVgm-icv (see, e.g., Lemay et al. (2012) Mol. Ther., 20: 1791-1799), and the like), Paramyxovirus (e.g., MV-eGFP (Edmonston strain) (see, e.g., Donnelly et al. (2013) Gene Ther.20: 7-15), and the like).
- VSV-GFP Indiana serotype
- VSVgm-icv see, e.g., Lemay et al. (2012) Mol. Ther., 20: 1791-1799
- Paramyxovirus e.g., MV-eGFP (Edmonston strain) (see, e.g., Donnelly et al. (2013) Gene Ther.20: 7-15
- ICD induction is accomplished using any of the compounds and/or modalities described in Table 2. Table 2. Illustrative compounds and/or modalities to induce immunogenic cell death (ICD).
- the methods of inducing ICD can involve contacting the cells with materials, e.g., nanomaterials that induce ICD. It was a surprising discovery that certain materials (e.g., nanomaterials), as a result of intrinsic nanomaterial properties, are capable of inducing ICD, e.g., as determined by CRT induction, in a manner comparable to the positive control, oxaliplatin. Such materials include, but are not limited to CuO, graphene oxide, and certain others (see, e.g., Example 3).
- ICD is induced by contacting the cancer cells with a nanomaterial that induces ICD (e.g., CuO, Cu 2 O, As 2 O 3 , Bi 2 O 3 , P 2 O 3 , ZnO, TiO 2 , graphene oxide, 2D materials other than graphene or graphene oxide (e.g., graphene, graphyne, borophene, germanene, silicene, Si2BN, stanene, phosphorene, bismuthene, molybdenite, metals, 2D supracrystals, and the like)).
- the nanomaterial comprises copper oxide.
- the nanomaterial comprises graphene oxide (GO), CuO, Cu 2 O, Sb 2 O 3 , As 2 O 3 , Bi 2 O 3 , P 2 O 3 , ZnO, TiO2, graphene oxide, and 2D materials other than graphene or graphene oxide
- GO graphene oxide
- CuO Cu 2 O
- Sb 2 O 3 As 2 O 3 , Bi 2 O 3 , P 2 O 3 , ZnO, TiO2, graphene oxide, and 2D materials other than graphene or graphene oxide
- nanomaterial libraries including metals, metal oxides, rare earth oxides, graphene, graphene oxide, multi- and single walled carbon nanotubes, fumed silica, long aspect ratio nanomaterials, redox active nanomaterials, nanomaterials with functionalized catalytic surfaces and coatings etc
- our nanomaterial safety screening laboratory in the California Nano Systems Institute at UCLA have demonstrated a variety of mechanisms, involving intrinsic nanomaterial properties, that can induce a wide variety of different types of cell death,
- 2D materials include, but are not limited to BN, MoS2, NbSe 2 , Bi 2 Sr 2 CaCu 2 O x (Id.), single layers of single layers of manganese (see, e.g., Omomo et al. (2003) J. Am. Chem. Soc., 125: 3568-3575), oxides of cobalt (see, e.g., Kim et al. (2009) Chem. Eur. J., 15: 10752-10761), tantalum (Fukuda et al. (2007) Inorg. Chem.46: 4787- 4789), ruthenium (Fukuda et al. (2010) Inorg.
- these ICD-inducing nanomaterials exhibit a range of tunable physicochemical properties that can readily be adapted to achieve the optimal ICD-inducing catalytic outcomes.
- these properties include, inter alia, nanosheet size, surface oxidation status, and the like
- metal oxides these properties include, inter alia, the particle size, dissolution characteristics, zeta potential, and the like.
- the list of nanomaterials above that induce immunogenic cell death is illustrative and non-limiting.
- ICD is characterized by elevated expression of calreticulin (CRT), and/or elevated expression and/or release of e.g., HMGB1 or ATP as compared to the same cells in which ICD is not induced.
- CRT calreticulin
- ICD is characterized by elevated expression of calreticulin (CRT), and/or elevated expression and/or release of e.g., HMGB1 or ATP as compared to the same cells in which ICD is not induced.
- CTR calreticulin
- HMGB1 or ATP e.g., HMGB1 or ATP
- the vaccination will be by intramuscular, subcutaneous, or intradermal injection.
- injection may be performed by needle or pressure.
- mucosal immunization can be performed and such modalities include, but are not limited to intraocular, intranasal and/or oral.
- jet injectors such as Antares Pharma's MediJector VISION, deliver medication through high-speed, pressurized liquid penetration of the skin without a needle. These have been developed as single-use devices and multiuse systems. A high peak pressure behind the liquid is required so it can drill a hole in the skin, and then the pressure is reduced to allow the rest of the liquid to enter the skin.
- transdermal approaches deliver the antigen in a solid form. These approaches have the added benefit that the therapeutic agent is more stable and therefore may not need cold storage.
- Another illustrative, but non-limiting approach uses the pharmaceutical formulation itself to puncture the skin. Glide Pharma has developed a low-velocity, spring- powered administrator that pushes a pointed rod of pharmaceutical material through the skin in a fraction of a second. This administrator enables constant, reliable delivery of a solid dosage form and could be applied to various vaccines including vaccines comprising cancer ICD-induced cancer cells as described herein.
- the antigen e.g., ICD- induced cancer cells
- the hydrogel is an injectible hydrogel.
- injectable hydrogels can be prepared using a wide range of materials. Cyto- and bio-compatibility as well as reactive chemistries are typical factors considered for selecting base materials that can be used in hydrogels for cell delivery. Material crosslinking (formation and concentration of physical or covalent linkages), biodegradability, and biochemical properties can influence the structural, mechanical, and biological properties of the hydrogels initially and over time.
- Hydrophilic polymers used for hydrogel construction generally can be divided into two categories: natural polymers derived from tissues or other natural sources and synthetic polymers fabricated using organic chemistry and molecular engineering principles.
- Biocompatible natural polymers such as hyaluronic acid, chitosan, heparin, alginate, fibrin, collagen, chondroitin sulfate, and silk, mimic aspects of the native microenvironment, including its mechanical and biochemical properties for modulating cell adhesion, migration, and other functions (see, e.g., Munarin et al. (2012) J. Appl. Biomater. Funct. Mater.10(2): e67-81).
- Synthetic polymers such as poly(ethylene glycol) (PEG), poly(vinyl alcohol) (PVA), poly(N-isopropylacrylamide) (PNIPAAm), and polycaprolactone (PCL) have frequently been used for the design of injectable, cell-compatible hydrogels due to their commercial availability, low batch-to-batch variation, versatility for chemical modification, and consequently, the ease of tuning the mechanical properties of the resulting hydrogels. Since synthetic polymers lack the inherent biochemical cues for interaction with cells, In certain embodiments they can be used in combination with natural polymers or biomimetic peptides to facilitate cell adhesion, migration, and protein secretion.
- PEG poly(ethylene glycol)
- PVA poly(vinyl alcohol)
- PNIPAAm poly(N-isopropylacrylamide)
- PCL polycaprolactone
- the cells can be delivered by use of an injectable (or implantable) cryogel.
- Cryogels are a type of hydrogel made up of cross-linked hydrophilic polymer chains that can hold up to 99 percent water. They are created by freezing a solution of the polymer that is in the process of gelling. When thawed back again to room temperature, the substance turns into a highly interconnected pore- containing hydrogel, which is similar in composition to bodily soft tissues in terms of their water content, structure, and mechanics.
- By adjusting their shape, physical properties, and chemical composition sponge-like, porous cryogels can be formed that can be infused with living cells, biological molecules or drugs.
- cyrogel is formed from methacrylated alginate (MA-alginate) as described by Bencherif et al. (2016) Nat. Comm., 6: 7556.
- Adjuvants are formed from methacrylated alginate (MA-alginate) as described by Bencherif et al. (2016) Nat. Comm., 6: 7556.
- Adjuvants are formed from methacrylated alginate (MA-alginate) as described by Bencherif et al. (2016) Nat. Comm., 6: 7556.
- Adjuvants are formed from methacrylated alginate (MA-alginate) as described by Bencherif et al. (2016) Nat. Comm., 6: 7556.
- Adjuvants are examples of the vaccination utilizing cancer cells in which ICD has been induced.
- adjuvants enhance and direct the adaptive immune response to vaccine antigens.
- Adjuvants may exert their effects through different mechanisms.
- Some adjuvants such as alum and emulsions (e.g., MF59®), function as delivery systems by generating depots that trap antigens at the injection site, providing slow release in order to continue the stimulation of the immune system. These adjuvants enhance the antigen persistence at the injection site and increase recruitment and activation of antigen presenting cells (APCs).
- Particulate adjuvants e.g., alum
- have the capability to bind antigens to form multi-molecular aggregates that encourage uptake by APCs see, e.g., Leroux-Roels (2010) Vaccine.28S(3) :C25-3).
- Some adjuvants are also capable of directing antigen presentation by the major histocompatibility complexes (MHC) (Id.).
- MHC major histocompatibility complexes
- Other adjuvants essentially ligands for pattern recognition receptors (PRR), act by inducing the innate immunity, predominantly targeting the APCs and consequently influencing the adaptive immune response. AlOOH described below is one such example.
- PRR pattern recognition receptors
- Members of nearly all of the PRR families are potential targets for adjuvants. These include Toll-like receptors (TLRs), NOD-like receptors (NLRs), RIG-I- like receptors (RLRs) and C-type lectin receptors (CLRs). They signal through pathways that involve distinct adaptor molecules leading to the activation of different transcription factors.
- transcription factors e.g., NF- ⁇ B, IRF3
- cytokines and chemokines that play a key role in the priming, expansion and polarization of the immune responses.
- Activation of some members of the NLR family, such as NLRP3 and NLRC4 triggers the formation of a protein complex, called inflammasome, implicated in the induction of the pro-inflammatory cytokines IL-1 ⁇ (see, e.g., Li et al. (2008) J. Immunol.181(1): 17- 21.) and IL-18.
- the NLRP3 and NLRC4 inflammasomes have been involved in the innate immunity induced by certain adjuvants.
- Alum & emulsions [0415] Alum is the most commonly used adjuvant in human vaccination. Alum provokes a strong Th2 response. Alum induces the immune response by a depot effect and activation of APCs. The NLRP3 inflammasome has been linked to the immunostimulatory properties of alum.
- a high aspect ratio AlOOH variant of alum can be used as an adjuvant.
- the high aspect ratio AlOOH that is 1-2 orders of magnitude better than Alum, based, inter alia, on the principle that the long aspect ratio of the material and its surface reactivity provide superior stimulation to the NRLP3 inflammasome in dendritic cells (see, e.g., Sun et al. (2013) ACS Nano, 7(12): 10834-10849).
- emulsions can trigger depot generation and induction of MHC responses.
- IFA Incomplete Adjuvant
- MF59® is a potent stimulator of both cellular (Th1) and humoral (Th2) immune responses.
- PRR Ligands New adjuvants are being developed that are natural ligands or synthetic agonists for PRRs, either alone or with various formulations. PRR activation stimulates the production of pro-inflammatory cytokines/chemokines and type I IFNs that increase the host’s ability to eliminate the pathogen.
- PAMPs pathogens associated molecular patterns
- TLR3 and RLR Ligands Double-stranded RNA (dsRNA), which is produced during the replication of most viruses, is a potent inducer of innate immunity. Synthetic analogs of dsRNA, such as poly(I:C), have been utilized as adjuvants. They act through TLR 3 and RIG-I/MDA-5, inducing IL-12 and type I IFNs production, facilitating antigen cross-presentation to MHC class II molecules, and improving generation of cytotoxic T cells.
- TLR4 Ligands Bacterial lipopolysaccharides (LPS), which are ligands for TLR4, have long been recognized as potent adjuvants.
- TLR5 Ligands [0421] The TLR5 ligand, bacterial flagellin, is a potent T-cell antigen and has been utilized as a vaccine adjuvant. Unlike other TLR agonists, flagellin tends to produce mixed Th1 and Th2 responses rather than strongly Th1 responses. Flagellin can be used as an adjuvant mixed with the antigen.
- TLR7/8 Ligands [0422] The TLR7/8 pathway, specialized in the recognition of single stranded viral RNA, has also been explored for use as vaccine adjuvants.
- Imidazoquinolines e.g., imiquimod, gardiquimod, and R848
- Imidazoquinolines are synthetic compounds that activate TLR7/8 in multiple subsets of dendritic cells leading to the production of IFN- ⁇ and IL-12 thus promoting a Th1 response.
- the formulations and/or drug delivery nanocarriers described herein can easily include imiquimod.
- TLR9 Ligands Oligodeoxynucleotides containing specific CpG motifs (CpG ODNs such as ODN 1826 and ODN 2006) are recognized by TLR9. They enhance antibody production and strongly polarize the cell responses to Th1 and away from Th2 responses.
- various drug delivery nanocarriers described herein e.g., a bilayer-coated nanoparticle
- can readily be modified to present CPG oligonucleotides on the surface e.g., LB-coated nanoparticles can present CPG oligo’s on the lipid bilayer).
- NOD2 Ligands Fragments of bacterial cell walls, such as muramyl dipeptide (MDP), have long been recognized as adjuvants. More recently, it was discovered that MDP triggers the activation of NOD2 and the NLRP3 inflammasome.
- Adjuvants may be combined to achieve a stronger effect or a more potent skewing of immune responses. For example, alum has been combined with TLR9 agonists (see, e.g., Siegrist et al. (2004) Vaccine, 23(5): 615-622). In experimental models, administration of other combinations such as CpG ODNs with MDP or MPLA has proven effective (see, e.g., Kim et al.
- any one or more of the these adjuvants may be used to enhance response to the vaccination with cancer cells in which ICD has been induced.
- the foregoing vaccination methods are illustrative and non-limiting. Using the teachings provided herein, numerous other methods and compositions for vaccinating subjects with cancer cells in which ICD is induced will be available to one of skill in the art.
- IDO inhibitors [0428] A number of IDO inhibitors are well-known to those of skill in the art and useful in the methods described herein. Illustrative, but non-limiting examples of IDO inhibitors are shown in Table 3 and the structures of several of these are shown in Figure 2. Table 3. Illustrative, but non-limiting IDO inhibitors.
- IDO inhibitors include, but are not limited to the inhibitors described in U.S. Patent Publication Nos: US 2016/0362412, US 2016/0289171, US 2016/0200674, US 2016/0143870, US 2016/0137595, US 2016/0060237, US 2016/0002249, US 2014/0323740, US 2014/0066625, US 2013/0289083, US 2013/0183388, US 2012/0277217, US 2011/0136796, US 2011/0112282, US 2011/0053941, US 2010/0233166, US 2010/0166881, US 2010/0076066, US 2009/0042868, US 2007/0173524, US 2007/0105907, which are all incorporated herein by reference for the IDO inhibitors described therein.
- the methods described herein can use one or more of these IDO inhibitors and/or any other IDO inhibitors known to those of skill in the art.
- the one or more IDO inhibitors comprise indoximod. Conjugated IDO inhibitors and vesicles thereof.
- one or more IDO inhibitors e.g., any one or more of the IDO inhibitors shown in Table 3 are conjugated to a moiety that forms a vesicle (e.g., a liposome or a micelle) structure in aqueous solution or that can form a component of a lipid bilayer comprising a liposome.
- the conjugated IDO inhibitors can be used directly (e.g., described in approach 2 above), provided as components in a combined formulation (e.g., in combination with an ICD inducer), and in certain embodiments, the IDO inhibitor is conjugated to a moiety that forms a component of a lipid bilayer that can be disposed on a nanoparticle, e.g., as described below and in Example 1).
- the moiety that is conjugated to the the IDO pathway inhibitor comprises a lipid (e.g., a phospholipid), vitamin E, cholesterol, and/or a fatty acid.
- the an ester bond is used to make the conjugate.
- the NH2 group in the indoximod is protected before the conjugation reaction.
- IDO inhibitor e.g., indoximod
- the NH 2 group can be protected.
- Examples 8 and 9 illustrate various conjugation strategies. These reactions, however, are illustrative and non-limiting. Numerous IDO inhibitors have other groups readily available for conjugation directly to a vesicle-forming moiety or to a linker.
- the IDO pathway inhibitor can be conjugated to a lipid (e.g., a phospholipid), or cholesterol.
- a lipid e.g., a phospholipid
- the other vesicle-forming agents having conjugated IDO inhibitor(s) can also be incorporated into a lipid bilayer.
- the inhibitor of the IDO pathway is conjugated to cholesterol or to a modified cholesterol (e.g., cholesterol hemisuccinate (CHEMS), lysine- based cholesterol (CHLYS), PEGylated cholesterol (Chol-PEG), and the like).
- CHEMS cholesterol hemisuccinate
- CHLYS lysine- based cholesterol
- Chol-PEG PEGylated cholesterol
- the IDO pathway inhibitor is conjugated to cholesterol by a linker.
- the IDO pathway inhibitor is conjugated directly to cholesterol (see, e.g., Formulas II, IIa, and IIb in Figure 8).
- the inhibitor of the IDO pathway is conjugated to a phospholipid comprising a saturated fatty acid with a C14-C20 carbon chain, and/or an unsaturated fatty acid with a C14-C20 carbon chain, and/or a natural lipid comprising a mixture of fatty acids with C12-C20 carbon chains.
- the phospholipid comprises a saturated fatty acid selected from the group consisting of phosphatidylcholine (DPPC), dimyristoylphosphatidylcholine (DMPC), distearoylphosphatidylcholine (DSPC), and diactylphosphatidylcholine (DAPC).
- the phospholipid comprises a natural lipid selected from the group consisting of egg phosphatidylcholine (egg PC), and soy phosphatidylcholine (soy PC).
- the phospholipid comprises an unsaturated fatty acid selected from the group consisting of 1,2-dimyristoleoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoleoyl-sn- glycero-3-phosphocholine,1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), and 1,2- dieicosenoyl-sn-glycero-3-phosphocholine, and the like.
- DOPC 1,2-dieicosenoyl-sn-glycero-3-phosphocholine
- the 1- methyl-tryptophan component of the conjugated IND can be a "D" isomer or an L isomer.
- the IDO pathway inhibitors can be incorporated into the lipid bilayer forming the vesicle witout conjugation to a lipid bilayer component.
- epacadostat is a potent direct IDO enzyme inhibitor with an IC50 of ⁇ 125 nM in a whole blood assay (Yue et al. (2017) ACS Med. Chem. Letts.8: 486-491).
- Epacadostat is highly soluble in ethanol (>20 mg/mL), which allows its incorporation into a liposomal membrane through the use of the ethanol injection method ((see, e.g., Pons, et al. (1993) J. Pharmaceutic.95: 51-56).
- the ethanol injection method produces homogeneous unilamellar liposomes (Pereira et al.
- the effect can be attributed to the superior ICD inducing effect of mitoxantrone over doxirubicin, rendering a liposomal mitoxantrone candidate that can be used for multiple cancer types.
- the mitoxantrone-only liposome was so effective that an additional effect for cholesterol-IND was not observed, reflecting the possibility that the 4T1 triple negative breast cancer model may represent a TN cancer subset in which IDO-1 does not play a major role.
- the same triple negative cancer also fails to respond to anti-PD1, the ligand of which is controlled by the same IFN-gamma response pathway that is responsible for the expression of PD-1 ligand.
- TN breast cancer may be no different from a series of solid cancers in which there is only a 25-30% response rate to checkpoint inhibitors, likely due to a variable contribution by different immune escape mechanisms.
- the liposome formulations are the same as liposome formulations described herein comrpsing IND, but the lipid bilayer components do not comprise a conjugated IDO inhibitor.
- Remote loading of Silicasomes, and Vesicles/Liposomes can be optimized by using a "remote loading" strategy in which the addition of the drug (e.g., ICD-inducer such as doxorubicin) to preformed vesicles or silicasomes (LB-coated nanoparticles) which achieves high loading levels using a a pH gradient or an ion gradient capable of generating a pH gradient (see, e.g., Ogawa et al.
- the remote loading method involves adding a cargo-trapping reagent (e.g., protonating reagent such as TEA8SOS, ammonium sulfate, etc.) which can be added to the lipid biofilm prior to the sonication in the formation of silicasomes, or can be incorporated into the nanovesicle lipids prior to the formation of the nanovesicle e.g., as described in Example 2.
- a cargo-trapping reagent e.g., protonating reagent such as TEA8SOS, ammonium sulfate, etc.
- a DOX/IND nanovesicle can be prepared as follows: 1) a total of 50 mg lipids of IND-Chol plus other vesicle-forming lipids (e.g., DPPC/Chol-IND/DPPG/DSPE-PEG (e.g., DSPE- PEG2k, DSPE-PEG5k, and the like), in certain embodiments at a molar ratio of ⁇ 40% (DPPC): ⁇ 35% (Chol-IND): ⁇ 20%DPPG: ⁇ 5% DSPE-PEG) can be dissolved in 5 mL chloroform in a 50 mL round bottom glass flask.
- DPPC DPPC/Chol-IND/DPPG/DSPE-PEG
- DSPE-PEG e.g., DSPE- PEG2k, DSPE-PEG5k, and the like
- the solvent can be evaporated under a rotatory vacuum to form a uniform thin lipid film that can be dried further under vacuum overnight.
- the film can be hydrated with a cargo-trapping agent (e.g., with 2 mL of ammonium sulfate (123 mM) and probe sonicated, e.g., for 1 h, then subsequently extruded, e.g., 15 times, through a Mini-Extruder (Avanti Polar Lipids), using, e.g., a polycarbonate membrane with 100 nm pores (Avanti Polar Lipids) at 80 °C.
- a cargo-trapping agent e.g., with 2 mL of ammonium sulfate (123 mM) and probe sonicated, e.g., for 1 h, then subsequently extruded, e.g., 15 times, through a Mini-Extruder (Avanti Polar Lipids), using, e.g.
- IND nanovesicle (IND-NV) size and morphology can be assessed by dynamic light scattering and cryoEM, respectively as desired.
- Unincorporated cargo-trapping agent e.g., ammonium sulfate
- the drug to be loaded e.g., 6.4 mg of DOX•HCl (10 mg/mL) in DI water
- the nanovesicles can be fractionated across a PD-10 column, allowing the removal of free DOX.
- citrate can be used to load mitoxantrone.
- this protocol is illustrative and non-limiting. Using this teaching, numerous other nanovesicles comprising an ICD-inducer and various lipid formulatiosn can be produced by one of skill in the art. [0449] Similarly, preparation and remote-loading of a silicasome comprising an IDO pathway inhibitor and an ICD-inducer is illustrated in example 2.
- a DOX/IND-MSNP dual- delivery carrier is designed by trapping DOX in the mesoporous interior of a ⁇ 65 nm MSNP, using a lipid bilayer into which IND-Chol can be incorporated.
- DOX was then remotely loaded using the protocol as previously described (Id).
- this involves preparing the MSNPs, e.g., by a sol-gel synthesis process (see. e.g., Meng et al.
- the MSNPs are then soaked in the cargo-trapping agent (e.g., ammonium sulfate) to load the agent into the pores of the MSNPs.
- the lipid formulation that will comprise the bilayer surrounding the silicasome is prepared, e.g., as described in Example 2, where the lipid formulation incorporates the IDO inhibitor (e.g., IND-Chol).
- the cargo-trapping agent loaded MSNPs are added to the IDO-inhibitor lipid film followed by sonication (e.g., 30 min probe sonication) to provide the trapping agent (e.g., ammonium sulfate)-loaded IND-Chol coated MSNP.
- the particle suspension can be passed through a PD-10 size exclusion column.
- Ammonium sulfate-containing IND-LB coated MSNPs will elute from column faster than free ammonium sulfate due to its large size.
- Remote Dox loading can be accomplished by incubating 6.5 ⁇ 32.4 mg of DOX•HCl (10 mg/mL) in DI water with cargo-trapping agent loaded laden IND-LB components coated MSNP at 65 °C for 40 min. The pure MSNPs can be collected by centrifuging at 15,000 rpm for 15 min, three times. [0451] This protocol also is illustrative and non-limiting.
- silicasomes comprising an IDO pathway inhibitor and ICD-inducer and various lipid formulatiosn can be produced by one of skill in the art.
- the lipid conjugation technology described herein can be used to make prodrugs out of chemo agents, which can be folded into a liposome.
- ICD chemo agents like the taxanes can be incorporated into a phospholipid bilayer based on hydrophobicity, and this has been demonstrated for a MSNP where we used paclitaxel incorporation into the encapsulating phospholipid bilayer. The same can be done for a liposome.
- the versatility of the liposomal platform described herein allows the encapsulation of ICD-inducing drugs such as paclitaxel, docetaxel, mitroxantrone, irinotecan and etoposide through the use different loading strategies that depend on the chemical structure of the drugs.
- ICD-inducing drugs such as paclitaxel, docetaxel, mitroxantrone, irinotecan and etoposide
- mitoxantrone which is a weak basic molecule with MW of 444.4, water solubility of 89 mg/mL and log P value of -3.1 (mitoxantrone. www.drugbank.ca/drugs/DB01204)
- mitoxantrone which is a weak basic molecule with MW of 444.4, water solubility of 89 mg/mL and log P value of -3.1 (mitoxantrone. www.drugbank.ca/drugs/DB01204)
- mitoxantrone which is
- the size of the liposomes can be controlled by the ratio of ethanol to water. While paclitaxel (PTX) is moderately soluble in ethanol (1.5 mg/mL), up to ⁇ 5 wt% PTX can be loaded into the liposomal membrane by ethanol injection (Koudelka & Turánek(2012) J. Control. Release, 163: 322-334). [0454] These embodiments are illustrative and non-limiting. Using the teachings provided herein numerous variants will be available to one of skill in the art. Cargo trapping reagents.
- a cargo-trapping reagent can be utilized to facilitate incorporation of a cargo (e.g., DOX, MTX, OX, irinotecan etc. (see, e.g., Table 2)) into the dual-delivery (ICD-inducer/IDO-inhibitor) LB coated MSNP (ICD/IDO silicasome), and/or the dual-delivery lipid vesicles (e.g., ICD/IDO-lipid vesicles).
- the cargo- trapping reagent can be selected to interact with a desired cargo. In some embodiments, this interaction can be an ionic or protonation reaction, although other modes of interaction are contemplated.
- the cargo-trapping agent can have one or more ionic sites, i.e., can be mono- ionic or poly-ionic.
- the ionic moiety can be cationic, anionic, or in some cases, the cargo- trapping agent can include both cationic and anionic moieties.
- the ionic sites can be in equilibrium with corresponding uncharged forms; for example, an anionic carboxylate (-COO-) can be in equilibrium with its corresponding carboxylic acid (-COOH); or in another example, an amine (-NH 2 ) can be in equilibrium with its corresponding protonated ammonium form (-NH3 + ). These equilibriums are influenced by the pH of the local environment.
- the cargo can include one or more ionic sites.
- the cargo-trapping agent and cargo can be selected to interact inside the dual-delivery (ICD-inducer/IDO-inhibitor) LB coated MSNP (ICD/IDO silicasome), and/or the dual- delivery lipid vesicle (e.g., ICD/IDO-lipid vesicle). This interaction can help retain the cargo within the nanoparticle until release of the cargo is desired.
- the cargo can exist in a pH-dependent equilibrium between non-ionic and ionic forms.
- the non-ionic form can diffuse across the lipid bilayer and enter the vesicle or the pores of the MSNP.
- the cargo-trapping agent e.g., a polyionic cargo-trapping agent
- the interaction can be an ionic interaction, and can include formation of a precipitate.
- Trapping of cargo within the nanocarrier can provide higher levels of cargo loading compared to similar systems, e.g., nanocarriers that omit the cargo-trapping agent, or liposomes that do include a trapping agent.
- Release of the cargo can be achieved by an appropriate change in pH to disrupt the interaction between the cargo and cargo-trapping agent, for example, by returning the cargo to its non-ionic state which can more readily diffuse across the lipid bilayer.
- the cargo is irinotecan and the cargo-trapping agent is TEA 8 SOS.
- the cargo trapping agent need not be limited to TEA 8 SOS.
- the cargo trapping comprises small molecules like citric acid, (NH4)2SO4, and the like (see, e.g., Examples 2 and 9).
- Other trapping agents include, but are not limited to, ammonium salts (e.g., ammonium sulfate, ammonium sucrose octasulfate, ammonium ⁇ - cyclodextrin sulfate, ammonium ⁇ -cyclodextrin sulfate, ammonium ⁇ -cyclodextrin sulfate, ammonium phosphate, ammonium ⁇ -cyclodextrin phosphate, ammonium ⁇ -cyclodextrin phosphate, ammonium ⁇ -cyclodextrin phosphate, ammonium citrate, ammonium acetate, and the like), trimethylammonium salts (e.g., trimethylammonium sulfate, trimethylammonium sucrose octasulfate, tri
- transmembrane pH gradients can also be generated by acidic buffers (e.g. citrate) (Chou et al. (2003) J. Biosci. Bioengineer., 95(4): 405-408; Nichols et al. (1976) Biochimica et Biophysica Acta (BBA)- Biomembranes, 455(1): 269-271), proton-generating dissociable salts (e.g. (NH4)2SO4) (Haran et al.
- acidic buffers e.g. citrate
- NH4SO4 proton-generating dissociable salts
- the cargo-trapping reagent is particular suitable for use with a cargo that comprises an organic compound that includes at least one primary amine group, or at least one secondary amine group, or at least one tertiary amine group, or at least one quaternary amine group, or any combination thereof, capable of being protonated.
- the general characteristics of these cargo molecules include the following chemical properties: [0461] (i) organic molecular compounds that include primary, secondary, tertiary or quaternary amine(s); [0462] (ii) a pKa ⁇ 11 to allow protonation and entrapment behind the LB (Zucker et al. (2009) J. Control.
- drugs that can be imported across the lipid bilayer of these carriers.
- These include, but are not limited to, weak basic compounds, with medicinal chemical features.
- alkaloids e.g. irinotecan, topotecan, 10-hydroxycamptothecin, belotecan, rubitecan, vinorelbine, LAQ824, vinblastine, vincristine, homoharringtonine, trabectedin
- anthracyclines e.g.
- doxorubicin doxorubicin
- epirubicin pirarubicin
- daunorubicin daunorubicin
- rubidomycin valrubicin
- amrubicin alkaline anthracenediones
- alkaline alkylating agents e.g.
- cyclophosphamide mechlorethamine, temozolomide
- purine or pyrimidine derivatives e.g.5-fluorouracil, 5'-deoxy-5-fluorouridine, gemcitabine, capecitabine
- protein kinase inhibitors e.g., pazopanib, enzastaurin, vandetanib erlotinib, dasatinib, nilotinib, sunitinib, osimertinib, palbociclib, ribociclib
- agents can be remote loaded (e.g., loaded using a cargo trapping agent) into the silicasomes (e.g., dual-delivery (ICD-inducer/IDO-inhibitor) LB coated MSNP (ICD/IDO silicasome)), and vesicles (e.g., the dual-delivery lipid vesicles (e.g., ICD/IDO-lipid vesicles)) described herein.
- lipid vesicles e.g., ICD/IDO-lipid vesicles
- the dual-delivery (ICD-inducer/IDO-inhibitor) LB coated MSNPs (ICD/IDO silicasomes), and/or the dual-delivery lipid vesicles (e.g., ICD/IDO-lipid vesicles), and/or dual delivery lipid-coated ICD-inducing nanomaterial carriers can be conjugated to one or more targeting ligands, e.g., to facilitate specific delivery in endothelial cells, to cancer cells, to fusogenic ligands, e.g., to facilitate endosomal escape, ligands to promote transport across the blood-brain barrier, and the like.
- targeting ligands e.g., to facilitate specific delivery in endothelial cells, to cancer cells, to fusogenic ligands, e.g., to facilitate endosomal escape, ligands to promote transport across the blood-brain barrier, and the like.
- the nanocarrier e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc.
- a fusogenic peptide such as histidine-rich H5WYG (H2N- GLFHAIAHFIHGGWHGLIHGWYG-COOH, (SEQ ID NO:1)) (see, e.g., Midoux et al., (1998) Bioconjug. Chem.9: 260-267).
- the nanocarrier e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc.
- targeting ligand(s) can include antibodies as well as targeting peptides.
- Targeting antibodies include, but are not limited to intact immunoglobulins, immunoglobulin fragments (e.g., F(ab)'2, Fab, etc.) single chain antibodies, diabodies, affibodies, unibodies, nanobodies, and the like.
- antibodies will be used that specifically bind a cancer marker (e.g., a tumor associated antigen).
- cancer markers are known to those of skill in the art.
- the markers need not be unique to cancer cells, but can also be effective where the expression of the marker is elevated in a cancer cell (as compared to normal healthy cells) or where the marker is not present at comparable levels in surrounding tissues (especially where the chimeric moiety is delivered locally).
- Illustrative cancer markers include, for example, the tumor marker recognized by the ND4 monoclonal antibody. This marker is found on poorly differentiated colorectal cancer, as well as gastrointestinal neuroendocrine tumors (see, e.g., Tobi et al. (1998) Cancer Detection and Prevention, 22(2): 147-152).
- Acute lymphocytic leukemia has been characterized by the TAAs HLA-Dr, CD1, CD2, CD5, CD7, CD19, and CD20.
- Acute myelogenous leukemia has been characterized by the TAAs HLA-Dr, CD7, CD13, CD14, CD15, CD33, and CD34.
- Breast cancer has been characterized by the markers EGFR, HER2, MUC1, Tag-72.
- Various carcinomas have been characterized by the markers MUC1, TAG-72, and CEA.
- Chronic lymphocytic leukemia has been characterized by the markers CD3, CD19, CD20, CD21, CD25, and HLA-DR.
- Hairy cell leukemia has been characterized by the markers CD19, CD20, CD21, CD25.
- Hodgkin's disease has been characterized by the Leu-M1 marker.
- Various melanomas have been characterized by the HMB 45 marker.
- Non-hodgkins lymphomas have been characterized by the CD20, CD19, and Ia marker.
- various prostate cancers have been characterized by the PSMA and SE10 markers.
- many kinds of tumor cells display unusual antigens that are either inappropriate for the cell type and/or its environment, or are only normally present during the organisms' development (e.g., fetal antigens).
- glycosphingolipid GD2 a disialoganglioside that is normally only expressed at a significant level on the outer surface membranes of neuronal cells, where its exposure to the immune system is limited by the blood-brain barrier.
- GD2 is expressed on the surfaces of a wide range of tumor cells including neuroblastoma, medulloblastomas, astrocytomas, melanomas, small-cell lung cancer, osteosarcomas and other soft tissue sarcomas. GD2 is thus a convenient tumor-specific target for immunotherapies.
- tumor cells display cell surface receptors that are rare or absent on the surfaces of healthy cells, and which are responsible for activating cellular signaling pathways that cause the unregulated growth and division of the tumor cell. Examples include (ErbB2) HER2/neu, a constitutively active cell surface receptor that is produced at abnormally high levels on the surface of breast cancer tumor cells.
- Other useful targets include, but are not limited to CD20, CD52, CD33, epidermal growth factor receptor and the like.
- An illustrative, but not limiting list of suitable tumor markers is provided in Table 4. Antibodies to these and other cancer markers are known to those of skill in the art and can be obtained commercially or readily produced, e.g. using phage-display technology.
- Such antibodies can readily be conjugated to the drug delivery nanocarrier (e.g., LB-coated nanoparticle) described herein, e.g., in the same manner that iRGD peptide is conjugated in Example 3.
- Table 4 Illustrative cancer markers and associated references, all of which are incorporated herein by reference for the purpose of identifying the referenced tumor markers.
- any of the foregoing markers can be used as targets for the targeting moieties comprising the nanocarrier (e.g., ICD/IDO silicasomes, ICD/IDO lipid vesicles, ICD- inducing nanomaterial carriers, etc.) constructs described herein.
- the nanocarrier e.g., ICD/IDO silicasomes, ICD/IDO lipid vesicles, ICD- inducing nanomaterial carriers, etc.
- the target markers include, but are not limited to members of the epidermal growth factor family (e.g., HER2, HER3, EGF, HER4), CD1, CD2, CD3, CD5, CD7, CD13, CD14, CD15, CD19, CD20, CD21, CD23, CD25, CD33, CD34, CD38, 5E10, CEA, HLA-DR, HM 1.24, HMB 45, 1a, Leu-M1, MUC1, PMSA, TAG-72, phosphatidyl serine antigen, and the like.
- the foregoing markers are intended to be illustrative and not limiting. Other tumor associated antigens will be known to those of skill in the art.
- a ligand to that receptor can function as targeting moieties.
- mimetics of such ligands can also be used as targeting moieties.
- peptide ligands can be used in addition to or in place of various antibodies.
- An illustrative, but non-limiting list of suitable targeting peptides is shown in Table 5. In certain embodiments any one or more of these peptides can be conjugated to a drug delivery vehicle described herein. Table 5.
- the nanocarrier e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc.
- the nanocarrier can be conjugated to moieties that facilitate stability in circulation and/or that hide the nanocarrier from the reticuloendothelial system (REC) and/or that facilitate transport across a barrier (e.g., a stromal barrier, the blood brain barrier, etc.), and/or into a tissue.
- the nanocarriers are conjugated to transferrin or ApoE to facilitate transport across the blood brain barrier.
- the nanocarriers are conjugated to folate.
- nanocarrier e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc.
- targeting agents include, but are not limited to the use of biotin and avidin or streptavidin (see, e.g., U.S.
- Patent No: US 4,885,172 A by traditional chemical reactions using, for example, bifunctional coupling agents such as glutaraldehyde, diimide esters, aromatic and aliphatic diisocyanates, bis-p-nitrophenyl esters of dicarboxylic acids, aromatic disulfonyl chlorides and bifunctional arylhalides such as 1,5-difluoro-2,4- dinitrobenzene; p,p'-difluoro m,m'-dinitrodiphenyl sulfone, sulfhydryl-reactive maleimides, and the like.
- bifunctional coupling agents such as glutaraldehyde, diimide esters, aromatic and aliphatic diisocyanates, bis-p-nitrophenyl esters of dicarboxylic acids, aromatic disulfonyl chlorides and bifunctional arylhalides such as 1,5-difluoro-2,4- dinitrobenzene; p,p'-difluoro
- a peptide e.g., iRGD
- the (e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc.) by substituting a lipid (e.g., DSPE-PEG 2000 ) with a lipid coupled to a linker (e.g., DSPE- PEG2000-maleimide), allowing thiol-maleimide coupling to the cysteine-modified peptide.
- a linker e.g., DSPE- PEG2000-maleimide
- the targeting (and other) moieties can be conjugated to other moieties comprising the lipid bilayer on a silicasome or vesicle, or comprising the nanomaterial carrier. It is also possible to improve tumor delivery of the IDO inhibitor-ICD inducing nanoparticle, (e.g., OX laden IND-Lipid bilayer-MSNP (IND-LB- MSNP), MTX loaded Chol-IND-MSNP, etc.), through co-administration (not conjugated) of the iRGD peptide to enhance particle transcytosis.
- the former conjugates and coupling methods are illustrative and non-limiting.
- the nanocarrier e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc.
- a physiologically-acceptable carrier such as physiological saline or phosphate buffer
- the nanocarriers can be formulated as a sterile suspension, dispersion, or emulsion with a pharmaceutically acceptable carrier.
- normal saline can be employed as the pharmaceutically acceptable carrier.
- Suitable carriers include, e.g., water, buffered water, 0.4% saline, 0.3% glycine, 5% glucose and the like, including glycoproteins for enhanced stability, such as albumin, lipoprotein, globulin, etc.
- the carrier is preferably added following nanocarrier formation.
- the nanocarrier can be diluted into pharmaceutically acceptable carriers such as normal saline.
- the ICD-inducing nanomaterials can be introduced into carriers that facilitate suspension of the nanomaterials (e.g., emulsions, dilutions, etc.).
- the pharmaceutical compositions may be sterilized by conventional, well- known sterilization techniques.
- the resulting aqueous solutions, suspensions, dispersions, emulsions, etc. may be packaged for use or filtered under aseptic conditions.
- the drug delivery nanocarriers e.g., LB-coated nanoparticles
- the compositions may also contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH-adjusting and buffering agents, tonicity adjusting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, etc.
- the pharmaceutical formulation may include lipid-protective agents that protect lipids against free-radical and lipid-peroxidative damage on storage.
- Lipophilic free-radical quenchers such as alpha-tocopherol and water- soluble iron-specific chelators, such as ferrioxamine, are suitable.
- the concentration of the nanocarrier e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc.
- concentration of the nanocarrier can vary widely, e.g., from less than approximately 0.05%, usually at least approximately 2 to 5% to as much as 10 to 50%, or to 40%, or to 30% by weight and are selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.
- the concentration may be increased to lower the fluid load associated with treatment. This may be particularly desirable in patients having atherosclerosis-associated congestive heart failure or severe hypertension.
- nanocarriers composed of irritating lipids may be diluted to low concentrations to lessen inflammation at the site of administration.
- the amount of nanocarriers administered will depend upon the particular drug used, the disease state being treated and the judgment of the clinician but will generally be between approximately 0.01 and approximately 50 mg per kilogram of body weight, preferably between approximately 0.1 and approximately 5 mg per kg of body weight.
- PEG-ceramide, or ganglioside G MI -modified lipids can be incorporated in the nanocarrier (e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD- inducing nanomaterial carrier, etc.). Addition of such components helps prevent nanocarrier aggregation and provides for increasing circulation lifetime and increasing the delivery of the loaded nanocarriers to the target tissues.
- concentration of the PEG-modified phospholipids, PEG-ceramide, or GMI-modified lipids in the nanocarriers will be approximately 1 to 15%.
- overall nanocarrier charge is an important determinant in nanocarrier clearance from the blood. It is believed that highly charged nanocarriers (i.e. zeta potential > +35 mV) will be typically taken up more rapidly by the reticuloendothelial system (see, e.g., Juliano (1975) , Biochem. Biophys. Res. Commun.63: 651-658 discussing liposome clearance by the RES) and thus have shorter half-lives in the bloodstream. Nanocarriers with prolonged circulation half-lives are typically desirable for therapeutic uses.
- drug delivery nanocarriers e.g., LB-coated nanoparticles
- nanocarriers e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc.
- topical dosage forms including but not limited to gels, oils, emulsions, and the like, e.g., for the treatment of a topical cancer.
- the suspension containing the nanocarrier is formulated and administered as a topical cream, paste, ointment, gel, lotion, and the like.
- pharmaceutical formulations comprising nanocarrier e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc.
- the buffering agent may be any pharmaceutically acceptable buffering agent.
- Buffer systems include, but are not limited to citrate buffers, acetate buffers, borate buffers, and phosphate buffers.
- buffers include, but are not limited to citric acid, sodium citrate, sodium acetate, acetic acid, sodium phosphate and phosphoric acid, sodium ascorbate, tartaric acid, maleic acid, glycine, sodium lactate, lactic acid, ascorbic acid, imidazole, sodium bicarbonate and carbonic acid, sodium succinate and succinic acid, histidine, and sodium benzoate, benzoic acid, and the like.
- pharmaceutical formulations comprising nanocarrier e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc. described herein additionally incorporate a chelating agent.
- the chelating agent may be any pharmaceutically acceptable chelating agent.
- Chelating agents include, but are not limited to ethylene diaminetetraacetic acid (also synonymous with EDTA, edetic acid, versene acid, and sequestrene), and EDTA derivatives, such as dipotassium edetate, disodium edetate, edetate calcium disodium, sodium edetate, trisodium edetate, and potassium edetate.
- Other chelating agents include citric acid (e.g., citric acid monohydrate) and derivatives thereof. Derivatives of citric acid include anhydrous citric acid, trisodiumcitrate-dihydrate, and the like.
- Still other chelating agents include, but are not limited to, niacinamide and derivatives thereof and sodium deoxycholate and derivatives thereof.
- pharmaceutical formulations comprising nanocarrier e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc.
- an antioxidant may be any pharmaceutically acceptable antioxidant.
- Antioxidants are well known to those of ordinary skill in the art and include, but are not limited to, materials such as ascorbic acid, ascorbic acid derivatives (e.g., ascorbylpalmitate, ascorbylstearate, sodium ascorbate, calcium ascorbate, etc.), butylated hydroxy anisole, buylated hydroxy toluene, alkylgallate, sodium meta-bisulfate, sodium bisulfate, sodium dithionite, sodium thioglycollic acid, sodium formaldehyde sulfoxylate, tocopherol and derivatives thereof, (d-alpha tocopherol, d-alpha tocopherol acetate, dl-alpha tocopherol acetate, d-alpha tocopherol succinate, beta tocopherol, delta tocopherol, gamma tocopherol, and d-alpha tocopherol polyoxyethylene glycol 1000 succinate) monothioglycerol, sodium sulfit
- such materials when present, are typically added in ranges from 0.01 to 2.0%.
- pharmaceutical formulations comprising nanocarrier (e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc.) described herein are formulated with a cryoprotectant.
- the cryoprotecting agent may be any pharmaceutically acceptable cryoprotecting agent. Common cryoprotecting agents include, but are not limited to, histidine, polyethylene glycol, polyvinyl pyrrolidine, lactose, sucrose, mannitol, polyols, and the like.
- pharmaceutical formulations comprising nanocarrier (e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc.) described herein are formulated with an isotonic agent.
- the isotonic agent can be any pharmaceutically acceptable isotonic agent. This term is used in the art interchangeably with iso-osmotic agent, and is known as a compound that is added to the pharmaceutical preparation to increase the osmotic pressure, e.g., in some embodiments to that of 0.9% sodium chloride solution, which is iso-osmotic with human extracellular fluids, such as plasma.
- Illustrative isotonicity agents include, but are not limited to, sodium chloride, mannitol, sorbitol, lactose, dextrose and glycerol.
- pharmaceutical formulations of the nanocarrier e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc.
- a preservative include, but are not limited to, those selected from the group consisting of chlorobutanol, parabens, thimerosol, benzyl alcohol, and phenol.
- Suitable preservatives include but are not limited to: chlorobutanol (e.g., 0.3-0.9% w/v), parabens (e.g., 0.01-5.0%), thimerosal (e.g., 0.004-0.2%), benzyl alcohol (e.g., 0.5-5%), phenol (e.g., 0.1-1.0%), and the like.
- compositions comprising the nanocarriers (e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc.) described herein are formulated with a humectant, e.g., to provide a pleasant mouth-feel in oral applications.
- Humectants known in the art include, but are not limited to, cholesterol, fatty acids, glycerin, lauric acid, magnesium stearate, pentaerythritol, and propylene glycol.
- an emulsifying agent is included in the formulations, for example, to ensure complete dissolution of all excipients, especially hydrophobic components such as benzyl alcohol.
- Many emulsifiers are known in the art, e.g., polysorbate 60.
- a pharmaceutically acceptable flavoring agent and/or sweetener Compounds such as saccharin, glycerin, simple syrup, and sorbitol are useful as sweeteners.
- the nanocarrier e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD- inducing nanomaterial carrier, etc.
- the nanocarrier e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD- inducing nanomaterial carrier, etc.
- a subject e.g., patient
- the nanocarrier e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc.
- parenterally e.g., intraarticularly, intravenously, intraperitoneally, subcutaneously, or intramuscularly.
- the pharmaceutical compositions are administered intravenously, intraarteraly, or intraperitoneally by a bolus injection (see, e.g., U.S. Pat. Nos.3,993,754; 4,145,410; 4,235,871; 4,224,179; 4,522,803; and 4,588,578 describing administration of liposomes).
- a bolus injection see, e.g., U.S. Pat. Nos.3,993,754; 4,145,410; 4,235,871; 4,224,179; 4,522,803; and 4,588,578 describing administration of liposomes.
- Particular pharmaceutical formulations suitable for this administration are found in Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, Pa., 17th ed. (1985).
- the formulations comprise a solution of the drug delivery nanocarrier suspended in an acceptable carrier, preferably an aqueous carrier.
- suitable aqueous solutions include, but are not limited to physiologically compatible buffers such as Hanks solution, Ringer's solution, or physiological (e.g., 0.9% isotonic) saline buffer and/or in certain emulsion formulations.
- the solution(s) can contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- the active agent(s) can be provided in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
- penetrants appropriate to the barrier to be permeated can be used in the formulation.
- compositions may be sterilized by conventional, well-known sterilization techniques, or may be sterile filtered.
- the resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous solution prior to administration.
- the compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc., e.g., as described above.
- ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc. may be contacted with the target tissue by direct application of the preparation to the tissue.
- the application may be made by topical, "open” or “closed” procedures.
- topical it is meant the direct application of the pharmaceutical preparation to a tissue exposed to the environment, such as the skin, oropharynx, external auditory canal, and the like.
- Open procedures are those procedures that include incising the skin of a patient and directly visualizing the underlying tissue to which the pharmaceutical formulations are applied.
- a surgical procedure such as a thoracotomy to access the lungs, abdominal laparotomy to access abdominal viscera, or other direct surgical approaches to the target tissue.
- Closed procedures are invasive procedures in which the internal target tissues are not directly visualized, but accessed via inserting instnces through small wounds in the skin.
- the preparations may be administered to the peritoneum by needle lavage.
- the pharmaceutical preparations may be administered to the meninges or spinal cord by infusion during a lumbar puncture followed by appropriate positioning of the patient as commonly practiced for spinal anesthesia or metrizamide imaging of the spinal cord.
- the preparations may be administered through endoscopic devices.
- the pharmaceutical formulations are introduced via a cannula.
- the pharmaceutical formulations comprising the nanocarrier e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc.
- inhalation can be a particularly effective delivery route for administration to the lungs and/or to the brain.
- the drug delivery nanocarriers are conveniently delivered in the form of an aerosol spray from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas
- the nanocarrier e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc.
- suitable formulations can be readily formulated by combining the drug delivery nanocarriers) with pharmaceutically acceptable carriers suitable for oral delivery well known in the art.
- Such carriers enable the active agent(s) described herein to be formulated as tablets, pills, dragees, caplets, lozenges, gelcaps, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.
- suitable excipients can include fillers such as sugars (e.g., lactose, sucrose, mannitol and sorbitol), cellulose preparations (e.g., maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose), synthetic polymers (e.g., polyvinylpyrrolidone (PVP)), granulating agents; and binding agents.
- sugars e.g., lactose, sucrose, mannitol and sorbitol
- cellulose preparations e.g., maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose
- synthetic polymers e.g., polyvinylpyrrolidone (PVP)
- disintegrating agents may be added, such as the cross- linked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
- solid dosage forms may be sugar-coated or enteric-coated using standard techniques. The preparation of enteric-coated particles is disclosed for example in U.S. Pat. Nos. 4,786,505 and 4,853,230.
- the nanocarrier e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc.
- the nanocarrier e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc.
- rectal or vaginal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
- active agents for rectal or vaginal delivery are well known to those of skill in the art (see, e.g., Allen (2007) Suppositories, Pharmaceutical Press) and typically involve combining the active agents with a suitable base (e.g., hydrophilic (PEG), lipophilic materials such as cocoa butter or Witepsol W45), amphiphilic materials such as Suppocire AP and polyglycolized glyceride, and the like).
- a suitable base e.g., hydrophilic (PEG), lipophilic materials such as cocoa butter or Witepsol W45
- amphiphilic materials such as Suppocire AP and polyglycolized glyceride, and the like.
- the route of delivery of the nanocarrier (e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc.) described herein can also affect their distribution in the body.
- Passive delivery of nanocarrier e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc.
- routes of administration e.g., parenterally, although other effective administration forms, such as intraarticular injection, inhalant mists, orally active formulations, transdermal iontophoresis, or suppositories are also envisioned.
- each route produces differences in localization of the drug delivery nanocarrier.
- dosage regimens for pharmaceutical agents are well known to medical practitioners, the amount of the liposomal pharmaceutical agent formulations that is effective or therapeutic for the treatment of a disease or condition in mammals and particularly in humans will be apparent to those skilled in the art.
- the optimal quantity and spacing of individual dosages of the formulations herein will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and such optima can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, e.g., the number of doses given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.
- the nanocarrier e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc.
- the nanocarriers and/or pharmaceutical formations thereof described herein are particularly well suited in conditions that require: (1) repeated administrations; and/or (2) the sustained delivery of the drug in its bioactive form; and/or (3) the decreased toxicity with suitable efficacy compared with the free drug(s) in question.
- the nanocarriers and/or pharmaceutical formations thereof are administered in a therapeutically effective dose.
- the term "therapeutically effective" as it pertains to the nanocarriers described herein and formulations thereof means that the combination of ICD inducer and IDO inhibitor produces a desirable effect on the cancer.
- Such desirable effects include, but are not limited to slowing and/or stopping tumor growth and/or proliferation and/or slowing and/or stopping proliferation of metastatic cells, reduction in size and/or number of tumors, and/or elimination of tumor cells and/or metastatic cells, and/or prevention of recurrence of the cancer following remission.
- Exact dosages will vary depending upon such factors as the particular ICD inducer(s) and IDO inhibitors and the desirable medical effect, as well as patient factors such as age, sex, general condition, and the like.
- the prescribing physician will ultimately determine the appropriate dosage of the drug for a given human (or non-human) subject, and this can be expected to vary according to the age, weight, and response of the individual as well as the nature and severity of the patient's disease.
- the dosage of the drug provided by the nanocarrier(s) can be approximately equal to that employed for the free drug.
- the nanocarriers described herein can significantly reduce the toxicity of the drug(s) administered thereby and significantly increase a therapeutic window. Accordingly, in some cases dosages in excess of those prescribed for the free drug(s) will be utilized.
- the dose of each of the drug(s) (e.g., ICD inducer, IDO inhibitor) administered at a particular time point will be in the range from about 1 to about 1,000 mg/m 2 /day, or to about 800 mg/m 2 /day, or to about 600 mg/m 2 /day, or to about 400 mg/m 2 /day.
- a dosage is utilized that provides a range from about 1 to about 350 mg/m 2 /day, 1 to about 300 mg/m 2 /day, 1 to about 250 mg/m 2 /day, 1 to about 200 mg/m 2 /day, 1 to about 150 mg/m 2 /day, 1 to about 100 mg/m 2 /day, from about 5 to about 80 mg/m 2 /day, from about 5 to about 70 mg/m 2 /day, from about 5 to about 60 mg/m 2 /day, from about 5 to about 50 mg/m 2 /day, from about 5 to about 40 mg/m 2 /day, from about 5 to about 20 mg/m 2 /day, from about 10 to about 80 mg/m 2 /day, from about 10 to about 70 mg/m 2 /day, from about 10 to about 60 mg/m 2 /day, from about 10 to about 50 mg/m 2 /day, from about 10 to about 40 mg/m 2 /day, from about
- the does administered at a particular time point may also be about 130 mg/m 2 /day, about 120 mg/m 2 /day, about 100 mg/m 2 /day, about 90 mg/m 2 /day, about 85 mg/m 2 /day, about 80 mg/m 2 /day, about 70 mg/m 2 /day, about 60 mg/m 2 /day, about 50 mg/m 2 /day, about 40 mg/m 2 /day, about 30 mg/m 2 /day, about 20 mg/m 2 /day, about 15 mg/m 2 /day, or about 10 mg/m 2 /day.
- Dosages may also be estimated using in vivo animal models, as will be appreciated by those skill in the art.
- the effective therapeutic dose of the OX/IND nanocarrier in a KPC-derived orthotopic animal model is about 5 mg OX/kg with 50 mg IND/kg, which is equivalent to 15.5 mg OX/m 2 IND 150 mg/m 2 in a 60 kg human subject. Fibonacci analysis indicates this dose can be achieved by starting and intermediary OX doses of 37.5 and 75 mg/m 2 . It is noted that 75 mg/m 2 OX is quite conservative and higher dosages are contemplated.
- the dose administered may be higher or lower than the dose ranges described herein, depending upon, among other factors, the bioavailability of the composition, the tolerance of the individual to adverse side effects, the mode of administration and various factors discussed above. Dosage amount and interval may be adjusted individually to provide plasma levels of the composition that are sufficient to maintain therapeutic effect, according to the judgment of the prescribing physician. Skilled artisans will be able to optimize effective local dosages without undue experimentation in view of the teaching provided herein. [0515] Multiple doses (e.g., continuous or bolus) of the compositions as described herein may also be administered to individuals in need thereof of the course of hours, days, weeks, or months.
- methods of treatment for example, but not limited to, 1, 2, 3, 4, 5, or 6 times daily, every other day, every 10 days, weekly, monthly, twice weekly, three times a week, twice monthly, three times a month, four times a month, five times a month, every other month, every third month, every fourth month, etc.
- Methods of treatment are provided.
- the method(s) comprise a method of treating a cancer.
- the method can comprise administering to a subject in need thereof an effective amount of a nanocarrier (e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD- inducing nanomaterial carrier, etc.), and/or a pharmaceutical formulation comprising a nanocarrier as described herein, where the drug(s) comprising the nanocarrier and/or said pharmaceutical formulation comprises an anti-cancer drug.
- a nanocarrier e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc.
- pharmaceutical formulation is a primary therapy in a chemotherapeutic regimen.
- the nanoparticle drug carrier and/or pharmaceutical formulation is a component in an adjunct therapy in addition to chemotherapy using one or more other chemotherapeutic agents, and/or surgical resection of a tumor mass, and/or radiotherapy.
- the nanocarrier e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc.
- pharmaceutical formulation is a component in a multi-drug chemotherapeutic regimen.
- the multi- drug chemotherapeutic regimen comprises at least two drugs selected from the group consisting of irinotecan (IRIN), oxaliplatin (OX), 5-fluorouracil (5-FU), and leucovorin (LV).
- the multi-drug chemotherapeutic regimen comprises at least three drugs selected from the group consisting of irinotecan (IRIN), oxaliplatin (OX), 5- fluorouracil (5-FU), and leucovorin (LV).
- the multi-drug chemotherapeutic regimen comprises at least irinotecan (IRIN), oxaliplatin (OX), 5- fluorouracil (5-FU), and leucovorin (LV).
- nanocarrier e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc.
- pharmaceutical formulation(s) threeof described herein are effective for treating any of a variety of cancers.
- the cancer is pancreatic ductal adenocarcinoma (PDAC).
- the cancer is a cancer selected from the group consisting of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), adrenocortical carcinoma, AIDS-related cancers (e.g., Kaposi sarcoma, lymphoma), anal cancer, appendix cancer, astrocytomas, atypical teratoid/rhabdoid tumor, bile duct cancer, extrahepatic cancer, bladder cancer, bone cancer (e.g., Ewing sarcoma, osteosarcoma, malignant fibrous histiocytoma), brain stem glioma, brain tumors (e.g., astrocytomas, glioblastoma, brain and spinal cord tumors, brain stem glioma, central nervous system atypical teratoid/rhabdoid tumor, central nervous system embryonal tumors, central nervous system germ cell tumors, craniopharyngioma, ependymoma
- ALL
- bile extrahepatic
- ductal carcinoma in situ DCIS
- embryonal tumors endometrial cancer, ependymoma, esophageal cancer, esthesioneuroblastoma, extracranial germ cell tumor, extragonadal germ cell tumor, extrahepatic bile duct cancer, eye cancer (e.g., intraocular melanoma, retinoblastoma), fibrous histiocytoma of bone, malignant, and osteosarcoma, gallbladder cancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumors (GIST), germ cell tumors (e.g., ovarian cancer, testicular cancer, extracranial cancers, extragonadal cancers, central nervous system), gestational trophoblastic tumor, brain stem cancer, hairy cell leukemia, head and neck cancer, heart cancer, hepatocellular (liver) cancer, histiocytosis, langerhan
- the nanocarrier e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc.
- the nanocarrier is not conjugated to an iRGD peptide and the nanocarrier is administered in conjunction with an iRGD peptide (e.g., the nanocarrier and the iRGD peptide are co-administered as separate formulations).
- the nanocarrier e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc.
- the nanocarrier and/or pharmaceutical formulation is administered as an injection, from an IV drip bag, or via a drug-delivery cannula.
- the subject is a human and in other embodiments the subject is a non-human mammal.
- the nanocarriers described herein e.g., comprising an inducer of immunogenic cell death (ICD), and an IDO inhibitor
- ICD immunogenic cell death
- methods contemplated herein include the administration of a drug delivery nanovesicle and/or a drug delivery nanocarrier as described herein in conjunction with one or more checkpoint inhibitors.
- Illustrative checkpoint inhibitors include, but are not limited to inhibitors of PD-1, PD-L1, PD-L2, PD-L3, PD-L4, CTLA-4, LAG3, B7-H3, B7-H4, KIR and/or TIM3 receptors.
- the immune checkpoint inhibitor can be a small peptide agent that can inhibit regulatory T cell function, including any one or a combination of the inhibitory receptors listed above.
- the immune checkpoint inhibitor can be a small molecule (e.g. less than 500 Daltons) that can inhibit T regulatory cell function. including the immune checkpoint receptors listed above.
- the immune checkpoint inhibitor can be a molecule providing co-stimulation of T-cell activation. In some embodiments, the immune checkpoint inhibitor can be a molecule providing co- stimulation of natural killer cell activation. In some embodiments, the immune checkpoint inhibitor can be an antibody. In some embodiments, the immune checkpoint inhibitor is a PD- 1 antibody. In some embodiments, the immune checkpoint inhibitor is a PD-L1 antibody. In some embodiments, the immune checkpoint inhibitor is a PD-L2 antibody. In some embodiments, the immune checkpoint inhibitor is a PD-L3 antibody. In some embodiments, the immune checkpoint inhibitor is a PD-L4 antibody. In some embodiments, the immune checkpoint inhibitor is a CTLA-4 antibody.
- the immune checkpoint inhibitor is an antibody of CTLA-4, LAG3, B7-H3, B7-H4, KIR, or TIM3.
- the antibody can be selected from ⁇ -CD3-APC, ⁇ - CD3-APC-H7, ⁇ -CD4-ECD, ⁇ -CD4-PB, ⁇ -CD8-PE-Cy7, ⁇ -CD-8-PerCP-Cy5.5, ⁇ -CD11c- APC, ⁇ -CD11b-PE-Cy7, ⁇ -CD11b-AF700, ⁇ -CD14-FITC, ⁇ -CD16-PB, ⁇ -CD19-AF780, ⁇ - CD19-AF700, ⁇ -CD20-PO, ⁇ -CD25-PE-Cy7, ⁇ -CD40-APC, ⁇ -CD45-Biotin, Streptavidin- BV605, ⁇ -CD62L-ECD, ⁇ -CD69-APC-Cy7,
- any of a variety of antibodies can be used in the methods described herein, including, but nor limited to antibodies having high-affinity binding to PD-1 PD-L1, PD-L2, PD-L3, or PD-L4.
- Human mAbs (HuMAbs) that bind specifically to PD-1 e.g., bind to human PD-1 and may cross-react with PD-1 from other species, such as cynomolgus monkey
- HuMAbs that bind specifically to PD-L1 with high affinity have been disclosed in U.S. Pat.
- Anti-PD-L1 mAbs have been described in, for example, U.S. Pat. Nos.7,635,757 and 8,217,149, U.S. Publication No.2009/0317368, and PCT Publication Nos.
- the anti-PD-1 HuMAbs can be selected from 17D8, 2D3, 4H1, 5C4 (also referred to herein as nivolumab), 4A11, 7D3 and 5F4, all of which are described in U.S. Pat. No.8,008,449.
- the anti-PD-1 HuMAbs can be selected from 3G10, 12A4 (also referred to herein as BMS-936559), 10A5, 5F8, 10H10, 1B12, 7H1, 11E6, 12B7, and 13G4, all of which are described in U.S. Pat.
- the antibodies comprises antibodies that are are approved for clinical use.
- Such antibodies include, but are not limited to antibodies that target PD-1 (e.g., Pembrolizumab (Keytruda), Nivolumab (Opdivo)), antibodies that target PD-L1 (e.g., Atezolizumab (Tecentriq), Avelumab (Bavencio), Durvalumab (Imfinzi), and the like), and/or antibodies that target CTLA-4 (e.g., Ipilimumab (Yervoy)).
- target PD-1 e.g., Pembrolizumab (Keytruda), Nivolumab (Opdivo)
- antibodies that target PD-L1 e.g., Atezolizumab (Tecentriq), Avelumab (Bavencio), Durvalumab (Imfinzi), and the like
- CTLA-4 e.g., Ipilimumab (Yervoy
- kits are provided containing reagents for the practice of any of the methods described herein.
- the kit comprises a container containing an inhibitor of the indoleamine 2,3-dioxygenase (IDO) pathway (IDO inhibitor); and/or a container containing an agent that induces immunogenic cell death (ICD) (ICD- inducer).
- IDO indoleamine 2,3-dioxygenase
- ICD immunogenic cell death
- the IDO inhibitor comprises an agent selected from the group consisting of 1-methyl-D-tryptophan (indoximod), 1-methyl-L-tryptophan, methylthiohydantoin-dl-tryptophan, Necrostatin-1, Ebselen, Pyridoxal Isonicotinoyl Hydrazone, Norharmane, CAY10581, 2-Benzyl-2-thiopseudourea hydrochloride, Norharmane hydrochloride, INCB024360, S-allyl-brassinin, S-benzyl-brassinin, 5-Bromo- brassinin, 4-phenylimidazole Exiguamine A, and NSC401366.
- indoximod 1-methyl-D-tryptophan
- 1-methyl-L-tryptophan 1-methyl-L-tryptophan
- methylthiohydantoin-dl-tryptophan methylthiohydantoin-dl-tryptophan
- the IDO inhibitor comprises an agent shown in Table 3, supra. In certain embodiments the IDO inhibitor comprises indoximod. In certain embodiments the IDO inhibitor is conjugated to an agent that forms a vesicle. In certain embodiments the agent is selected from the group consisting of a lipid, PHGP, vitamin E, cholesterol, and a fatty acid. In certain embodiments the agent comprises a phospholipid. In certain embodiments the IDO inhibitor is IDO-PL.
- the ICD inducer comprises a chemotherapeutic agent selected from the group consisting of oxaliplatin, cisplatin, doxorubicin, epirubicin, idarubicin, mitoxantrone, anthracenedione, bleomycin, bortezomib, R2016, irinotecan and cyclophosphamide.
- the ICD inducer comprises oxaliplatin.
- the ICD inducer is a compound or a biological agent in Table 2.
- the kit contains both an IDO inhibitor and an ICD inducer.
- the IDO inhibitor and the ICD inducer are in separate containers.
- the IDO inhibitor and said ICD inducer are in the same container.
- the IDO inhibitor and said ICD inducer are provided as a nanoparticle drug carrier (e.g., a drug delivery nanocarrier) as described herein.
- the kit contains an ICD inducer that comprise a nanomaterial or a formulation thereof (e.g., a sterile formulation).
- the nanomaterial comprises a material selected form the group consisting of CuO, Sb 2 O 3 , ZnO, TiO2, and graphene oxide.
- the kit comprises a container containing a nanocarrier (e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc.) described herein.
- a nanocarrier e.g., ICD/IDO silicasome, ICD/IDO lipid vesicle, ICD-inducing nanomaterial carrier, etc.
- kits can include instructional materials disclosing the means of the use of the ICD inducer to induce immunogenic death in cancer cells for vaccination, and/or the use of the ICD inducer and the IDO inhibitor as a cancer therapeutic for local administration, and/or the use of a drug-loaded drug delivery nanocarrier (e.g., LB-coated nanoparticle) or nanocarrier immunoconjugate as a therapeutic for a cancer (e.g., a pancreatic cancer, gastric cancer, cervical cancer, ovarian cancer, etc.).
- a drug-loaded drug delivery nanocarrier e.g., LB-coated nanoparticle
- nanocarrier immunoconjugate e.g., a therapeutic for a cancer (e.g., a pancreatic cancer, gastric cancer, cervical cancer, ovarian cancer, etc.).
- kits optionally include labeling and/or instructional materials providing directions (e.g., protocols) for the use of the materials described herein, e.g., alone or in combination for the treatment of various cancers.
- Instructional materials can also include recommended dosages, description(s) of counterindications, and the like.
- the instructional materials in the various kits typically comprise written or printed materials they are not limited to such. Any medium capable of storing such instructions and communicating them to an end user is contemplated by this invention. Such media include, but are not limited to electronic storage media (e.g., magnetic discs, tapes, cartridges, chips), optical media (e.g., CD ROM), and the like. Such media may include addresses to internet sites that provide such instructional materials.
- IDO Indoleamine-2,3-dioxygenase
- IDO is an intracellular heme-containing enzyme that initiates the first and rate-limiting step of tryptophan degradation along the kynurenine pathway. In mammalian organisms, tryptophan is an essential amino acid for cell survival; it cannot be synthesized de novo. IDO was shown to be expressed in normal tissues such as the endothelial cells in the placenta and lung, the epithelial cells in the female genital tract, and the lymphoid tissues in mature dendritic cells. Munn et al.
- IDO has a central role in preventing T cell-driven rejection of allogeneic fetuses during pregnancy as trophoblast expressing IDO was found to induce maternal tolerance to fetal allograft (see, e.g., Munn et al. (1998) Science, 281(5380): 1191–1193).
- This discovery broke ground for further research addressing the immunomodulatory potential of IDO, including the discovery of IDO inhibitor for cancer treatment.
- the immunosuppressive roles of IDO have also been investigated for elucidation of therapeutic targets in the management of many diseases including cancer (Gajewski et al. (2013) Nature Immunol.14: 1014–1022; Moon et al. (2015) J. ImmunoTherapy Cancer, 3: 51).
- Indoximod has a functional carboxyl group (see, e.g., Figure 2), that can be readily conjugated to other compounds containing a hydroxyl moiety. A few representative compounds are provided (see, e.g., Figure 3).
- Example 2 Self-Asssembled Nanovesicles for the Co-Delivery of an IDO Pathway Inhibitor Prodrug and Remote Loading of an Immunogenic Cell Death Inducing Agent.
- OX/IND-MSNP carrier A potential limitation of the OX/IND-MSNP carrier is its relatively low loading capacity for Pt-based drugs, such as OX (i.e. ⁇ 10% wt).
- Pt-drugs are coordination complex compounds, they are usually not suitable for remote loading by a proton gradient, such as has been reported for irinotecan encapsulation in LB-coated MSNPs (see, e.g., Liu et al. (2016) ACS Nano, 10: 2702-2715). We therefore developed new particle iterations capable of achieving a higher loading capacity for ICD-inducing chemo agents.
- DOX is chosen to illustrate remote loading of IND-NVs based on its composition as a weak basic substance.
- DOX typically precipitates as crystals, yielding a carrier that morphologically resembles the DOXIL® liposome.
- DOX/IND liposome or an MTX/IND liposome as leading carrier prototypes for initiating antitumor immunotherapy in settings such as breast cancer and other cancer types.
- Synthesis of DOX/IND nanovesicle [0550] The IND-Chol prodrug synthesis and preparation of liposomes comprising IND-Chol is described in Example7.
- a DOX/IND nanovesicle can be prepared as follows: 1) a total of 50 mg lipids of IND-Chol plus other vesicle-forming lipids (e.g., DPPC/Chol-IND/DPPG/DSPE-PEG (e.g., DSPE-PEG2k, DSPE- PEG5k, and the like), in certain embodiments at a molar ratio of ⁇ 40% (DPPC): ⁇ 35% (Chol- IND): ⁇ 20%DPPG: ⁇ 5% DSPE-PEG) can be dissolved in 5 mL chloroform in a 50 mL round bottom glass flask.
- DPPC DPPC/Chol-IND/DPPG/DSPE-PEG
- DSPE-PEG2k e.g., DSPE-PEG2k, DSPE- PEG5k, and the like
- the solvent is evaporated under a rotatory vacuum to form a uniform thin lipid film, which is dried further under vacuum overnight.
- the film is hydrated with 2 mL of ammonium sulfate (123 mM) and probe sonicated for 1 h, which is subsequently extruded 15 times through a Mini-Extruder (Avanti Polar Lipids), using a polycarbonate membrane with 100 nm pores (Avanti Polar Lipids) at 80 °C.
- IND-NV size and morphology were assessed by dynamic light scattering and cryoEM, respectively.
- Unincorporated ammonium sulfate can be removed by running through a PD-10 size exclusion column.
- DOX/IND nanovesicle can be constructed by self-assembly of IND- Chol/LP (see, e.g., Figure 5).
- the prodrug is amphipathic, allowing self-assembly into nanovesicles (IND-NV) in the presence of an aqueous biological buffer. Moreover, the entrapment of a protonating agent (such as ammonium sulfate) at the time of self-assembly, permits the nanovesicle to import DOX from the surrounding drug suspension. DOX can precipitate as crystals in the nanovesicle. This provides a nanocarrier that morphologically resembles the DOXIL® liposome. Additional possible weak base laden co-delivery IND-NVs. [0552] In addition to DOX loading into nanovesicles, there are other possible drugs that can be imported across the lipid bilayer of this carrier.
- Such copounds include, but are not limited to weak basic compounds with medicinal chemical features.
- Such copounds include, but are not limited to alkaloids (e.g. irinotecan, topotecan, 10-hydroxycamptothecin, belotecan, rubitecan, vinorelbine, LAQ824, vinblastine, vincristine, homoharringtonine, trabectedin), anthracyclines (e.g. doxorubicin, epirubicin, pirarubicin, daunorubicin, rubidomycin, valrubicin, amrubicin), alkaline anthracenediones (e.g. mitoxantrone), alkaline alkylating agents (e.g.
- alkaloids e.g. irinotecan, topotecan, 10-hydroxycamptothecin, belotecan, rubitecan, vinorelbine, LAQ824, vinblastine, vincristine, homoharringtonine,
- cyclophosphamide mechlorethamine, temozolomide
- purine or pyrimidine derivatives e.g.5-fluorouracil, 5'-deoxy-5-fluorouridine, gemcitabine, capecitabine
- protein kinase inhibitors e.g., pazopanib, enzastaurin, vandetanib erlotinib, dasatinib, nilotinib, sunitinib, osimertinib, palbociclib, ribociclib
- Doxorubicin is an ICD-inducing chemoagent in breast cancer leading to development of a co-delivery liposome for breast cancer nano-immunotherapy by contemporaneous triggering of immunogenic cell death and restraining the IDO pathway
- BC localized breast cancer
- the Breast Cancer Coalition has pointed out that there is marginal improvement on mortality rate since 1975 (DeSantis et al. (2017) CA Cancer J Clin.67: 439-448). This is particularly true for metastatic disease, where none of the current treatments (e.g., radiation, chemotherapy, and estrogen blockers) are capable of eliminating BC once metastatic spread has taken place (Howlader et al. (eds).
- the overarching challenge that we address to improve BC mortality is to improve the response rate to immunotherapy through the delivery of immunogenic cell death (ICD) stimuli by nanocarriers (see, e.g., Figure 1).
- ICD immunogenic cell death
- Our data show reproducible induction of tumor infiltrating lymphocytes (TILs) in an orthotopic BC animal model by an ICD-inducing nanocarrier.
- TILs tumor infiltrating lymphocytes
- TEE hot immune environment
- ICD could strengthen the effect of immune checkpoint blocking antibodies as well as indoleamine 2,3-dioxygenase (IDO) inhibitors that interfere in this metabolic immune surveillance pathway.
- IDO indoleamine 2,3-dioxygenase
- a doxorubicin (DOX) encapsulating nanocarrier provides a more potent ICD stimulus than the free drug, and can do so synergistically with a small molecule inhibitor (indoximod) of the IDO-1 pathway.
- the nanocarrier is capable of facilitating this task by improving the PK of DOX and indoximod (IND) at the tumor site.
- a first generation nanocarrier providing an ICD stimulus and an IDO inhibitor as a promising synergistic immunotherapy platform for BC, including triple negative BC (TNBC) (most responsive to immune checkpoint inhibitors) as well as ER- positive tumors (numerically the largest BC subtype responsible for mortality).
- TNBC triple negative BC
- MTX mitoxantrone
- the ability of the DOX- or PTX-treated cells to significantly suppress tumor growth at the challenge site is compared to the negative control. Additional in vitro ICD profiling (HMGB1 and ATP release as well as CRT cell surface visualization) has been determined.
- tumors are excised from the mice from each group and the averaged tumor weight determined.
- bioluminescence visualization of 4T1 tumor development in the vaccination experiment can be performed using IVIS imaging at different time points. Mouse body weight monitoring can be provided. Synthesis of a DOXIL® look-like DOX-laden IND-Liposome (DOX/IND-Liposome).
- DOXIL® look-like DOX-laden IND- Liposome (DOX/IND-Liposome)
- DOXIL® is a PEGylated liposome for the delivery of DOX and has been in the marketplace for two decades. Encapsulated DOX delivery holds significant advantages over free DOX in patients with Kaposi’s sarcoma, ovarian carcinoma and BC (Barenholz et al. (2012) J. Control. Rel.160: 117-134). This advantage is in part derived from the improved PK of DOX at the tumor site as well as a reduction in cardiovascular and systemic DOX toxicity (Id.).
- DOX is loaded into DOXIL® by using a trapping agent, which generates a proton gradient that allows the import of weak- basic DOX through the liposomal lipid bilayer.
- DOXIL® One potential downside of DOXIL® is the preferential concentration of DOX in the skin, which can result in the hand-foot syndrome (redness and inflammation) (Id.). Clinical guidelines to avoid this side effect by adapting the DOXIL® dosing schedule exist. against this background of this FDA-approved technology, we asked whether it was possible to develop a liposome for dual DOX and indoximod (IND) delivery. In addition to the improving the PK of DOX, we hypothesized that we would also be able to improve the circulatory half-life (T 1/2 ) and tumor levels of indoximod (IND).
- IND-Chol cholesterol-conjugated IND prodrug
- IND D-1-methyl tryptophan or D-1MT
- a classic DOX remote loading strategy can be employed using ammonium sulfate as gradient. Following the evaporation of organic solvent that contains phospholipids, IND-Cholesterol, and DSPE-PEG2K, a uniform lipid film is formed along the bottom of the round flask.
- a protonating agent (NH 4 ) 2 SO 4 can be added into the flask afterwards, followed by probe sonication and PD-10 desalting column purification to render the pure (NH 4 ) 2 SO 4 -loaded IND-Liposome. Then DOX . HCl solution is incubated with (NH4)2SO4-loaded IND-Liposome at 65 °C for the active loading of DOX into the hydrophilic pocket of IND-Liposome.
- DOX a weak basic molecule, can easily be loaded into the liposome by using ammonium sulfate as a protonating agent in the self-assembly solution.
- ICD immunogenic cell death
- IDO immunosuppressive indoleamine 2,3-dioxygenase pathway
- This can be accomplished by conjugating the IDO inhibitor, indoximod (IND), to Cholesterol (Chol) or another component of a lipid bilayer that allows the prodrug to self- assemble into nanovesicles (IND-NV) or to be incorporated into a lipid bilayer that encapsulates mesoporous silica nanoparticles (MSNP).
- IDO inhibitor indoximod
- Chol Cholesterol
- MSNP mesoporous silica nanoparticles
- the porous MSNP interior allows contemporaneous delivery of the ICD-inducing chemotherapeutic agent, oxaliplatin (OX).
- OX oxaliplatin
- IND-NV plus free OX or OX/IND-MSNP can induce effective innate and adaptive anti-PDAC immunity when used in a vaccination approach, direct tumor injection or intravenous biodistribution to an orthotopic PDAC site.
- significant tumor reduction or eradication cajn accomplished by recruited cytotoxic T lymphocytes, concomitant with downregulation of FoxP3 + T-cells.
- ICD is a modified form of apoptosis that can be used to initiate an effective immune response against endogenous tumor antigens (Kroemer et al. (2013) Ann. Rev. Immunol., 31: 51-72). ] Since this model was 1 st proposed against the backdrop of a select number of cancer drugs (Id.), we focused on the use of OX, because it is FDA-approved for PDAC treatment. As a component of the FOLFIRINOX regimen (in combination with irinotecan, 5-FU and folinic acid).
- CRT is an endoplasmic reticulum (ER) stress protein that translocates to the surface membrane of cancer cells undergoing ICD (Obeid et al. (2017) Nat. Med., 13(1): 54-61; Fucikova et al. (2011) Canc. Res.71(14): 4821-4833).
- ER endoplasmic reticulum
- Spaghetti curves show a decrease in KPC tumor growth in the contralateral flank in animals treated with DOX, OX, and acitivated DOX (6, panel E).
- Tumor collection was performed after euthanizing the animals to conduct IHC. IHC staining of CD8 and Foxp3 T cells was used to calculate CD8/FoxP3 T cell ratio in each group (see, e.g., Figure 6, panel F). Discussion
- PDAC is an often-fatal and notoriously treatment-resistant disease, in desperate need of new treatment approaches for dealing with the primary tumor growth as well as metastatic spread. We demonstrate a first treatment modality to generate an anti- PDAC response, premised on the ability of OX to induce ICD.
- the ICD is responsible for enhanced tumor antigen presentation as well as providing stimulatory effects to the participating DCs. This triggers the activation of cytotoxic T cells and anti-PDAC immunity that was synergistically enhanced by an intervention in the IDO pathway.
- the first treatment modality comprises a subcutaneous vaccination approach that utilizes ex vivo induction of ICD by OX in a KPC cell line, it is sufficient to a generate systemic immune response that can interfere with tumor growth at a remote site as well as allowing adoptive transfer to non- immune animals. [0572] In view of these results it is believed that two additional treatment modalities are available.
- the second treatment modality involves local injection of OX plus an IND- nanovesicle (e.g., and IND-Chol nanovesicle) to induce the recruitment of cytotoxic CD8 + lymphocytes, depletion of Tregs, reversal of the CD8 + /Foxp3 + ratio, cytotoxic tumor killing, and tumor shrinkage at the local injection site.
- IND- nanovesicle e.g., and IND-Chol nanovesicle
- the 3 rd treatment approach combines OX and an IND-nanovesicle (e.g., and IND-Chol nanovesicle) into a single MSNP-based nanocarrier, that allows systemic biodistribution and drug delivery to orthotopic KPC tumor sites. It is believed the dual delivery approach can achieved synergistic enhancement of adaptive and innate anti-PDAC immunity, leading to a significant improvement in animal survival.
- Our proposed nano-enabled approach for boosting immunotherapy offers distinct advantages over current immunotherapy strategies for PDAC, including peptide and protein vaccines (e.g., mutant Kras, survivin, vascular endothelial growth factor receptor, gastrin and heat shock proteins) (Paniccia et al. (2015) Chinese J.
- ICD In contrast, the use of ICD prepares the dying cancer cells for uptake and processing by local APCs, with the possibility that the full complement of mutant or neo-antigens can participate in dynamically fashion in T cell selection, allowing effective TCR proofreading for immune activation. This allows the cognitive immune system to adapt to an array of continuously evolving tumor antigens rather than restricting the immune response to selected antigens.
- ICD induction by a an already FDA-approved chemotherapeutic agent constitutes a more effective means to achieve anti-PDAC immunity because it targets autologous cancer cells rather than preselected PC cell lines (which may not dynamically display the full complement of tumor antigens).
- chemotherapeutic agent such as OX or irinotecan
- OX is an integral component of the FOLFIRINOX regimen, and constitutes one of a short list of chemotherapeutics capable of inducing ICD, other than anthracyclines (Kepp et al. (2014) Oncatarget, 5(14): 5190-5191). The unique ability of these chemotherapeutics to induce ICD is dependent on their ability to initiate a sequence of events that differ from regular apoptosis.
- CRT expression serves as an “eat me” signal for antigen-presenting DCs, which also receive adjuvant signals at subsequent stages of ICD by the release of the nuclear protein, HMGB1, and ATP from the dying tumor cells (Obeid et al. (2017) Nat. Med., 13(1): 54-61; Kroemer et al. (2013) Ann. Rev. Immunol., 31: 51-72).
- CRT and HMGB-1 interacts with CD91 and TLR4, respectively.
- Immune activation in the PDAC microenvironment has to overcome a number of immune suppressive mechanisms, including the presence of CD4 + /Foxp3 + Tregs, secretion of anti-inflammatory cytokines, expression of checkpoint inhibitors and overproduction of IDO. While our results indicate that OX alone is capable of increasing the CD8 + /Foxp3 + ratio at local and systemic tumor sites, it is believed the co-administration of a vesicle- conjugated IDO inhibitor, (e.g., IND-Chol liposome) can significantly enhance this integrative response parameter, which reflects the transition from an immune suppressive to an immune stimulatory TME.
- a vesicle- conjugated IDO inhibitor e.g., IND-Chol liposome
- IDO inhibitors are currently undergoing clinical trials in several cancer types, including breast, prostate, melanoma, brain and pancreas. This includes the use of IND together with gemcitabine, nab-paclitaxel and anti-PDL1 antibody.
- IND-Chol or other IND-prodrug.
- Free IND is relatively water insoluble and has unfavorable PK characteristics.
- an IND-NV can significantly increase the uptake and release of IND in tumor cells which translates to a more robust interference in IDO-mediated immune suppressive signaling pathways in vitro and in vivo.
- the dual delivery carrier can also improve the PK of OX ( Figure 7, panel c). It is also believed that the harmonized PK and contemporaneous delivery can further contribute to the in vivo synergy of the OX/IND-MSNP at the tumor site. [0579] How can this discovery be practically implemented to provide PDAC immunotherapy in the clinic?
- possible ways to improve immunotherapy in patients could include: (i) tumor cell harvesting from resected cancer tissues during surgery, with the possibility of developing a cell culture-based vaccine approach; (ii) local injection of OX and IND-Chol (or other IND conjugated prodrug) into the tumor under remote guidance, during collection of biopsies or direct visualization during surgery; (iii) systemic administration of one or a combination of treatment modalities, which may include the use of free drugs, IND-NV or the dual-delivery carrier.
- Nanocarriers to deliver other FDA-approved drugs (e.g., cardiac glycosides, GADD34/PP1 inhibitors, Ca 2+ -activated K-channel agonists, poly-I/C, etc.) [14] to achieve ICD, individually or in combination with chemotherapeutics or ICD-inducing nanoparticles.
- FDA-approved drugs e.g., cardiac glycosides, GADD34/PP1 inhibitors, Ca 2+ -activated K-channel agonists, poly-I/C, etc.
- Another approach could be to combine chemotherapy and IND delivering nanoparticles with immune checkpoint blockers, irradiation, photodynamic therapy or cytotoxic viruses to achieve additional immune response enhancement.
- the same principles could also apply to the treatment of a host of other cancers.
- Example 5 Nanomaterial ICD Inducers [0580] A number of immunogenic cell death (ICD) inducers are known to those of skill in the art.
- Illustrative ICD inducers include, but are not limited to oxaliplatin, anthracenedione, bleomycin, bortezomib, cisplatin, daunorubicin, docetaxel, doxorubicin, doxorubicin, epirubicin, idarubicin, mitoxanthrone, oxaliplatin, paclitaxel, R2016, irinotecan and cyclophosphamide (see, e.g., Moon et al. (2015) J. ImmunoTherapy Cancer, 3: 51; Bezu et al. (2015) Front. Immunol., 6:187).
- nanomaterial physicochemical properties that can trigger cell death response pathways.
- These include nanomaterial properties (e.g., from transition metal oxides, rare earth oxides, graphene oxide) that induce oxidative stress, which can induce mitochondrial triggering and the initiation of apoptosis.
- nanomaterial properties e.g., from transition metal oxides, rare earth oxides, graphene oxide
- oxidative stress which can induce mitochondrial triggering and the initiation of apoptosis.
- rare earth oxide nanoparticles that can trigger a cell death response pathway by triggering lysosomal damage and interference in autophagy flux. These particles can induce cellular pyroptosis, which is a different form of inflammatory cell death.
- FIG. 33 shows the results of screening of nanomaterials (NMs) for induced immunogenic cell death (ICD) in KPC pancreatic cancer cell after 24 h treatment with engineered nanoparticles.
- NMs nanomaterials
- ICD induced immunogenic cell death
- FIG. 33 shows the results of screening of nanomaterials (NMs) for induced immunogenic cell death (ICD) in KPC pancreatic cancer cell after 24 h treatment with engineered nanoparticles.
- Calreticulin (CRT) one of the hallmarks dictating ICD, is translocated onto the cell surface membrane from endoplasmic reticulum following ICD inducer treatment. Flow cytometry analysis was performed to quantitatively measure the induction of CRT level compared to control group.
- nanomaterials believed to induce immunogenic cell death include, but are not limited to Al2O3, CeO2, CoO, Co3O4, Cr2O3, CuO, Dy2O3, Er2O3, Eu2O3, Fe 2 O 3 , Fe 3 O 4 , Gd 2 O 3 , HfO 2 , Ln 2 O 3 , La 2 O 3 , Mn 2 O 3 , Nd 2 O 3 , NiO, Ni 2 O 3 , SiO 2 , Sm 2 O 3 , SnO 2 , TiO2, WO3, Y2O3, Yb2O3, ZnO, ZrO2, AP-WMCNT, PF108-MWCNT, COOH-MWCNT, GO-S, GO-L, and the like.
- Figures 33 shows the results of vaccination experiment using metal and metal oxide. Animal were treated using 2 rounds of vaccination (dying KPC cells treated with metal oxide nanoparticles) one week apart, followed by injecting live KPC cells SC on the contralateral side.
- Figure 33, panel A shows spaghetti curves to show KPC tumor growth in the contralateral flank.
- Figure 33, panel B shows percent CRT.
- Example 6 [0585] Regarding the transition from lab scale synthesis to industrial scale production of lysolipid-conjugated 1-MT (either D- or L- form), we have conceptualized a total synthesis approach as a more economic approach for prodrug synthesis.
- LysoPC conjugated 1- MT is essentially a conjugation of 4 building blocks: i) the drug (1-MT), ii) a glycerol backbone, iii) a fatty acid lipid chain, and iv) a phosphocholine head group.
- the following idealized example can be used for block-by-block assembly of 1-MT, glycerol, fatty acid, and phosphocholine, wherein the order of the building blocks can be swapped around if needed.
- the following idealized example consists of six synthesis steps, linking together the key building blocks. The sequence of procedures could be carried out commercially or synthesized in-house, using the most economic acquisition of the required starting materials as needed.
- the first stage of the total synthesis starts from the protection of the amine (-NH2) group of the 1-(D/L)-MT using di-tert-butyl decarbonate (Boc2O) or other amine protection groups (e.g.
- Boc-1MT fluorenylmethyloxycarbonyl chloride (Fmoc-Cl)) to obtain Boc-1MT (or Fmoc-1MT).
- the amine protection avoids self-reaction when conjugating to other building blocks via ester bonds (1-MT can undergo amidation to form amide bond between to -NH2 and -COOH of two 1-MT molecules).
- Boc2O protection was shown in the following example, yielding compound (1) ( Figure 9, Stage I).
- the second stage of the synthesis is to conjugate compound (1) with a glycerol building block via Steglich esterification reaction ( Figure 9).
- Double-(hydroxyl) protected glycerol via the formation of isopropylidene acetal (e.g. solketal), or 1,3-O-benzylidene, or mono-choloro substituted double-hydroxyl protected glycerol (e.g.4-chloromethyl-2,2-dimethyl-1,3-dioxolane) can also be used for sequential lipid prodrug conjugation through similar approaches.
- Stage III-IV [0591] The next stage of the synthesis aims for the installation of a lipid (fatty acid) chain on to the 1-MT-conjugated glycerol backbone (Stage II compounds).
- the fatty acid chloride equivalent version of fatty acid anhydride could also be used as a source of reactive acyl groups.
- Stage V-VI focuses on two synthesis options: Stage V – a, to install a phosphatidylcholine head group onto the 1MT conjugated glycerol backbone yielding lyso- phosphatidylcholine (LysoPC) derivative drug conjugates); alternatively, in Stage V – b, a secondary lipid (fatty acid) chain was conjugated, yielding mono-substitute triglyceride (TG) derivative drug conjugates, i.e. drug conjugated diglyceridediacylglycerol (DAG) derivatives.
- TG mono-substitute triglyceride
- DAG diglyceridediacylglycerol
- Stage V - a is achieved by first attaching a dioxaphospholane ring via 2-Chloro-1,3,2- dioxaphospholane 2-oxide or 2-chloro-1,3,2-dioxaphospholane followed by a ring opening reaction and the addition of a choline head via trimethylamine (Me3N, a.k.a. TMA), yielding compound (5a), (5b), and (5c).
- Stage V – b is essentially the same reaction as Stage III, which the second fatty acid (FA-2) could be the same as the first fatty acid installed (FA-1) or different from FA-1 to mimic natural triglyceride configurations, yielding compound (5d), (5e), and (5f).
- the single fatty acid conjugation is simply achieved by performing a Steglich esterification reactions between compound (1), the Boc-1MT and a fatty alcohol (saturated or poly-/mono- unsaturated), yielding compound (7) followed by amine deprotection to afford compound (8) as the final drug conjugate.
- Ester conjugated 1MT-cholesterol is simply synthesized by conjugating Boc-1MT and cholesterol followed by amine deprotection, yielding compound (9) and (10), respectively.
- 1MT cnd be directly conjugated with a cholesteryl chloroformate yielding a 1MT-Cholesterol conjugate via carbamate as compound (11).
- the design is based on the use of medicinal chemistry criteria such as presence of reactive functional groups, steric hindrance, analysis of side products, product yield and avoidance of toxic/unstable/expensive chemicals to identify API candidate(s) to direct prodrug design.
- This prodrug can be used to formulate dual delivery liposomes, capable of co-delivery of mitoxantrone (MTX) and doxorubicin (DOX), which have the potential to act as ICD stimuli.
- MTX mitoxantrone
- DOX doxorubicin
- the synthesis involves 4 simple steps: Boc-protection of IND, Cholesterol conjugation, Boc removal and de-salting.
- the raw materials and supplies that were used to make Chol-IND are summarized in Table 6.
- the overall yield is 20 ⁇ 30%. Table 6.
- Step 1 Synthesis of Boc-Indoximod (Boc-IND).
- Indoximod (1-Methyl-D-tryptophan, 95%) powder 3.2 g (13.93 mmol) and sodium bicarbonate (NaHCO3) were suspended in 80 mL THF/H2O (1:1 v/v) and chilled on ice.
- Di-tert-butyl decarbonate (Boc2O anhydride) 4.16 g (19 mmol) was pre-dissolved in 20 mL THF/H2O (1:1 v/v) and added drop-wise to the suspension.
- Step 2 Synthesis of Cholesteryl-Indoximod-Boc (Chol-IND-Boc): [0600] Recrystallized Boc-IND (purity ⁇ 90%, 900 mg, 1 mmol) was loaded into a 100 mL round bottom flask containing anhydrous dichloromethane (25 mL) with a magnetic stir. This was followed by the addition of a catalytic amount of DMAP (12 mg, 0.1 mmol), and cholesterol (purity 92.5%, 836 mg, 2 mmol) powder to form a solution that was chilled on ice. The solution was kept under nitrogen during the reaction.
- the reaction mixture was purified by sequential extraction with 0.5N HCl (50 mL x 2), saturated NaHCO 3 (50 mL x 2), and an optional brine wash (50 mL x 1).
- the residual water in the organic phase was absorbed by anhydrous MgSO 4 , from which the MgSO 4 hydrate was removed by filtration.
- TFA removal can be done using a commercially available resin (siliaPrepTM Carbonate (or Si-CO3) resin) or purification column, according to the manufacturer’s instructions (see Item #24 in Table 6). Using a different industrial protocol a TFA removal % of 99.96% was observed.
- Use of Chol-IND to make dual delivery liposome for concurrent ICD induction and IDO inhibition [0603] We have experimentally demonstrated the feasibility of making co-delivery liposomes that incorporate indoximod (IND) as well as MTX and DOX.
- the ICD inducing chemo agents are loaded into the liposome by trapping agents, which include citric acid for MTX and ammonium sulfate for DOX (Fig.20).
- Cholesteryl hemisuccinate is a cholesterol derivative that is frequently used in formulation studies (see, e.g,. Serpe et al. (2004) Eur. J. Pharm. Biopharm.58: 673-680; Ding et al. (2005) Int. J. Pharam.300: 38-47). It carries one negative charge at a pH greater than 6.5.
- a simulation study (membrane protein crystallization) suggested that protonated form of CHEMS mimics many of the membrane properties of cholesterol quite well (Kulig et al. (2014) J. Mol. Model.20: 2121).
- FIG. 25 shows a determination of MTD doses for free MTX and liposomal MTX in normal mice. MTD doses for free MTX and liposomal MTX were 3 and 15 mg/kg for single IV administration.
- Figure 26, panel B shows pilot tumor size measurement in 4T1 orthotopic tumor-bearing mice receiving IV free drug or MTX-only liposome. "Industrial" synthesis of Chol-IND.
- mitoxatrone was selected as an ICD inducer because MTX leads to a very strong ICD effect in multiple cancer types.
- Cholesterol-IND as an immunological modulation agent based on the formulation work (see, e.g., Example 7).
- the effect can be attributed to the superior ICD introducing effect of mitoxantrone over doxorubicin, rendering a liposomal mitoxantrone candidate that can be used for multiple cancer types.
- the mitoxantrone-only liposome was so effective that an additional effect for cholesterol-IND could not be observed. Without being bound to a particular theory, it is believed this reflects the possibility that the 4T1 triple negative breast cancer model may represent a TN breast cancer subset in which IDO-1 does not play a major role.
- TN breast cancer is no different from a series of solid cancers in which there is only a 25-30% response rate to checkpoint inhibitors, likely due to a variation on the theme of participation by different immune escape mechanisms.
- IND in spite of a synergistic effect for IND in the 4T1 model, that there is a strong ICD response in the immunohistochemistry data, implying that the contribution of turning the “cold” tumor “hot” is a valid approach irrespective of the IDO-1 contribution.
- a potent ICD agent such as mitoxantrone could exert similar effects on other solid tumors, increasing the 25% response rate.
- liposomes containing mitoxantrone (MTX), but not containing an IDO inhibitor are also present.
- immunogenic cell death is a specialized form of tumor cell death in response to specific chemotherapeutic drugs (e.g. anthracyclines, MTX, oxaliplatin), radiation therapy, photodynamic therapy or certain engineered nanomaterials.
- chemotherapeutic drugs e.g. anthracyclines, MTX, oxaliplatin
- Our data showed MTX and certain nanomaterials led to very strong ICD in multiple models such as breast cancer and colon cancer models.
- ICD facilitates tumor antigen cross presentation in dendritic cells as a result of calreticulin (CRT) expression on the dying tumor cell surface.
- CRT provides an “eat-me” signal for DC uptake via the CD91 receptor.
- HMGB-1 high mobility group box 1
- ATP a TLR-4 ligand
- CTLs from regional lymph node
- CTLs induce primary and metastatic tumor cell death by perforin and granzyme B release.
- the reason for using a combinatorial regimen is that the expression of IDO-1 and PD-L1 is paradoxically increased by the recruitment of CTLs at the ICD site. It is also possible to use certain engineered nanomaterials (e.g. metal oxide and graphene) to trigger an ICD effect.
- engineered nanomaterials e.g. metal oxide and graphene
- ICD induction e.g. CRT, HMGB1 and LC3
- immune activation e.g. CD8/Foxp3 ratio, perforin
- Figure 31 illustrates the efficacy of the dual MTX plus Chol-IND delivery by a liposome in the 4T1 model, along with survival data.
- Orthotopic tumor-bearing 4T1 mice were IV injected with the encapsulated MTX liposomes to deliver 3 mg/kg IND plus 3 mg/kg MTX every 3 days, for a total of 3 administrations, as illustrated in panel A.
- CT26 subcutaneous tumor bearing mice received 4 IV injection of MTX/IND co-delivery liposome at indicated time points ( Figure 32, panel A).
- the co-delivery liposome is labeled as “LCIM”, in which “I” means IND-Cholesterol; “M” stands for MTX; “C” denotes CHEMS; and “L” means liposome) ( Figure 32).
- Example 10 Use of Engineeried Nanometerials to Trigger ICD
- chemo-induced ICD which is usually a “Type 1” ICD agent that primarily induces cell death by impacting the cell nucleus, with secondary effects on the endoplasmic reticulum (ER).
- ER endoplasmic reticulum
- engineered nanomaterials such as metal oxide and graphene, to induce ICD through “Type 1” or “Type 2” or even both.
- KPC pancreatic cells were treated by using PBS (negative control), OX (positive control) and indicated engineered nanomaterials at low and high concentrations. The choice of particle concentration is based on an MTS assay ( Figure 33, panel A). Twenty- four hours post incubation, the total cells were harvested for CRT analysis through flow cytometry. This suggested a highly strong CRT induction effects (more potent than OX chemo) by nano-sized Ag, Cu, SiO2, V2O5, ZnO and graphene ( Figure 33, panel B).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Ceramic Engineering (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962914950P | 2019-10-14 | 2019-10-14 | |
US16/687,368 US11433143B2 (en) | 2017-05-18 | 2019-11-18 | Nano-enabled immunotherapy in cancer |
PCT/US2020/055585 WO2021076630A1 (en) | 2019-10-14 | 2020-10-14 | Nano-enabled immunotherapy in cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4045054A1 true EP4045054A1 (en) | 2022-08-24 |
EP4045054A4 EP4045054A4 (en) | 2023-11-29 |
Family
ID=75538134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20876826.7A Pending EP4045054A4 (en) | 2019-10-14 | 2020-10-14 | Nano-enabled immunotherapy in cancer |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP4045054A4 (en) |
AU (1) | AU2020367786A1 (en) |
CA (1) | CA3157508A1 (en) |
WO (1) | WO2021076630A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11433143B2 (en) | 2017-05-18 | 2022-09-06 | The Regents Of The University Of California | Nano-enabled immunotherapy in cancer |
CN113332311A (en) * | 2021-06-01 | 2021-09-03 | 山东第一医科大学(山东省医学科学院) | Preparation method and application of manganese ion-CpG oligonucleotide nanoparticles |
CA3232648A1 (en) * | 2021-09-22 | 2023-04-06 | Amit Praful Khandhar | Compositions and methods for enhanced protein production |
WO2023230233A1 (en) * | 2022-05-25 | 2023-11-30 | Malcolm Thomas | Allogeneic hypoimmune biomimetic nanovesicle for the treatment of cancer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1338702C (en) * | 1987-03-05 | 1996-11-12 | Lawrence D. Mayer | High drug:lipid formulations of liposomal- antineoplastic agents |
US10828255B2 (en) * | 2013-03-05 | 2020-11-10 | The Regents Of The University Of California | Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents |
WO2017201528A1 (en) * | 2016-05-20 | 2017-11-23 | The University Of Chicago | Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof |
WO2018213631A1 (en) * | 2017-05-18 | 2018-11-22 | The Regents Of The University Of California | Nano-enabled immunotherapy in cancer |
US11433143B2 (en) * | 2017-05-18 | 2022-09-06 | The Regents Of The University Of California | Nano-enabled immunotherapy in cancer |
-
2020
- 2020-10-14 WO PCT/US2020/055585 patent/WO2021076630A1/en unknown
- 2020-10-14 EP EP20876826.7A patent/EP4045054A4/en active Pending
- 2020-10-14 CA CA3157508A patent/CA3157508A1/en active Pending
- 2020-10-14 AU AU2020367786A patent/AU2020367786A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP4045054A4 (en) | 2023-11-29 |
CA3157508A1 (en) | 2022-04-22 |
WO2021076630A1 (en) | 2021-04-22 |
AU2020367786A1 (en) | 2022-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018269742B2 (en) | Nano-enabled immunotherapy in cancer | |
US11433143B2 (en) | Nano-enabled immunotherapy in cancer | |
US10335420B2 (en) | Nanoparticle-based tumor-targeted drug delivery | |
EP4045054A1 (en) | Nano-enabled immunotherapy in cancer | |
WO2009026427A2 (en) | Liposome compositions for in vivo administration of boronic acid compounds | |
US20230241000A1 (en) | Gsk3 inhibitor-loaded nano formulations as a cancer immunotherapeutic | |
US20230338363A1 (en) | Combination chemo-immunotherapy for pancreatic cancer using the immunogenic effects of an irinotecan silicasome nanocarrier plus anti-pd-1 | |
WO2017137958A1 (en) | Cellular signalling inhibitors, their formulations and methods thereof | |
Gu et al. | Dual‐Targeting Nanoliposome Improves Proinflammatory Immunomodulation of the Tumor Microenvironment | |
US20240009321A1 (en) | Immunogenic nanovesicles for cancer immunotherapy | |
US20230398077A1 (en) | Silicasome nanocarrier for metal-based drug delivery | |
US20220378936A1 (en) | Delivery system complexes comprising a precipitate of an active agent and methods of use | |
US20210100791A1 (en) | Combined pharmaceutical formulation comprising drug-containing liposome composition and immune checkpoint inhibitor | |
WO2023172300A1 (en) | A drug nanocarrier system to deliver a combination of tlr agonists and/or a lipoxin plus immunogenic cell death inducing chemotherapeutic agents for cancer immunotherapy | |
WO2023081514A1 (en) | Cxcr4 antagonist loaded liposomes and silicasomes | |
US20240299516A1 (en) | Multilamellar rna nanoparticle vaccine against cancer | |
WO2024108173A1 (en) | Prodrug strategy that enhances efficacy and lowers systemic toxicity of mertansine | |
WO2024161391A1 (en) | Nanoparticles directed to cxcr4 and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220510 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230524 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20231031 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/04 20060101ALI20231025BHEP Ipc: A61P 35/00 20060101ALI20231025BHEP Ipc: C07J 43/00 20060101ALI20231025BHEP Ipc: A61K 31/704 20060101ALI20231025BHEP Ipc: A61K 31/58 20060101ALI20231025BHEP Ipc: A61K 31/555 20060101ALI20231025BHEP Ipc: A61K 31/405 20060101ALI20231025BHEP Ipc: A61K 31/282 20060101ALI20231025BHEP Ipc: A61K 31/136 20060101ALI20231025BHEP Ipc: A61K 45/06 20060101ALI20231025BHEP Ipc: A61K 47/69 20170101ALI20231025BHEP Ipc: C07H 9/00 20060101ALI20231025BHEP Ipc: C07H 1/00 20060101ALI20231025BHEP Ipc: A61K 47/55 20170101ALI20231025BHEP Ipc: A61K 47/54 20170101ALI20231025BHEP Ipc: A61K 31/56 20060101AFI20231025BHEP |